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Chapter 1 
INTRODUCTION 
9 

Historical overview 
Identification of leukaemia 
In October 1845, John Hughes Bennett (1812-1875), a lecturer in clinical medicine and 
pathologist at the Royal Infirmary Edinburgh, reported on a peculiar case. The blood of 
one of his patients had changed its color and consistency, as it was mixed with pus. When 
he examined it microscopically, there were in fact huge numbers of corpuscles, which he 
and many others were used to seeing in pus.' By applying acetic acid he could see the 
nucleus: "The nucleus was generally composed of one large granule ... but here and 
there two or three smaller granules" .2 Although he could find no source of inflammation, 
he nevertheless concluded that his patient died from "the presence of purulent matter in 
the blood". A few months later RudolfVirchow, a demonstrator in pathological anatomy 
at the Charite Hospital in Berlin, made a similar observation, but he interpreted it dif-
ferently. He remembered that the normal blood contains colourless corpuscles quite sim-
ilar to those in pus and his patient's blood. The only difference was that the normal ratio 
of red and white corpuscles seemed reverse in this instance. Therefore he named the con-
dition 'leukaemia' (white blood).' Bennett preferred the more exact title of leuco-
cythaemia, or white cell blood.2 
In 1868 Ernst Neumann, professor of pathological anatomy at Konigsberg estab-
lished the link between blood and bone marrow and later stated that leukaemia is a dis-
ease of the marrow. 1•2 
Early classification of leukaemia 
Soon after the identification of leukaemia, some differences in the manifestation of the 
disease were observed. Virchow divided leukaemia into two forms, one characterized by 
an enlargement of the lymph nodes (lymphatic leukaemia) and the other by great 
swelling of the spleen (splenic leukaemia). In 1878 Ernst Neumann suggested that bone 
marrow is the major source of splenic leukaemia and therefore the marrow derived 
(myeloid) leukaemia replaced the term splenic leukaemia. 
In 1889 Wilhelm Ebstein, a professor of medicine in Gottingen, introduced a further 
subdivision of leukaemia based on the clinical progression of the disease. The 'acute' 
leukaemia was unresponsive to all forms of treatments and led to death, usually within 
weeks if not days; while the 'chronic' leukaemia could often be temporary relieved. 1 
Early treatments and prognoses 
In 1893 Cabot, an American physician from Boston, studied a cohort of 34 patients with 
acute leukaemia which is probably the first study of its kind. The mean survival of the 
cohort was 4,5 weeks and the maximum survival comprised 9 weeks.2 This is though not 
surprising as in those days no effective therapy was available. 
Virchow's prescription for patients suffering from advanced leukaemia included 
nourishing diet, iron for anaemia, iodine and ointments for external use and footbaths. 1 
The other therapeutic agents available at that time were opioids for diarrhea and pain, 
quinine for fever and arsenic. Arsenic trioxide 1% solution had already been used since 
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1786 for malarial fever and headaches. In 1865, Lissauer, a German physician, adminis-
tered arsenic to a woman with chronic myeloid leukaemia and so induced a temporary 
remission.2 This remission was described by one ofLissauer's colleagues as: "looks bet-
ter, has a smoother skin and better digestion" .1 This success made Arsenic the first choice 
treatment for leukaemia for over 30 years. This treatment could reduce the number of 
white blood cells and the size of enlarged organs, such as spleen and lymph nodes. 
Besides, the number of red blood cells would increase and relieve anaemia. However, the 
major problem was that Arsenic was not effective against all kind of leukaemias. It 
seemed useless in acute leukaemia and was temporarily effective for the chronic forms. 
Therefore, when other treatments such as x-ray were discovered, Arsenic was put aside 
although not completely forgotten. In 1938 Forknef recommended its use in certain 
cases like in those who had become refractory. 
In the course of time, physicians learned not to think of leukaemia as a single dis-
ease. Leukaemia is a heterogeneous disease that differs in manifestation and response to 
therapy. Therefore it is impossible to expect a single agent like Arsenic to be effective 
against different forms of the disease. Recently, arsenic compounds have become a sub-
ject of renewed attention in the treatment of certain leukaemias, including acute promye-
locytic leukaemia. '·2•4•5 
Experimental haematology in progress 
In 1877, the medical student Paul Ehrlich developed triacid stain, a method by which one 
could differentiate between types of blood cells. Using this method he differentiated 
between three distinct types of granulocytes. Based on their chemical affinities to ani-
line dyes, Ehrlich named these granulocytes acidophil (later changed to eosinophil), 
basophil and neutrophiL Triacid stain simplified the distinction of myeloid from lym-
phoid leukaemias.2 Until then, distinctions had been made mainly on the basis of obvi-
ous pathological changes in the spleen, lymph nodes and marrow.6 
Towards the end of the nineteenth century, the source of blood and some of its imme-
diate precursors were identified. As leukaemia was a disease of blood, some physicians 
applied blood transfusions to treat patients. The first blood transfusion was carried out 
by George Callender in 1873 and resulted in a short relief of the patient. The second 
transfusion however, terminated fatally. It was not until 1900 that the most important 
advance in safe transfusion, the distinction between human blood groups, was discovered 
by Karl Landsteiner.2 
The discovery of X-ray in 1895 by Wilhelm Rontgen brought a new treatment for 
leukaemia, with initially temporary results similar to those produced by arsenic. 2 
However, Minot and his colleagues, in their survey of 1924, proved that acute leukaemias 
were resistant to X-ray therapies.7 Later, in 1930, radiation was used as a combination 
therapy in RAT regimen together with arsenic and thorium-X.8 
The advances in chemotherapy started after World War I, when mustard gas proved 
to induce myelosuppression. Because of the considerable toxic effects of nitrogen mus-
tard, the search for agents with more specific actions continued.2•6 Alkylating agents were 
introduced, such as Busulphan6 and folic acid antagonists such as Aminopterin and later 
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methoteraxate.2 Nonetheless, the outlook in leukaemia remained very gloomy until the 
1960s, 8 when the treatment of leukaemia with methotrexate and 6-mercaptopurine was 
evaluated by Boggs et aU In their study it was pointed out that only one in five patients 
benefited from this therapy. However, these results did not discourage further experi-
ments with various chemotherapeutic regimens.2 In the middle of the 1970s Donnall 
Thomas'0 presented his data on 100 patients: 54 with acute myelogenous leukaemia 
(AML) and 46 with acute lymphoblastic leukemia (ALL), treated with HLA-matched 
sibling marrow transplantation. The attitude of most haematologists in those days was: 
'look what he put them through for only a few survivals' .8 In contrast, several other 
haematologists who were experimenting with marrow transplantation were encouraged 
by these results. In due course other technologies, such as infection control, transfusion 
support, various kind of chemotherapies and immune suppression therapies developed 
and gradually improved the outcome.• In the past 20-25 years allogeneic bone marrow 
transplantation has been the most active treatment for AML with a success rate of 50-
60%." 
This brief overview described the gradual progress in experimental haematology, 
which in the end can be called a success story. This reminds us of Virchow's words of 
1858: 'I do not wish by any means to infer that leukaemia is incurable; I hope on the con-
trary that for it too remedies will at length be discovered.2 
Acute myeloid leukaemia 
Acute myeloid leukaemia (AML) is the most common type of acute leukaemia in adults 
with an incidence of approximately 3 per 100,000. AML affects adults of all ages but is 
especially common in elderly patients (median age of 55-60 years).'2•13 The disease is 
characterised by a maturation arrest of myeloid progenitors, which may occur at various 
stages of development. In normal bone marrow, myeloid progenitors develop into dis-
tinct blood cell types, i.e. erythrocytes, granulocytes, macrophages and platelets (Figure 
1 ). The development of distinct blood cell types can be completely or partially blocked 
in AML as a result of acquired genetic changes in progenitor cells.'4-'9 The genetic 
changes may involve mutations that lead to activation of proto-oncogenes, inactivation 
of tumour suppressor genes or generation of chimeric proteins that interfere with growth, 
differentiation and survival of haematopoietic progenitors.20 As a result of such abnor-
malities, myeloid progenitors accumulate in blood and bone marrow and replace the nor-
mal functional blood cells. Since the differentiation arrest may occur at various stages of 
development, different immature cell types may accumulate and exhibit clinically and 
biologically distinct subtypes of AML.21 •22 
Classification by morphology 
In 1976, a group of morphologists from France, the United States, and Great Britain 
(FAB) suggested a classification system to define distinctAML subtypes. The FAB mor-
phologic classification distinguishes subtypes of AML according to the normal marrow 
cells that they most closely resemble (Figure 1 ). Based on this classification AML is 
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Figure 1. Schematic representation of blood cell differentiation in myeloid lineage 
in the context of morphologic classification of AML (FAB). The myeloid progeni-
tors develop into distinct blood cell types, e.g. erythrocytes, granulocytes, 
macrophages and platelets. The FAB morphologic classification (MO-M7) shows 
the kind of normal marrow cells that most closely resemble the AML cells. 
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divided into 8 subtypes (MO-M7). AML-MO and Ml are the most poorly differentiated 
AML, whereas M2 exhibits moderate myeloid maturation. AML-M3, M4 and M5 are 
respectively characterized by accumulation of promyelocytes, myelomonocytes and 
monocytes. The M6 and M7 are rare subtypes of AML that are associated with erythroid 
and megakaryocytic leukaemia. 23 
Cytogenetic abnormalities in AML 
Cytogenetic abnormalities are observed in approximately 60% of AML patients.24 Some 
of these abnormalities are recurrent. Approximately 23% of the patient group relevant to 
this thesis, carried a recurrent chromosomal translocation, e.g. t(8;21), t(15;17), idt(16) 
and llq23 abnormalities. Some recurrent cytogenetic abnormalities are linked to FAB 
categories, indicating that the cell stage at which transformation occurs is closely relat-
ed to the type of genetic aberration.25"28 Table 1 shows common karyotypic abnormalities 
in AMLin relation to FAB and prognosis of the patients. It is noteworthy that approxi-
mately 20% of the AML cases carry infrequent cytogenetic abnormalities, which are not 
mentioned in this table. 
Table 1. Karyotypic abnormalities in AML: common karyotypic abnormalities 
in AMLin relation to FAB and prognosis of the patients. 
Cytogenetic Genes FAB Prognosis Percentage 
M2 
CBF(3-MYH 11 M4Eo 
-RARct avourable 7% 
MLL le 4% 
es 
Unknown Varied 
-7/7q- Unknown Varied 
DEK-CAN 
t(9;22)(q34;qll) BCR-ABL Usually Ml 
3q26 abnormalities 1 Varied 
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Cytogenetics and risk-classification 
The World Health Organization (WHO) has adapted recurrent cytogenetic abnormalities 
to define subgroups of AML.31 Based on the WHO classification, AML can be subdi-
vided into four different groups. 1- AML with recurrent translocations, 2- AML with 
dysplasia in two or more major lineages (erythroid, granulocyte/ monocyte and 
megakaryocyte), 3- therapy-related AML and 4- non-categorized AML, which accounts 
for half of the casesY Although WHO classification in contrast to the FAB system 
includes cytogenetics, it offers no clear position for abnormalities such as monosomies 
of chromosome 5 or 7, 5q-, 7q-, t(9;11), 3q26 or complex karyotype (3 or more differ-
ent cytogenetical aberrations). Consequently, using this approach approximately 50% of 
AML patients are not classified.32 
In 1987, Keating et al.33 proposed a new classification of AML based on cytogenetic 
abnormalities. The 4IWCL multi-centre study had already shown the value of cytoge-
netics in determining AML prognosis.34 The classification method of Keating et aP' 
offered a clear stratification of disease into favourable, unfavourable and intermediate-
risk AML. According to this classification, patients with translocations t(8;21 ), t(15; 17) 
and idt(16) are classified in the favourable risk group. Patients with monosomies or dele-
tions of chromosome 5 or 7, translocation t(6;9), and complex karyotypes are assigned 
to an unfavourable risk group and the remaining patients belong to an intermediate risk 
category with either a normal or an unknown-risk karyotype.24 The prognosis of patients 
with 11q23 abnormalities seems to be affected by the partner genes.36"38 Translocation 
t(9;11) for example, often associates with intermediate prognosis while t(11; 19) is pre-
sented with an unfavourable outcome (reviewed by Bernasconi et al.).2° Figures 2 and 3 
16% 
18% 
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Figure 2. Distribution of AML within distinct cytogenetic risk groups. The figure 
is based on the data of patients included in this thesis (see chapter 2). 
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Figure 3. Overall survival of 319 de 
novo AML patients based on distinct 
cytogenetical risk-groups: 
favourable risk [t(8;21 ), t(15; 17) and 
idt( 16)], unfavourable risk 
[ monosomies or deletions of 
chromosome 5 or 7 translocation 
t(6;9), 3q26 abnormalities and 
complex karyotype], intermediate 
risk [normal or an unknown-risk 
karyotype]. The figure is based on 
the data of patients included in this 
thesis (see chapter 2). 
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show the distribution and survival probabilities of distinct AML risk groups. 
Intermediate-risk category is probably most heterogeneous and poorly defined. Patients 
in this category may present with rare or complex cytogenetic abnormalities or with an 
apparent normal karyotype. The clinical features and prognoses of these patients differ 
greatly. As a result, the therapy response of a patient with an intermediate risk karyotype 
remains comparatively unpredictable. For this category of AML patients, more than for 
any other category, we require additional prognostic markers. 
Molecular genetics of AML 
Acute myeloid leukaemia is a heterogeneous disease, in which a large variety of genetic 
abnormalities can be involved.3039 In the past decades, an extensive number ofleukaemia-
associated mutations and chromosome abnormalities have been identified.39 
Chromosome abnormalities can be divided into unbalanced defects, with loss or gain of 
chromosome material (deletions, nonreciprocal translocations, monosomies and tri-
somies) and balanced defects, without loss or gain of chromosome material (transloca-
tions and inversions).3039•2° Classical cytogenetic analysis based on e.g. Giemsa banding 
is the most commonly used method for identifying aberrations in AML. However, not all 
the chromosomal abnormalities e.g. small or rare cryptic rearrangements can be detect-
ed in this way. Moreover, 40% of the AML patients do not show any abnormality using 
standard cytogenetics. Nowadays, molecular genetic techniques, such as RT-PCR, 
nucleotide sequencing, Southern blot analysis and Fluorescence in situ hybridisation 
(FISH) have made it possible to detect several leukaemia associated mutations in disease 
genes, e.g. AMLJ, ETV6, RARa andMLL.'9 
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Balanced chromosomal abnormalities 
A common theme in leukaemia with balanced translocations is the involvement of genes 
that encode transcription regulators.30 Many of these regulators control differentiation.40.41 
Abnormalities in the structure or expression of the genes encoding transcription factors 
may have drastic effects on haematopoiesis (Figure 4). In this paragraph, the recurrent 
and the less frequent chromosomal abnormalities engaging particular transcription reg-
ulators are introduced. 
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Figure 4. Schematic representation of blood cell differentiation in myeloid lineage in 
the context of transcriptional control system. A few prominent transcription factors 
that regulate myeloid lineage commitment are presented in this figure. 
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I. RECURRENT TRANSLOCATIONS IN AML: FREQUENT INVOLVEMENT OF TRANSCRIPTION 
REGULATORS 
Translocations t(8;21), t(15;17), inv(16)/t(16;16), as well as llq23 abnormalities are 
recurrent chromosomal abnormalities in AML. Their common characteristics are the 
presence of transcriptional regulatory genes at one side of the breakpoints i.e. retinoic 
acid receptor alpha (RARa) in cases of translocation t(15;17), core binding factors 
(CBFs) in AML with either t(8;21) or with idt(16) and the mixed lineage leukaemia 
(MLL) gene in cases with 11q23 translocations.20•30'42 The fusion proteins that are formed 
by such translocations generally interfere with the normal function of one or both of the 
rearranged genes!2 
a. Translocation t(15; 17) involving retinoic acid receptor alpha. 
Translocations involving retinoic acid receptor alpha (RARa) are associated with acute 
promyelocytic leukaemia (APL)!3 RARa is a transcription regulator with differentiation-
promoting and growth-suppressing activity in normal haematopoiesis.44 In the absence of 
retinoic acid (RA), RARa takes part in a complex that represses transcription!547 
However, physiologic concentrations ofRA normally induce a conformational change in 
RARa, causing release of co-repressors and recruitment of co-activator molecules, lead-
ing to activation of gene transcription (reviewed by Scandura et al!2). The Rara knock-
out mice show early postnatal lethality and testis degeneration. These mice have the same 
characteristics as mice fed with a vitamin A-deficient diet!8 The translocation t(15;17) 
gives rise to the fusion transcript PML-RARa and also a smaller fusion product RARa-
PML, which is present in most but not all APL patients!9 In PML-RARa, the promoter of 
PML gene on chromosome 15 stimulates expression of the PML-RARa fusion gene that 
contains the largest part of PML and the RAR-binding and DNA binding domains of 
RARa!3•50-52 Grignani et al.'3 demonstrated that PML-RARa recruits the nuclear co-
repressor histone deacety1ase complex through the RARa CoR box. This recruitment 
inhibits transactivation of RARa target genes and thus suppresses the expression of 
genes required for promyelocytic differentiation. The maturation arrest at the promyelo-
cyte stage can be rescued by the addition of high dose all-trans retinoic acid (ATRA).54 
ATRA binds to the RARa part of PML-RARa and releases the nuclear co-repressor 
complex. Subsequently the genes required for differentiation of promyelocytes to neu-
trophils will be expressed.'9•53 Nowadays, treatment of newly diagnosed APL patients 
with ATRA in combination with chemotherapy results in complete remission (CR) rates 
of 80 to 90%.55 
b. Translocation t(8;21) and idt(16) involving core binding factors. 
The core-binding factor (CBF) is a heterodimeric transcription factor composed of the 
CBFa and CBFI3 subunits. CBFa2 (AMLI) is the DNA binding element of the complex 
and its affinity is greatly increased in the presence ofCBFj3.56 Both Cbfsubunits are crit-
ical to haematopoietic development, as mouse embryos lacking any of the genes showed 
no fetal liver haematopoiesis and died at approximately E12.5.57•58 The two core binding 
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transcription factors, AML 1 and CBFI) are frequently involved in leukaemic transloca-
tions.30 In translocation t(8;21), theN-terminal part of AMLJ is fused to almost the entire 
ET0.59 The leukaemogenic activity of AMLl-ETO is partly due to its dominant negative 
activity on the wild type AMLl that is being produced by the unrearranged chromosome 
21.60 The zinc finger motifs present at the C-terminus ofETO in the fusion protein, inter-
act with nuclear co-repressor molecules such as N-coR, HDACl and mSin3 and repress 
gene transcription.61 
AMLJ fusions with other genes such as EVIl in translocation t(3;21)62 or TEL in 
translocation t(l2;21Y3 are rather infrequent in AML. However, approximately 30% of 
childhood B-cell acute lymphoblastic cases carry a t(l2;21).64 The AMLl-TEL, fusion 
protein interferes in a dominant negative manner with AMLl-dependent transcription.64 
Besides AMLJ translocations, mutations in this gene also play a role in AML. Point 
mutations in AMLJ occur in less than 5% of de novo AML patients and especially in 
those that are poorly differentiated (MO). 27 
InAML with inv(l6), CBFI) is fused to MYHJJ (myosin heavy chain 11).65 The CBFj)-
MYHll fusion protein binds AMLl and represses transcription through mSin3 and possi-
bly other co-repressor molecules.66 Like AMLl fusion proteins, the CBFj)-MYHll fusion 
seems to act as a dominant negative suppressor of wild-type CBF. Both CBFI)-MYHll 67 
and AMLJ-ETO 68 knock-in embryos die in midgestation from haemorrhages and show a 
severe block in haematopoiesis, which resembles the phenotype seen in Cbfa and Cb.fl3 
knockout mice. Although this resemblance strengthens the perception that CBF fusion pro-
teins have dominant negative effects on the wild type proteins, particular distinct charac-
teristics of the fusion protein indicate that each may also have specific functions. 62·67·68 
c. llq23 translocations involving mixed lineage leukaemia (MLL) gene. 
The mixed lineage leukaemia (MLL) gene located on chromosome llq23 is engaged in 
more than 40 different leukaemia-associated translocations. The most common translo-
cations in AML are t(9;1l)(p22;q23), and t(6;ll)(q27;q23), which result in fusions 
between MLL with AF9 and AF6 respectively. Other translocations such as 
t(ll;l9)(q23;pl3.3) and t(4;1l)(q21;q23) occur less frequently inAML.42·69 Mll is a pos-
itive regulator of Hox genes and is required for the development of multiple tissues, 
including skeletal, craniofacial, neural, and haematopoietic development during embryo-
genesis.70·71 The knockout models have shown that Mll is required for normal numbers of 
haematopoietic progenitors and their proper differentiation, especially along the myeloid 
and macrophage pathways. Loss of one functional copy of Mil already results in defec-
tive yolk sac haematopoiesis and loss of both copies is embryonically lethal.71 The Mil 
+!- bone marrow harbour a significantly reduced number of haematopoietic colony 
forming cells. Elimination of both copies of Mil results in an even greater reduction in 
the number and proliferative potential ofhaematopoietic progenitors.72 
MostMLL translocations result in in-frame fusions between the N-terminalAT-hooks 
and methyltransferase domain of MLL and the C-terminal part of the fusion partner.69 
Thus the DNA binding and repressor domains of MLL are kept in most of fusion pro-
teins, while the transcription activation domain of MLL is lost."2 MLL fusion proteins 
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seem to transform myeloid progenitors through deregulation of HOX genes expression.73 
Besides translocations, rearrangements of MLL occur in about 5% of adult de novo acute 
myeloid leukaemia. Many of these leukaemias are of M4 and M5 cytological type and 
have a poor prognosis.26 
II. LESS FREQUENT TRANSLOCATIONS IN AML 
a. Translocations involving 3q26 abnormalities (EVIl gene). 
EVIl ( ecotropic virus integration site-1) is involved in pathogenesis of human leukaemias 
carrying 3q26 abnormalities, including translocation t(3;3)(q2l;q26) and inv(3)(q21q26)_74-77 
Although EVIl translocations are infrequent in AML,78 they are of remarkable prognostic 
value.79'80 Patients with these translocations are frequently resistant to therapy.81 
EVIl is a DNA binding protein, localized in the nucleus, and is probably involved in 
transcription regulation. 82 It exists also as a longer protein that includes 188 additional 
amino acids at theN-terminus, named MDSl-EVIl. MDSI-EVII is generated as a result 
of intergenic splicing between MDSJ gene and EVIl. Both EVIl and MDSJ-EVII are 
expressed at very low levels in the normal bone marrow. Although related, the two pro-
teins have opposite properties.83•84 EVIl has important roles in general proliferation and 
cell-specific development. Disruption of the full length Evil protein in homozygous 
mutant mice leads to embryonic death at E10.5, widespread hypocellularity and disrup-
tion in the development of the heart, somites, and neural crest-derived cells. 85 
Overexpression of EVIl in immature haematopoietic cells interferes with erythroid and 
granulocytic development.86•87 In AML with rearrangements of chromosome 3, EVIl 
gene is transcriptionally activated as a result of juxtaposition to the regulatory elements 
of RPNJ gene at 3q21.74•75 Transcriptional activation of EVIl is also observed in AML 
without rearrangements of chromosome 3, meaning that juxtaposition to RPNI is not the 
only mechanism that leads to EVIl overexpression.77.88"90 The frequency of EVIl overex-
pression and its impact on patients' prognosis remain to be addressed. In Chapter 2 we 
aim at determining the frequencies and the prognostic value of EVIl and MDSl-EVIl 
overexpression in de novo AML, irrespective of 3q26 abnormalities. 
The reciprocal translocation t(1;3)(p36;q21), which associates with poor prognosis, 
occurs in a small subset of AML and involves a gene with high homology to EVIl, the 
MDSl-EVIl-like-l (MELI) gene. MELI is thought to be transcriptionally activated as a 
result of juxtaposition to the RPNJ gene at 3q2l."1 It is not known whether MELI expres-
sion is restricted to cases with this particular translocation. In Chapter 3 we study MELJ 
expression in AML other than AML t(l ;3). Furthermore, we examine whether an EVIl 
like transcript (ELI) can also be expressed from the same locus. The prognostic impact 
of MELI and ELI mRNA level will be evaluated in the same chapter. 
b. Translocations involving TEL gene. 
The TEL (translocation ets leukaemia) gene also known as ETV6 (ets translocation vari-
ant gene 6), a member of ETS family of DNA binding genes, is involved in at least 41 
different translocations associated with human malignancies.92•93 Translocation t(l2;21), 
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which generates TEL-AMLl fusion protein is the most common genetic lesion in paedi-
atric acute lymphoblastic leukaemia (ALL). This translocation is detected in up to 25-
30% of the patients and often associates with a fully or partially deleted non-rearranged 
TEL allele.9""96 The TEL translocations in AML are comparatively infrequent.97 
The TEL gene encodes for a protein with transcription repressor activity, that regu-
lates cell growth and differentiation.98 Tel knockout mice are embryonic lethal and exhib-
it defective yolk sac angiogenesis and intra-embryonic apoptosis of mesenchymal and 
neural cells. Although Tel absence does not seem to affect haematopoiesis at the yolk sac 
stage,99 it is indispensable for the development of all lineages in adult bone marrow. In 
chimeric mouse with Tel knockout ES cells, defective haematopoiesis becomes manifest 
within the first week after birth.61 
The fusion partners of TEL have heterogeneous characteristics.92•93 Interestingly, the 
contribution of TEL to the fusion oncoproteins is variable.92 For example, the TEL-EVIl 
fusion does not contain functional TEL domains, suggesting that the only part of TEL 
that is crucial in this translocation is the TEL-promoter. In other words, in cells with a 
TEL-EVIl fusion, the EVIl gene is overexpressed as the result of activation by the pro-
moter of TEL. 100 In other translocations, TEL either provides dimerization domains in e.g. 
the fusion TEL-MNJ ,101 BTL-TEL'02 or TEL-ABL, 103 resulting in constitutively activated 
signaling proteins. In other cases, the transforming fusion proteins contain domains that 
harbour transcriptional regulatory properties, i.e. the ETS DNA binding domain in e.g., 
TEL-PDGFRW04105 and TEL-AML1. 64 As genes that are frequently involved in leukaemic 
translocations, e.g. AMLJ, 27 MLV6•69 and EVIl 77·88.90 may also be affected otherwise, it is 
possible that TEL abnormalities in AML are not limited to translocations. In order to 
examine this hypothesis, we investigate the occurrence of TEL mutations and abnormal 
protein expression in de novo AML (Chapter 5). 
Unbalanced chromosomal abnormalities 
Unbalanced chromosome abnormalities are observed in the form of loss and/or gain of 
chromosomal segments, monosomies and trisomies. 39 The molecular consequences of 
such numerical aberrations are presently not known. Deletions and monosomies of chro-
mosomes 5 and 7 are associated with poor prognosis. It has been proposed that loss or 
haploinsufficiency of tumour suppressor genes, as a result of deletions, are the trans-
forming events in these cases. 106 
Submicroscopic mutations associated with AML 
Malignant transformation is a multi-step process involving accumulation of several 
genetic alterations. Some of these genetic alterations are detectable by cytogenetic analy-
sis while others are submicroscopic and are only detectable by molecular genetic tech-
niques.39 In this paragraph two different types of submicroscopic aberrations will be 
introduced: 1- mutations in haematopoietic transcription regulators (e.g. CEBPA, PUJ, 
AMLJ and MLL) that result in impaired differentiation; 2- activating point mutations in 
genes encoding receptor tyrosine kinases (e.g. FLT3 and c-KIT) that provide a prolifer-
ative and/or survival signal to haematopoietic progenitors. 107 
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I. MUTATIONS IN HAEMATOPOIETIC TRANSCRIPTION REGULATORS 
As mentioned earlier, haematopoietic transcription regulators play a major role in both 
myeloid differentiation and leukaemic transformation.40 Besides AML1 mutations 27 and 
MLL rearrangements/6 occurrence of acquired heterozygous mutations in the coding 
region of CEBPA (CCAAT/Enhancer Binding Protein aY0' and PU1 109 have recently 
been reported in AML. Both PU 1 and C/EBPa are major regulators of gene expression 
during myeloid development<o.Iro (Figure 4). 
C/EBPa is a transcription factor essential for granulocytic differentiation.m Cebpa 
knockout mice lack mature granulocytes, while the development of other haematopoiet-
ic lineages is not affected. u2 Mutations in the C-terminus CEBPA (bZIP region) are in-
frame insertions that result in proteins with deficient transcriptional activation and DNA 
binding. These proteins though do not possess dominant negative activity.ll3.rr4 In con-
trast, mutations in CEBPA N-terminus are not in-frame and result in both a non-func-
tional truncated protein and an increase in the production of a 30 kD protein,ll3.us which 
has a dominant negative effect on DNA binding and transactivation of the wild type 
C/EBPa. u3 The exact frequency of the N- and C-terminal mutations in de novo AML 
patient, the clinical characteristics and prognosis are presently not known. By screening 
a large cohort of de novo AML, we aim at assessing the frequency and prognostic value 
of CEBPA mutations (Chapter 4). 
PU.l, a member of the ets family of transcription factors and the product of Spi-1 onco-
gene, is expressed exclusively in the haematopoietic system. Mice homozygous for a dis-
ruption in the Pu.l DNA binding domain lack mature macrophages, neutrophils, B cells 
and T cellsY6 Consistent with the findings that PU.l has a major role in myeloid devel-
opment, somatic mutations inPU1 have been reported in 7% (9/126) ofAML patients. 109 
However, this finding could not be confirmed by others_m.us As PU1 mutation analyses 
were carried out in relatively small number of AML patients, the frequencies and prog-
nostic significance of such mutations remain unclear. In this thesis, we investigate the 
occurrence of PU1 mutations in patients with de novo AML. The results of this study 
will be discussed in Chapter 7 (General discussion and summary). 
II. MUTATIONS IN RECEPTOR TYROSINE KINASES 
FLT3 internal tandem duplication (lTD) is the most frequent genetic aberration inAML. 
It occurs in 20-30% of de novo AML patients and correlates with poor prognosis.28 •119•120 
In addition to internal tandem duplications, point mutations in FLT3 have been identi-
fied in approximately 8% of AML patients.28 FLT3 together with other members of 
receptor tyrosine kinases family, e.g. c-ABL, c-FES, c-FMS, PDGFR~ and c-KIT are 
thought to be involved in the regulation of haematopoiesis. Phosphorylation of tyrosine 
residues of the receptor tyrosine kinases, following ligand binding, is the first step in the 
transmission of activating signals from the cell surface to the nucleus. 121 Flt3 knockout 
mice show deficiencies in the primitive B lymphoid progenitors. Mice deficient for both 
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Flt3 and c-Kit exhibit a more severe phenotype characterized by overall decrease in 
haematopoietic cell numbers and postnatal lethality. 122 In AML, mutations in receptor 
tyrosine kinases usually result in constitutive activation of the receptor leading to uncon-
trolled cell proliferation, inhibition of apoptosis, and blockage of differentiation. 121 •123 
Several FLT3 inhibitors are currently in various stages of pre-clinical and clinical devel-
opment to specifically treat AML with FLT3 mutations. 124 
Murine myeloid leukaemia: a model for identification of leukaemia 
associated genes 
A powerful and rapid approach to identify transforming genes in leukaemia is retroviral 
insertional mutagenesis. In fact, by applying this technology a large series of potentially 
transforming genes have been identified by different research groups.125"130 The involve-
ment of a number of genes first identified in murine leukaemia has subsequently been 
demonstrated in human leukaemia, e.g. Evil/5 Pu.l(Spil)/09 Cbj,56 Myc, 131 YY1 132or 
Bcl2,133 Nfl/ 34 P53135 andHoxa9. 136 
Insertional mutagenesis in murine leukaemia usually activates transforming genes by 
enhancing their transcription.137 The same mechanism is observed in patients with 3q26 
abnormalities. In these cases, juxtaposition to the regulatory elements of RPNJ gene 
results in EVIl over expression.75 In this thesis we will investigate the mRNA expression 
patterns of potential transforming genes, identified in murine leukaemia, i.e. EVIl, 
HOXa9, HOXa7, MEISJ, CB2, PU.l, NM23-HJ, NM23-H2 and SOX4 in a cohort of de 
novo AML patients. Subsequently, the expression patterns will be related to clinical char-
acteristics and therapy outcome. The results of these studies will be discussed in 
Chapter 7 (General discussion and summary). 
Besides altering transcription, retroviral insertion may disrupt the coding region of 
genes, resulting in production of abnormal proteins. One example is c-MYB. Retroviral 
insertion within the c-Myb gene generates truncated N-terminus MYB protein that con-
tributes to oncogenicity of c-MYB.138 MYB is important for development of myeloid, 
lymphoid and erythroid cells and the c-Myb (-/-) mice lack all these lineages. 139•140 
Removal of the C-terminal negative regulatory domain increases the trans-activating 
capacity and oncogenic activation of c-Myb.14l,r42 Although an involvement of c-MYB in 
human AML has not been demonstrated, there is strong evidence that aberration in this 
gene results in defective haematopoiesis. Therefore, we decided to investigate the occur-
rence of c-MYB mutations in humanAML. The results of this study will be discussed in 
Chapter 7 (General discussion and summary). 
Challenges in determining prognosis of AML 
As introduced above, certain genetic abnormalities in AML are associated with progno-
sis. For example, translocations t(8;21), t(l5;17) and idt(l6) associate with favourable 
prognosis, whereas -5/5q- or -7/7q-, t(6;9), and complex karyotype are linked to poor 
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outcome. 24 Even though the two categories of favourable and unfavourable AML can be 
distinguished, intra-categorical variations in therapeutic response and outcome are 
observed,39 suggesting the involvement of additional genetic abnormalities. For example 
c-KITmutations, which are observed in one third of AML patients with inv(16), adverse-
ly affect the prognosis.143 
Besides the heterogeneity of the disease, patient-related factors such as age and gen-
der impact on the prognosis of the patients. AML patients older than 60 years have a sig-
nificantly lower response rate and shorter survival as compared to the younger patients. 
This is not only because of comorbidity and a higher incidence of secondary AML but 
also because of the distinct disease biology.24 Leith et al'44 demonstrate an increased fre-
quency of unfavourable cytogenetics and drug resistant phenotypes in patients of older 
age. For instance the multidrug resistance protein MDRl is expressed in 71% of the 
older patients and only in 30% in the younger cases. MDRI is a transmembrane efflux 
pump that actively exports drugs, such as anthracyclines, out of the leukaemic cells and 
reduces their intracellular concentration.145 The reduced intracellular concentration of 
anthracyclines is associated with a low response rate. 146•147 
Genetic variations affecting pharmacodynamics and pharmacokinetics of the drugs 
may also determine therapy response. 148 Examples of such variations are polymorphisms 
in Glutathion S-transferases (GSTs). GSTs are detoxifying cytosolic enzymes that con-
jugate glutathione (GSH) with compounds containing an electrophilic centre. 149•150 The 
Ml and Tl subtype of GST show deletion polymorphisms, which in case of homozy-
gosity (null genotype) leads to the absence of the enzymes.151 The percentages of GSTMJ 
and GSTTJ null genotypes vary from 22 -90% and 12 -38% respectively in different eth-
nical groups. Deletions of these genes might affect the response to several chemothera-
peutic agents, such as anthracyclines. GSTs can alter the cytotoxic effect of anthracy-
clines by 1- decreasing its cytotoxicity through glutathione conjugation which is neces-
sary for transportation of anthracyclines outside the cells by P-glycoprotein, MRPl and 
other ABCs, 152 2- preventing the access of anthracyclines to the nucleus following con-
jugation to glutathione,153 3- deactivating the reactive oxygen species, which are pro-
duced by anthracyclines and are partly responsible for their cytotoxic effects. 154•155 
Although several studies have focused on the relationship between GST null polymor-
phism and the failure of chemotherapy, the results of these studies remain contradictory. It 
should be noted that the lack of agreement might relate to differences in the study design 
(i.e. number and selection of patients included), chemotherapeutic regimens (type of 
anthracyclines and the dosage) and the ethnic background of the patients. In this thesis we 
aimed at determining the prognostic impact of GSTMJ and GSTTJ polymorphisms and 
expression levels in a large cohort of de novo AML patients (Chapter 6). 
At present, a profound understanding of the individual prognostic factors is becom-
ing of significant importance for treatment choice in AML. Treating AML patients car-
rying t(l5;17) withATRA is a classic example of this approach.24 However, in more than 
half of the AML cases we are still not capable of pointing out a single abnormality with 
defined prognostic value. New parameters with enhanced prognostic significance are 
required to both predict the outcome and apply risk-adapted treatment. 
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The scope of this thesis 
The main objective of this thesis is to identify novel prognostic markers in AML. We 
studied aberrations in important haematopoietic transcription regulators and examined 
the role of potential oncogenes, which had been identified by means of retroviral inser-
tional mutagenesis in murine leukaemia. Furthermore, we considered patient-related fac-
tors that may affect pharmacodynamics or pharmacokinetics of chemotherapeutic 
agents. The prognostic significance of a variety of these factors was investigated by mul-
tivariable analysis in patients with newly diagnosed AML. 
In chapter 2 we assessed the frequencies and prognostic impact of EVIl and MDSl-
EVIl overexpression in a cohort of 319 de novo AML patients. 
In chapter 3 we evaluated expression of MDSJ-EVIllike (MELJ) gene in AML other 
than AML t(l;3). Furthermore, we examined the existence of an EVIl like transcript 
(ELl). The clinical characteristics of AML with MELJ and ELl mRNA expression are 
also presented in this chapter. 
In chapter 4 we developed a rapid assay for simultaneous detection of CEBPA C-ter-
minal mutations and quantification of mRNA expression levels. Furthermore, we 
assessed the clinical, haematological and prognostic impact of CEBPA mutations and 
variation in CEBPA expression levels. 
In chapter 5 we investigated the involvement ofTEL (ETV6) aberrations in the novo 
AML cases by nucleotide sequencing and Western blot analysis. 
In chapter 6 we addressed the prognostic impact of GSTMJ and GSTTJ polymor-
phisms and expression levels in a cohort of de novo AML patients. 
In chapter 7 (general discussion) we discuss the factors determining the prognosis of 
AML patients. 
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Abstract 
The proto-oncogene EVIl encodes a DNA binding protein and is located on chromo-
some 3q26. The gene is aberrantly expressed in acute myeloid leukaemia (AML) patients 
carrying 3q26 abnormalities. Two mRNAs are transcribed from this locus, i.e. EVIl and 
a fusion of EVIl with MDSJ (MDSJ-EVJJ), a gene located 5' of EVIl. The purpose of 
this study was to investigate which of the 2 gene products is involved in transformation 
in human AML. To discriminate between EVIl and MDSJ-EVII transcripts, distinct real-
time quantitative polymerase chain reaction (PCR) assays were developed. Patients with 
3q26 abnormalities often showed high EVIl and MDSJ-EVII expression. In a cohort of 
319 AML patients, 4 subgroups could be distinguished: EVIl+ and MDSJ-EVII- (6 
patients; Group 1), EVIl+ and MDSJ-EVll+ (26 patients; Group II), EVIl- and MDSJ-
EVll+ (12 patients; Group III) and EVIl- and MDSJ-EVII- (275 patients; Group IV). 
The only 4 patients with a 3q26 aberration belonged to Groups I and II. Interestingly, 
high EVIl and not MDSJ !EVIl expression was associated with unfavourable karyotypes 
(e.g -7/7q-) or complex karyotypes. Moreover, a significant correlation was observed 
between EVIl expression and llq23 aberrations (MLL involvement). Patients from 
Groups I and II had significantly shorter overall and event-free survival than patients in 
Groups III and IV Our data demonstrate that high EVIl expression is an independent 
poor prognostic marker within the intermediate-risk karyotypic group. 
Introduction 
The EVIl proto-oncogene is located on human chromosome 3q26 and is involved in patho-
genesis of human acute myeloid leukaemia (AML) or myelodysplatic syndrome (IviDS) 
carrying 3q26 rearrangements.12 Although these rearrangements are infrequent in AML, 
they are of remarkable prognostic value. Patients with these karyotypes often do not 
respond to therapy, even when the most active antileukemic therapeutic options are used.3 
EVIl encodes a nuclear DNA binding protein with 2 zinc finger domains, i.e. anN-
terminal domain containing 7 zinc fingers and a more C-terminal domain with 3 zinc 
fingers. Both domains recognise and bind to specific DNA consensus sequences.4•5 
While most reports indicate that EVIl gene expression is not detectable in normal blood 
or bone marrow, 6"9 other studies suggest low but detectable expression of EVIl in normal 
bone marrow cells. 10 High expression of EVIl has been observed in developing oocytes 
and in kidney.u Although the exact mechanism of transformation by EVIl is still 
obscure, several studies have shown that inappropriate expression of EVIl in immature 
haematopoietic cells interferes with erythroid and granulocytic development. 12 It has pre-
viously become evident that EVIl may form a fusion transcript with the MDSJ gene. 
MDSJ is a 4-exon gene located upstream of EVIl. Splicing may occur from exon-2 of 
MDSJ to the second exon of EVIl, to form the fusion transcript MDSJ-EVII. This inter-
genic splicing may occur in normal tissues as well as in myeloid leukaemia. 1' 13 MDSJ-
EVll encodes a longer protein containing the entire EVIl protein but with an addition-
al, unique N-terminal extension. Although related, the two proteins EVIl and MDSl-
EVIl may have opposite properties. 14•15 
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Previous studies showed that EVIl may be expressed in patients without 3q26;8•9•16•17 how-
ever the sets of PCR primers that were chosen in these studies did not discriminate 
between EVIl and MDSI-EVIJ. We designed different primer and probe combinations 
to discriminate between EVIl and MDS-EVIJ and quantify the transcript levels by means 
of real-time PCR analysis. To provide an answer to the question, which of these tran-
scripts are expressed in patients with 3q26 rearrangements, we first screened 7 patients 
carrying 3q26 abnormalities. Using the same technique we studied the expression levels 
of these transcripts in the bone marrow samples of healthy volunteers. To investigate how 
frequently EVIl, MDSI-EVIJ or MDSI may be expressed in de novo AML, we deter-
mined expression levels of these transcripts in a cohort of 319 AML patients at diagno-
sis. The results were analysed in relation to haematological, cytogenetic and clinical 
characteristics as well as outcome of therapy. Our data demonstrate that expression of 
EVIl and not of MDSI-EVII is associated with highly aggressive AML. High EVIl 
expression occurs with high frequency in patients without 3q26 abnormalities, suggest-
ing other mechanisms of aberrant EVIl expression. 
Material and methods 
Patients and healthy volunteers 
Bone marrow samples of AML patients at diagnosis and of healthy volunteers (n=9) 
were obtained after informed consent. Blasts from AML patients and mononucleated 
fractions from normal bone marrow specimens were isolated from the samples by Ficoll-
Hypaque (Nygaard, Oslo, Norway) centrifugation. 18 The cells were then cryopreserved as 
described in Delwel et al.'9 After thawing cells were washed with Hanks Blanced Salt 
Solution (HBSS) and further processed for RNA isolation. AML samples treated accord-
ing to this procedures usually contain more than 90% blasts after thawing. 19 Seven 
patients with 3q26 rearrangements ( 4 patients with AML, 2 with refractory anaemia with 
excess blasts in transformation [RAEB-t] and 1 chronic myelogenous leukaemia) were 
selected that had not been included in a clinical trial. A total of 319 de novo AML 
patients who had been referred to our institution and collaborating centres between 1987 
and 2000 were chosen for analysis. Of these patients 229 patients were treated accord-
ing to the HOVON-29 (Dutch-Belgian Haematology-Oncology Group) protocol, 66 
according to the HOVON-4 protocol, and 13 according to the HOVON-31 protocol. 
These treatment protocols have been described elsewhere.20 Eleven patients received 
other forms of treatment. The clinical and haematological characteristics of the 319 
patients at diagnosis are shown in Table 1. AML samples were classified according to the 
French-American-British (FAB) nomenclature.21 
RNA isolation, eDNA synthesis and real-time PCR 
Total RNA was extracted with guanidium thiocyanate followed by centrifugation in 
cesium chloride solution. Then 1 ml RNA was transcribed into eDNA using Superscript 
(Life Technologies, Merelbeke, Belgium) and Random Hexamers in a 40 ml reaction, 
under standard conditions. 
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An aliquot of one 20th of the resulting eDNA was used for quantitative PCR amplifica-
tion. Real-time PCR amplification was performed with the ABI PRISM 7700 Sequence 
Detector (Applied Biosystems, Nieuwekerk aan den IJssel, the Netherlands), using 50 ml 
mix containing 2 ml eDNA sample; 250 mM dNTPs (Amersham Pharmacia Biotech Inc, 
Roosendaal, the Netherlands); 15 pmol forward and reverse primer (Life Technologies); 
3 mM MgC12 (5 mM for PBGD reaction), 200 nM probe, labelled at the 5' end with the 
reporter dye molecule FAM (6-carboxy-fluorescein) for EVIl, MDSJ-EVIJ and MDSJ, 
JOE (carboxyrhodamine) for PBGD, and at the 3' end with the quencher dye molecule 
TAMRA (6-carboxy-tetramethyl-rhodamine; Eurogentec, Maastricht, the Netherlands); 
5 ml10x buffer A; 30 ml water; and 1.25 U AmpliTaq Gold (Applied Biosystems). The 
thermal cycling conditions included 10 minutes at 95°C followed by 45 cycles of denat-
uration for 15 seconds at 95°C, annealing/extension at 60°C for 30 seconds. The 
primer/probe combinations were chosen such that we could discriminate between EVIl, 
MDSJ!EVII and MDSJ transcripts (Figure 1). The oligonucleotide sequence of the 
primers and probes are shown in Table 2. 
I 
I 
I 
Table 1. Demographic and clinical characteristics of 319 de novo AML patients. 
Sex, no. 
Male 
Female 
Age, median (range), y 
Age group, no. 
Younger than 35 y 
35-50y 
Older than 50 y 
FAB, no. 
MO 
M1 
M2 
M3 
M4 
M5 
M6 
Unclassified 
Cytogenetic risk group, no. 
Favorable 
Intermediate/unknown* 
Umfavoni.ble 
WBC count, median (range), 109/L 
Blast count, median (range), % 
Platelet coiJnt, median (range), 1 09/L 
167 
152 
45.1 (15.2-76.8) 
89 
112 
118 
10 
68 
74 
33 
56 
67 
4 
7 
57 
212 
50 
23.4 (0.3-282) 
69 (0-98) 
49 (3-931) 
FAB indicates French-American-British classification;21 and WBC, white blood cell. 
*For 6 patients of this group, no cytogenetic information was available at diagnosis. 
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Figure 1. Schematic representation of EVIl and MDSJ-EVIJ and the primer and 
probes used for real-time PCR. Primers 1 and 2 plus probe A were used to dete1mine 
MDSI-EVII expression levels. EVIl transcript levels were determined using primers 
3 and 2 plus probe A. MDSI expression was measured using primers 1 and 4 plus 
probe B. Probe C is used for northern blot analysis. 
Table 2. Oligonucleotide primer and probe sequences used for quantitative 
real-time PCR. 
Primer 1 
Primer 2 
Primer 3 
Primer 4 
Probe A 
Probe B 
PBGD forward primer 
PBGD reverse primer 
PBGD probe 
Oligonucleotide sequence (5'-3') 
GAAAGACCCCAGTTATGGATGG 
GTACTTGAGCCAGCTTCCAACA 
CTTCTTGACTAAAGCCCTTGGA 
TCTCTTCCCCAAATACAACCAAG 
TCTTAGACGAATTTTACAATGTGAAGTTCTG 
CTTCCAAGGTCTCGGAGGGTAAGCGTTC 
GGCAATGCGGCTGCAG 
GGGTACCCACGCGAATCAC 
CATCTTTGGGCTGTTTTCTTCCGCC 
Using seven different dilutions of a eDNA sample (equal to 0.0064-100 ng total RNA) 
prepared from AML cells that were positive for each of the transcripts (patient 2, Table 
3), standard curves were made for EVIl and MDSI-EVII. As the expression levels of 
MDSI transcripts were too low to measure the efficiency of amplification, MDSI expres-
sion was considered positive(+) when the threshold cycle (Ct) value was below 35. 
To determine the expression levels in AML, all samples were tested in duplicate, and 
the average values were used for quantification. To quantify the relative expression of 
EVIl and MDSI-EVII, the Ct values were normalised for endogenous reference (oCt = 
Ct target- Ct PBGD) and compared with a calibrator, using the 'delta-delta Ct 
method'(MCt= oCt Sample -OCt Calibrator). As calibrator we used the average Ct value of 
EVIl and MDSI-EVIJ in the 9 bone marrow samples of the healthy volunteers. We used 
the MCt value to calculate relative expression (2·Mc'). As the MCt method is applicable 
only when the amplification efficiencies of the target and the reference are essentially 
equal, we analysed the efficiencies for another 4 patients (patients 25, 28, 29, and 30; 
Table 4) using the same dilutions indicated above. The oCt values (Ct target- Ct PBGD) 
were plotted against the concentrations of total RNA (log). The slope of the fitted line 
was then determined. A slope of less than 0.1 is then indicative for equal efficiencies. 
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To define high EVIl and MDSJ-EVIl expression, a cutoff value of 50 (relative expres-
sion 2- aact) was chosen. This value was chosen to avoid the influence of particle distribu-
tion statistics, particularly in those cases with a slightly higher EVIl and MDSJ-EVIJ 
expression. To prevent bias the survival analysis was also performed at cut off points 10, 
25 and 100. 
Northern blotting 
Northern blotting was carried out on mRNA isolated from healthy bone marrow samples 
as well as AML samples. A portion (20 mg) total RNA of each sample was separated on 
a 1% agarose, 6% formaldehyde gel, and blotted with lOx SSC onto hybond-N+ nylon 
membrane (Amersham). The blot was hybridised in IN NaH2P04-buffer containing 7% 
sodium dextran sulphate, and 1 mM EDTA pH 8.0. As probe, human EVIl (600bp 
Hindiii-Ncol fragment) and murine GAPDH (777 bp Hindlll-EcoRI fragment)22 were 32P 
labelled by random priming (Boehringer, Mannheim, Germany). The blot was hybridised 
at 65 oc overnight and washed for 15 minutes at 65 OC in 2x SSC/ 0.5% SDS, and for 15 
minutes at 65 OC in 1x SSC/ 0.5 SDS. It was then analysed by autoradiography. 
Cytogenetic analysis and stratification according to karyotype risk group 
Cytogenetic analysis was carried out according to standard techniques, and the abnor-
malities were categorised in 3 cytogenetic groups. Patients with inv(16)/t(16;16), t(8;21) 
and t( 15; 17) abnormalities were considered as being in the favourable-risk category. The 
unfavourable-risk category was defined by the presence of -5/del(5q), -7del(7q), t(6;9), 
t(9;22), 3q26 abnormality or complex karyotype (more than 3 abnormalities). All other 
patients were classified as intermediate-risk. Karyotypes were described according to 
International System for Human Cytogenetic Nomenclature (1995). 
Analysis of FLT3 internal tandem duplication mutations in AML 
The internal tandem duplications in exon 11 of the human FLT3 gene were determined 
as described previously.23 Briefly, eDNA (derived form 50 ng total RNA) and genomic 
DNA (1 mg) were subjected to PCR using primers 11F 5' -CAATTTAGGTAT-3' and 11R 
5'-CAAACTCTAAATTTTCTCT-3'. The PCR cycling conditions were as follows: 3 
minutes 94°C followed by 30 cycles 1 minute 94°C, 1 minute 54°C, 1 minute 72°C; and 
a final step of 10 minutes 72°C. PCR products were resolved on a 2.5% agarose gel. 
Statistical Analysis 
Statistical analysis was performed with the Stata Statistical Software, Release 7.0. (Stata, 
College Station, TX). Spearman's rank correlation, Pearson's chi-square test and Kruskal-
Wallis test were used to assess the association between EVIl and MDSl-EVIl expression 
and the clinical and haematological characteristics of patients. Actuarial probabilities of 
overall survival (OS; with failure death due to any cause) and event-free survival (EFS; 
with failure in case of no complete remission [CR] at day 1, or at relapse or at death in 
first CR) were estimated by the method of Kaplan and Meier. The Cox proportional 
hazard model was applied to determine the association of high EVIl expression with OS 
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and EFS, without and with adjustment for other factors as age, cytogenetic risk and FLT3 
internal tandem duplication (FLT3-ITD). All tests were done two-sided, and a P of less 
than 0.05 was considered statistically significant. 
Results 
Quantification of EVIl, MDSl-EVIl and MDSl by real-time PCR 
EVIl, MDSl-EVIl and MDSl expression levels were analysed using real-time PCR 
employing specific primer/probe combinations (Figure 1; Table 2). Efficiency of the 
quantification method for EVIl andMDSl/EVII was examined by standard curves made 
using mRNA isolated from AML samples that were positive for EVIl or MDSl-EVII. 
Linear correlation between Ct values versus copy number was obtained for EVIl and 
MDSl-EVIl with correlation coefficients of 0.94 and 0.98 respectively. The efficiency 
of amplification, determined in eDNA obtained from a bone marrow sample of patient 
2, was approximately 1.00 for EVIl, 0.95 for MDSl-EVII and 0.96 for PBGD. To eval-
uate whether the MCt method that used in our study, was indeed applicable we verified 
the differences in efficiencies of amplification in another 4 AML samples (samples 25, 
28, 29 and 30). The slopes of the fitted lines for the mean oCt values at different mRNA 
concentrations were -0.089 for EVIl and 0.036 for MDSl-EVII, indicating that the MCt 
method was indeed applicable. The expression levels of MDSl transcripts were too low 
to measure the efficiency of amplification. Therefore we decided not to quantify the 
MDSl expression level but to show whether it is expressed(+) or not(-). 
As calibrator we used the average expression of EVIl and MDSl-EVII in 9 bone mar-
row samples of healthy volunteers. The mean Ct values of EVIl and MDSl-EVII in these 
normal samples were 38.4 ± 1.5 and 38.3 ±2.6 respectively. The values obtained were 
normalised for the internal reference, PBGD. The mean PBGD value for normal bone 
marrow samples was 23.2 ± 0.9. MDSl expression was undetectable in bone marrow 
samples of healthy volunteers. 
EVIl, MDSl-EVII and MDSl expression in AML patients 
carrying 3q26 abnormalities 
The relative expression of EVIl and MDSl-EVIl transcripts in patients with 3q26 abnor-
malities is shown in Table 3. In 3 AML patients carrying an inv(3)(q22;q26) and in 1 AML 
patient with a translocation t(3;3)(q22;q26), high expression of EVIl as well as MDSl-
EVIl transcripts was observed. One of the 2 RAEB-t patients with t(3;12) showed high 
EVIl levels and a moderate increase in MDSl-EVIl expression, while in the other RAEB-
t case MDSl-EVIl expression was high and EVIl expression was comparable to normal 
bone marrow. A CML patient with t(3; 17) showed weak expression of EVIl and no 
detectable expression of MDSl-EVIl. Expression of MDSl was observed in patient 6 only. 
Northern blot analysis was carried out using an EVIl eDNA probe on total mRNA iso-
lated from 2 patients (patient 2 and 3) carrying inv(3)(q22q26) and a CML patient 
(patient 7) with a translocation t(3; 17) (Figure 2). Although this probe does not 
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Table 3. EVIl, MDSJ-EVIJ, and MDSJ expression in 7 AML patients with 3q26 abnormalities. 
PatJent FAB 
MS 
Mt 
MO 
M4 
RAEB-t 
RAEB-t 
CML 
Cytogenetic abnormalities* 
inv(3)(q22q26),-7 
inv(3)(q22q26) 
inv(3)(q21q26) 
1(3;3)(q22;q26) 
t(3;12)(q26;p13) 
t(3;12)(q25a26;p12), del(7)(q22) 
t(3;17)(q26;q22),t(1 ;17;9;22) 
(p36;q12;q34;q11)/de1(11 )(p11.1 p14) 
otEVHt of MDS1-CVI1t MDS1¥ 
1 618 104 
4390 4390 
4 771 416 
2353 1 448 
1 951 35 
1 11 585 + 
30 
*According to the ISCN. t Values represent expression levels of Evil and MDSJ-EVIJ as compared 
with the average values determined in 9 healthy bone marrow samples 2 ·''''(see "Patients. materials 
and methods").¥ MDSl expression was considered positive(+) when the Ct value was below 35. 
3 2 C1 N1 7 34 9 8 C2 C3 N2 
discriminate between the EVIl and MDSl-EVIJ transcripts, high expression as 
observed by real-time PCR was confirmed. No expression was observed by Northern 
blot analysis in a normal bone marrow sample (N1) or in a sample from an AML 
patient without 3q26 abnormality (Cl); these 2 samples were negative for different 
transcripts as determined by real-time PCR (Figure 2). 
EVIl, MDSl-EVIJ and MDSl expression in a cohort of 319 de novo AML patients 
The expression levels of EVIl, MDSl-EVIJ and MDSJ were next investigated by real-time 
PCR in bone marrow samples of 319 newly diagnosed patients with AML. This cohort did 
not include the 7 patient from Table 3. Of these 319 patients, 44 expressed EVIl, MDS-
EVII or both (Table 4): 6 expressed EVIl only (Group I), 26 expressed EVIl as well as 
MDSl-EVIl (Group II) and 12 expressedMDSl-EVIJ only (Group III). In the remaining 
275 cases (Group N) neither EVIl nor MDSl-EVIJ was expressed. In 15 patients MDSl 
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Table 4. Cytogenetic characteristics and FAB classifications of 44 de novo AML 
patients with high EVIl and or MDSl-EVIl expression. 
Relative Relative 
expression expression of 
Patient no. and group Karyotype• FABt ofEl/11* MDS1-£\Il1'f; 
Group I, EV/1+ and 
MDS1-£VI1-
46,XX,r(2)(p?q?) ,add(5){q1 ?3),der(11 )t(11 ;12)(q1 ?4;p13), der(12)t(11 ;12) Mx 1176 
(q1 ?4;p13)del(12)(p13p13)[23Y4S.idem, - 7[3Y46.XX[6] 
9 46,XX[68] M4 3 821 
1D 46,XX,I(1;6)(p32;q24or25).del(2)(q34)[33]/46,XX[1] MD 4420 
11 43-45,XY. -3[19], -5[4],der(5)1(5;17)(q1 ?3;q2?1 )[15], - 7[19],i(8)(q1 D)[11], M6 4 705 
-11 [13], -17[19],ider(19)(q1 D)add (19)(q13)[1 8].add(2)(q1 ?3)[13]/ 
46,XY[2] 
12 45.XY.Inv(3)(q12q26.2).- 7[2D] MD 19 552 
13 46,)()(, -7[27]/46XX[3] M4 24920 
Group II, EVf1+ and 
MDS1-EVJ1+ 
14 46,XY[23] M5 53 22D 
15 46,XX,der(6)1(6; 11)(p12;q23),der(11 )1(6;11 )add(11 )(p15)[4V46,XX[6] M4 55 685 
16 47,XY,+8[4V46,XY[16] M5 93 220 
17 47,XX,+13[58V46,XX[1] M5 141 12810 
18 46,)()([34] M1 149 34D 
19 46.XY. -7.add(12)(p12)[13]/46,XY[15] Mt 179 95950 
2D 45.XY, -7.1(7;8)(q22;p11 )[25] M5 3D8 12 766 
21 46,XX,1(9;22)(q34;q11 )[1 D] M2 389 15 936 
22 46,XX,I(9;11)(q34;q23)[5] M1 578 15771 
23 46.XY,I(3;3)(q2?3;q26). -7,1(1 D;2D)(p13;q11 ), +r.ishr(7)(cen7 + )[5]146, Mx 699 25532 
ldem,l(21)(q1D)[8]/46,1dem.ins(12;?)(q1?5;?) [2]/46,XY[4] 
24 45.XY.-7[5V46XY[4] M2 69D 1 716 
25 46,XY,I(9;22)(q34;q11 )[22] M2 2436 14067 
26 46,XX,del(7)(q22)[41],46,XX[1] M2 2513 231 395 
27 46,XX[1D] M5 2 947 32 996 
28 46,XY,1(6;11)(q25;q23)[38] M1 3083 156 956 
29 46,XY[4D] M5 3456 151 085 
3D 45,XY. -7,1(9;11)(p21 ;q23)[33] M4 3916 29 944 
31 46,XY,t(11 ;19)(q23;p13)[11] M4 4513 31 542 
32 46.)()(,1(2;9;11 )(p13;p22;q23)[20] M4 4804 21174 
33 46,XX,I(9;11 )(p21 ;q23)[1 O] M5 7383 25268 
34 45,XY,-7[33]/46,XY[8] M3 9541 15286 
35 45,XY,inv(3)(q22q26),-7[25] M5 12119 551 
36 Failure M5 16 845 5349 
37 46,XV.I(6;11 ;1 8)(q26;q23;q23)[23] M5 17 560 150 562 
38 46,XY,der(3)de1(3)(p1?4q2?4)add(3)(q24),del(18)(q22q24)[5]146,idem, MD 19082 28 725 
del(6)(q11 q27)[2].del(7)(q272q36)[cp3]/45, idem, -7[9Y46,XY[1 0] 
39 45,XX,inv(3)(q22q26).-7[31V46.XX[1] M5 27 554 3 040 
Group Ill, EV/1- and 
MD$1-EV/1+ 
4D 46.XX[31] M5 53 
41 46,XY[32]. M2 67 
42 46,XX,inv(16)(p13q22)[B]/47,XX,idem,+22[47] M4 70 
43 46,XY,del(12)(q11q21),t(15;17)(q22;q11)[65] M3 73 
44 46,)()([37] M2 88 
45 47,XX, +21 [22V46,XX[7] M2 129 
46 46,XY.del(6)( q 14q16), 1(1 0; 17] (p 15;q21 ), ?der(11 )[7]146.XY[3] M1 151 
47 45.X,-Y ,1(8;21 )(q22;q22) ,-13[27]/46XV[1J M2 165 
48 44,XX,add(2),-5,-7[2]/45.XX,dic(5;7)(p1;p1)del(5)(q3?1q3?3)[2V37- M3 209 
42,XX,der(1 )1(1 ;4 )(q 1 ?;pt ?) , - 4,dlc(5;7)(p 1 ;p 1 )de1(5)( q3? 1 q3?3). 
del(8)(p?21 ;p2?2).inv(1 O)(p12q?23), -15.add(15)(q2?3).dlc(17;?) 
(p11 ;?),-18,del( 20)(q11q13)/46,XX[13] 
49 46,XX.Inv(111(p15q13),1(15;17)(q22;q12)[28]/46,XX[1] M3 209 
50 46,XY[52] M3 296 
51 46.XX[26] Mt 28 725 
Group IV (EVI1- and MD$1-EV!r-) contained 275 of the 319 patients analyzed. 
·According to the ISCN.22 
tMx Indicates FAB not defined. 
MDS1 
express.~ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
tValues represent expression levels of EV11 and MD$1-EV/1 as compared with the average values determined in 9 healthy bone marrow samples 2-BaCI (see "Patients, 
materials, and methods"}. 
§MD57 expression was considered positive ( +) when the Ct value was below 35. 
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gene (+)was detectable. MDSJ expression was always associated with high EVIl plus 
MDSJ-EVJllevels (Table 4). 
To confirm the results obtained by real-time PCR, Northern blot analysis was carried 
out in 6 cases. Patients who appeared to be highly positive for EVIl and/or MDSJ-EVIJ by 
real-time PCR (patients 8, 9 and 34) also showed the proper sized transcripts by Northern 
blotting analysis (Figure 2). Two patients who were negative by real-time PCR (C2 and C3) 
and a normal bone marrow sample (N2) showed no transcripts by Northern blot analysis. 
3q26 abnormalities in de novoAML samples expressing EVIl or MDSJ-EVIJ 
Cytogenetical analysis among the 44 patients who were positive for EVIl and/or MDSJ-
EVIJ, revealed that only 4 AML patients (patients 12, 23, 35, 39) carried a 3q26 abnor-
mality (Table 4). None ofthe patients within group IV (EVIl- andMDSJ-EVIl-) carried 
3q26 aberrations. 
EVIl expression correlates with unfavourable karyotypes 
3q26 defects in AML are frequently accompanied by additional unfavourable cytogenet-
ic abnormalities (e.g. -7/7q-). In fact, in 2 cases in Table 3 (patients 1 and 6) and all4 
cases with a 3q26 aberration shown in Table 4 (patients 12, 23, 35, 39), chromosome 7 
abnormalities were observed. We next investigated whether EVIl and/or MDSJ-EVIJ 
expression in de novo AML without a 3q26 abnormality also correlated with the pres-
ence of poor-risk karyotypes (Tables 4 and 5). In 67% cases ( 4 of 6) from group I (EVIl 
only) and 42% of patients (11 of 26) from group II (EVIl+ and MDSJ-EVIJ+), 
unfavourable karyotypic abnormalities, i.e. -7/7q-, -5/5q-, t(9;22), t(6;9) or complex 
karyotypes (> 3 abnormalities) were present. In contrast, only 8% (1 of 12) of the 
patients from group III (EVIl- andMDSJ-EVIJ+) and 12% (33 of275) ofthe patients 
from group IV (EVIl- and MDSJ-EVIl-) carried unfavourable karyotypes. Thus EVIl 
expression (Groups I and II) correlated with unfavourable karyotypes (p< 0.0001), 
whereas the presence of MDSJ-EVIJ alone (group III) did not. Moreover, favourable-risk 
karyotypes, i.e. t(8;21), t(15;17) or inv(l6) were not noted in any ofthe EVIl- express-
ing AML patients from Group I or Group II. In contrast, 33% (4 of 12) of the patients in 
group III (EVIl- and MDSJ-EVIJ+) and 19% (53 of 275) of the patients in group IV 
(EVIl- and MDSJ-EVIJ-) exhibited favourable-risk karyotypes (Table 5). 
Among the 212 cases that belong to the leukaemias with intermediate-risk karyotype, 
14 showed an 11q23 translocation (MLL rearrangement). Interestingly, 8 of these 14 
Table 5. Distribution of different karyotypic risk categories and FlT3-ITD 
mutations among groups of AML patients. 
Risk karyotype, no. 
Flt3-ITO, no. Favorable* Unfavorablet I ntermediatetunknown:j: 
Group I, EVf1+ and MDS1-EV11-
Graup U, EV/1+ and MDS1-EVf1+ 
Group Ill, EV/1- and MDS1·EVft+ 
Group IV, EV/1- and MDS1-EV11-
*t(8;21), t(15;17) or inv(16}, 
26 
12 
275 82 
t-717q-, -5/sq-, t(9;22), 1(6;9) or complex karyotype (>3 abnormalities). 
+Other cytogenetic aberrations or normal karyotype. 
44 
53 
12 
1 
33 
14 
7 
189 
patients (57%) were found in Group II, that is, patients expressing EVIl+ and MDSl-
EVIl+ (Table 4). These data suggest a strong correlation between EVIl expression and 
the presence of MLL rearrangements. 
Correlation of EVIl and MDSl!EVIl expression with other prognostic indicators 
We next investigated whether EVIl and/or MDSJ/EVII expression showed any correla-
tion with other known prognostic indicators. Internal tandem duplication in the FLT3 
receptor tyrosine kinase gene has been observed in approximately 20-30% of AML. 
Moreover, this mutation appears to confer a poor prognosis in many studies carried out 
in the past 5 years.24•25 In 85 (27%) of the 319 cases investigated a FlT3-ITD was found. 
As shown in Table 5, high EVIl and MDSJ-EVIJ expression rarely coincided with FlT3-
ITD mutation. Almost all the patients with an FlT3-ITD mutation belonged to group IV, 
and 82% (70 of 85) carried an intermediate-risk karyotype. No significant correlation 
was found between EVIl and/or MDSl-EVIl expression and sex, age, WBC count, 
platelet count, blast counts in blood or bone marrow or FAB classification (data not 
shown). 
EVIl an independent unfavourable prognostic marker 
in the intermediate-risk karyotypic group 
All patients received induction therapy and were included in the survival analysis. Clinical 
outcome was investigated in the distinct groups of patients based on their EVIl and 
MDSl-EVIl expression. Survival analysis was performed using a cut off value of 50. The 
remission rates for patients in Groups I, II, III and IV were 50%, 77%, 67% and 79% 
respectively (Table 6). All patients in group I died within 12 months and 25 of26 patients 
of group II (EVIl+ andMDSl-EVIl+) died within 30 months (Table 6; Figure 3A and B). 
Table 6. Therapy response and actuarial survival probability of survival at 60 months 
in relation to EVIl and MDSJ-EVII expression. 
Complete Actuarial probability of 
remission, no. survival at 60 mo. % Relapse, no. 
(%) EFS OS (%) 
Group I, EVft+ and MDS1-EVI1- 3 (50) 1 (33) 
Group II, E\111+ and MDS1·EVIT+ 26 20 (77) 15 (75) 
Group Ill, E\111- and MDSt-EVIf+ 12 8 (67) 25 33 3(38) 
Group IV, EVI1- and MDS1-£VI1- 275 218 (79) 27 33 100 (46) 
The actuarial survival probabilities at 60 months were 33% in Groups III and IV and only 
0% for group I and 8% for group II (Table 6; Figure 3A and B). Thus patients in Groups 
I and II had a significantly shorter overall survival (P= 0.002). The event-free survival 
probabilities at 60 months for groups I and II (0% and 4% respectively) were much lower 
than those for Groups III and IV (25% and 27% respectively). A significant difference 
(P= 0.009) was also observed between EFS in patient with high EVIl expression (Groups 
I and II) and that in AML patients without EVIl expression (Groups III and IV). We also 
analysed survival using alternative cutoff values (i.e.10, 25 and 100). Although the 
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Group N 0 
I 6 6 
II 26 24 
Ill 12 8 
IV 275 165 
l..ogrank P=0.002 
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numbers of patients within the 4 different subgroups were slightly different, changing the 
cutoff values did not alter the conclusions drawn from the analysis at cutoff value 50 
(data not shown). 
Cox regression analysis was applied to assess the prognostic significance of high EVIl 
expression for OS and EFS (Table 7). High EVIl expression was associated with an 
increased hazard ratio for death (OS; HR=l.85) or failure (EFS; no CR, death in CR or 
relapse, HR=l.82), which was statistically significant in univariable analysis. After 
adjustment for karyotypic risk factors, age and FLT3-ITD in a multivariable analysis 
high EVIl expression still associated with an increased hazard ratio (P= 0.09). As high 
EVIl expression is often associated with unfavourable karyotypes, its prognostic value 
seemed to be overshadowed. To exclude the effect of unfavourable cytogenetics, we 
decided to investigate the prognostic value of EVIl in intermediate-risk group. 
We investigated whether high EVIl expression would be of prognostic value for patients 
carrying intermediate-risk karyotypes, as half of the patients with EVIl expression (group 
I and II) belonged to this risk group. As shown in Figure 4A-B, intermediate-risk patients 
with high EVIl expression (n=l6) have a significantly shorter OS and EFS (P= 0.05 and 
P=0.03) than their EVIl negative counterparts (n= 196). Furthermore, the disease-free sur-
vival was significantly shorter in patients with high EVIl expression (P= 0.007). None of 
the EVIJ-overexpressing patients carried an FLT3-ITD, whereas FLT3-ITD was observed 
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Table 7. 
Univariable and 
multivariable 
analysis of high 
EVIl expression as 
prognostic factors 
for survival. 
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EFS OS 
HR (95%CI) p HR(95%CI) p 
Univariable analysis 
High EV/1 expression 1.82 (1.25·2.67) .002 1.85 (1.25-2.73) .002 
Multivariable analysis 
Cytogenetics risk <.0001 <.0001 
Favorable 1(-) 1 (-) 
Intermediate 2.29 (1.47-3.57) 2.85 (1.71-4.77) 
Unfavorable 3.10 (1.78-5.41) 4.20 (2.26-7.83) 
Age,y .64 .56 
Younger than 35 1(-) 1(-) 
35-50 0.98 (0.69-1.38) 1.12 (0.78-1.61) 
Older than 50 1.12 (0.81-1.57) 1.21 (0.85-1.73) 
FL T3 mutation vs no 
mutation 1.48 (1.11-1.98) .01 1.53 (1.12-2.09) .009 
High EV/1 expression 1.47 (0.96-2.25) .09 1.48 (0.96-2.29) .09 
-indicates not applicable. 
Group N 0 
EVI1- 196 132 
EVI1+ 16 16 
Logrank P = 0.05 
EVI1-
t4 I .Is I S6 60 
Months 
Group N 0 
EV11- 196 149 
EV11+ 16 16 
Logrank P = 0.03 
EVI1-
t4 ds Js k 
Months 
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in 36% (70/196) of the patients without high EVIl expression. Univariable and multivari-
able analysis revealed that high EVIl expression serves as an independent prognostic mark-
er for EFS and OS in the intermediate-risk group (Table 8). 
EFS 
HR(95%CI) 
Univariable analysis 
High EV/1 expression 1.76 (1.05-2.97) 
Multivariable analysis 
Age, y 
Younger than 35 1(-) 
35·50 0.84 (0.56-1.26) 
Older than 50 0.99 (0.67-1.47) 
Flt3 mutation vs no mutation 1.71 (1.22-2;38) 
High EV/1 expression 2.09 (1.22·3.60) 
-indicates not applicable. 
Discussion 
OS 
p HR(95%CI) 
.05 1.69 (1.01-2.87) 
.61 
1(-) 
0.97 (0.64-1.49) 
1.05 (0.69'1.61) 
.002 1.62 (1.14-2.30) 
.01 2.01 (1.16-3.47) 
p 
.06 
.91 
.009 
.02 
Table 8. Univariable 
and multivariable 
analysis of high EVIl 
expression as prognos-
tic factor for survival 
in intermediate-risk 
karyotype. 
We developed a sensitive method to quantify EVIl and its fusion transcript MDSl-EVIl 
in AML. Our data demonstrate that EVIl rather than MDSJ-EVIl is a strong indicator 
for poor treatment response and survival. MDSJ expression was seen in 5% (15 of 319) 
of the AML patients and was always associated with high EVIl and MDSJ-EVIl expres-
sion. High EVIl mRNA expression was observed in 10% (32 of319) of the patients with 
newly diagnosedAML. Poor clinical outcome of patients with 3q26 abnormality has pre-
viously been reported. 3•26"28 As we demonstrated in this study, patients with 3q26 abnor-
mality represent a minor subgroup of patients with high EVIl expression. In fact only 
12.5% ( 4 of 32) of the patients with high EVIl expression carried a 3q26 abnormality. 
High EVIl expression was significantly correlated with the presence of unfavourable 
cytogenetic abnormalities. Favourable-risk karyotypes were not present among the EVIl-
expressing groups. 
Evil was first discovered as a proto-oncogene in retrovirally induced myeloid 
leukaemias in the mouse. Retroviral insertions in the Evil locus in those tumours most-
ly occurred 5' in close vicinity of the first two or three exons of Evil, causing Evil over-
expression. 29 These data underline that EVIl rather than MDSJ-EVIl is the transforming 
gene in AML. This conclusion is further strengthened by the fact that in the present 
study, EVIl and not MDSJ-EVIl expression correlated with unfavourable-risk 
leukaernias. 
In contrast to what has been published previously, we demonstrate that EVIl expres-
sion in de novo AML may be an important parameter to define a subgroup of poor-risk 
AML. Langabeer et aP0 studied 197 de novo AML patients but did not find any prognos-
tic value for high EVIl expression. This is not surprising, however, as the investigators 
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did not discriminate between EVIl and MDSI-EVIJ expression. A number of EVIl-pos-
itive patients in this study carried a favourable-risk karyotype, indicating that these 
patients are most likely expressing MDSI-EVIJ rather than EVIl. Furthermore, previous 
studies were carried out using classical RT-PCR, while we performed quantitative real-
time PCR to be able to determine high EVIl expression levels based on a defined cutoff 
value. 
Cytogenetic analysis provides a powerful approach to discriminate between 
favourable-risk and unfavourable-risk groups among AML patients. However, using 
karyotyping, only 30% to 40% of the AML patients can be classified within these 2 sub-
groups. In other words, a majority of AML patients belong to intermediate or unknown 
karyotypic risk groups. A major challenge will be discriminating favourable-risk from 
unfavourable-risk patients within this heterogeneous group of patients by means of 
molecular biological approaches. Among the cases with intermediate-risk karyotype 
studied, 33% (70 of 212) harboured an FLT3-ITD mutation that predicts poor prognosis. 
Sixteen (8%) of the 212 patients had high EVIl expression and showed very poor sur-
vival. Interestingly, non-of the EVIl-positive cases harboured an FLT3-ITD, indicating 
that the EVIl-expressing group represents a distinct subclass of poor-responsive 
leukaemias. Within the same group with intermediate-risk karyotype a subpopulation of 
poor responders has been defined with very low rnRNA levels of the CEBPA gene (this 
thesis). Again no overlap was found with the other 2 molecularly defined classes. 
Moreover, mutation analysis revealed another subset of intermediate-risk AML cases 
that harboured 3' mutations within the CEBPA gene. These cases could be categorised as 
leukaemias with a good prognosis (this thesis). These observations encourage addition-
al gene expression studies and mutation analyses to further unravel different classes of 
AML, particularly within the intermediate-risk karyotypic subgroup of AML. 
In 8 of 14 patients with an 11 q23 abnormality, we observed high EVIl and MDSI-
EVIJ expression. In previous studies, the correlation between EVIl with 11q23 has been 
overlooked, as the cohorts were not large enough and the methods used did not discrim-
inate between EVIl and MDSI-EVIJ. Two of 16 EVIl-positive patients screened by 
Ohyashiki et al 17 and 1 out of29 EVIl-positive patients found by Langabeer et al,31 car-
ried an 11q23 abnormality. Translocations involving chromosome band 11q23 disrupt 
the MLL gene. MLL is a putative transcription regulator that may form complexes with 
other transcription factors. It contains both a strong activation domain and a repression 
domain. 32 In de novo leukaemia, 75% of breakpoints in MLL are mapped to the cen-
tromeric half of the breakpoint cluster region (RCR)/3 which is located in the repression 
domain. Disruption of the repression domain in these particular llq23 translocations 
might lead to an alteration of the repressor function of MLL, leading to an upregulation 
of downstream target genes. A possible explanation for high EVIl and MDSI-EVIJ 
expression in a large proportion of patients with 11q23 defects could therefore be that 
transcription of those genes is under the control ofMLL. We hypothesise that MLL nor-
mally repress EVIl and MDSI-EVIJ expression. This repression might then be disrupt-
ed as a result of a chimeric protein generated by llq23 translocation, as it has been sug-
gested for HOX genes.5 Cloning and nucleotide sequencing analysis of the MLL fusion 
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genes in EVIl-positive versus EV/1-negative patients may provide critical information 
on this issue. 
One of the goals of this study was to investigate whether EVIl, MDSJ-EVIJ or both 
transcripts were expressed in AML patients with 3q26 aberrations. All of the 8 AML 
patients with a classical t(3;3) or an inv(3) (Tables 3 and 4) showed high expression of 
EVIl. High EVIl expression in 7 patients was associated with high MDSJ-EVIJ. Thus, 
although our data suggest that EVIl rather than MDSJ-EVIJ is the critical gene involved 
in transformation of myeloid precursors, it is noteworthy that MDSJ-EVIl is also fre-
quently expressed. Since the 3q26 breakpoints are often located between the MDSJ and 
EVIl loci, the normal allele is responsible for MDSJ-EVIJ expression. MDSJ-EVIJ 
expression might be directly or indirectly up-regulated by EVIl expression. Another pos-
sible explanation is that aberrantly expressed EVIl as a result of 3q26 aberration main-
ly transforms progenitor cells that normally have high EVIl and/or MDSl-EVIllevels. 
Fractionated CD34+ progenitor cell populations indeed show high EVIl, MDSJ-EVIJ 
and MDSJ expression (our unpublished data). Previous studies10·34 also confirmed EVIl 
expression in early CD34+ progenitor cells. In fact, transformation in these progenitors 
may be a result of a disturbance in the tightly controlled balance between EVIl and its 
fusion transcript. 
The mechanism by which EVIl is expressed in cases without 3q26 is unknown. It is 
conceivable that defects in the EVIl promoter or in EVI ]-regulatory genes affect expres-
sion. It is also possible that CD34+ progenitor cells naturally expressing EVIl and/or 
MDSJ/EVIJ are transformed by other mechanisms and arrested at that particular stage 
of differentiation. It should be noted that high EVIl expression is often associated with 
the presence of poor-risk abnormalities. For example, complex karyotypes are seen twice 
as often in patients with high EVIl expression than in patients without EVIl expression. 
Our data point to a critical role that EVIl may play in genomic instability in AML 
patients expressing this gene. 
The data presented here demonstrate frequent EVIl overexpression in AML patients 
and its correlation with poor treatment outcome. We propose that EVIl gene expression 
measurements with real-time PCR should be incorporated into the diagnostic procedures 
for the novo AML patients, especially in the subpopulation with intermediate- or 
unknown-risk karyotypes. Determination of EVIl expression levels in this particular cat-
egory of AML patients will be useful in distinguishing a subgroup of patients with poor 
prognosis. Identification and classification of subtypes of AML with specific molecular 
defects will be of great value in designing unique stratified treatment approaches. 
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Abstract 
The expression of an MDSI-EVIJ-like-1 (MELI) gene is reported in acute myeloid 
leukaemia (AML) and myelodysplastic syndrome (MDS) with translocation 
t(1;3)(p36;q21). MELI (at chromosome band .lp36.3) is thought to be transcriptionally 
activated as a result of juxtaposition to the RPNI gene at 3q21. It is not known whether 
MELI expression is restricted to patients with this particular translocation. Using real-
time PCR, we measured MELI expression levels in 162 de novo AML patients, normal 
bone marrow and distinct blood cell fractions. We also investigated the existence of an 
EVIl-like gene (ELI) by applying the same method. The existence of these transcripts 
was confirmed by northern blot analysis. MELI expression was detected in 87% (141 of 
162) of de novo AML patients. The ELI (EJi7I-like) transcript was also detected in the 
majority of the patients. MELI and ELI showed variable expression levels in AML. 
However, ELI expression levels highly correlated with MELI expression levels. All the 
patients with favourable-risk karyotypes (i.e. t(l5;17), t(8;21) or inv(l6)), showed low 
MELI and ELI expression levels. Expression analysis of MELJ/ELI compared with 
MDSI-EVIJ!EVIJ in normal marrow or distinct blood cell fractions revealed that 1) all 
four gene-products are expressed in CD34+ progenitor cell fractions, 2) Both MELI and 
EVIl are turned down in neutrophils and monocytes/macrophages; while 3) MDSI-EVIJ 
and ELI remain expressed in mature blood cell fractions. Our data suggest that simulta-
neous low MELI I ELI expression in AML is abnormal and that favourable disease high-
ly associates with this abnormal phenotype. 
Introduction 
The MDSI-EVIJ-like-1 (MELI) gene is located at chromosome band 1p36.3. and is 
highly homologous with the MDSI-EVIJ fusion transcript. The N-terminal PR domain 
ofMELl is 52% identical to MDS1 protein. Furthermore, the C- and N-termina1 DNA-
binding domains of MEL1 show 74% and 96% homology with the two respective 
domains in EVI1. 1 MELI expression has been shown in acute myeloid leukaemia (AML) 
and myelodysplastic syndrome (MDS) patients carrying a reciprocal translocation 
t(l;3)(p36;q21).1 Likewise, high MDSI-EVII expression has been demonstrated in 
patients with a translocation t(3;3)(q26;q21). It is noteworthy that high MDSI-EVIJ 
expression is not restricted to patients with 3q26 abnormalities; a subgroup of patients 
without such aberrations do also show high MDSI-EVIJ expression.2 MELI expression, 
however, has not been reported in AML or MDS cells without a translocation 
t( 1 ;3 )(p3 6;q21 ).1 
MDSI-EVIJ transcript is an intergenic splicing product of MDSI and EVJ1. 3 AML 
cells may express MDSI-EVIJ, EVIl or both transcripts.2 Whether MELI also has an 
EVIl like (ELI) counterpart in primary AML or healthy bone marrow cells has not been 
documented. Northern blot analysis, using aMELI-specific probe, on mRNA isolated 
from AML blasts carrying a translocation t(l ;3)(p36;q21) revealed the existence of sev-
eral transcripts.1•4 Mochizuki et al. 1 demonstrated the presence of 2 different-sized MEL 1 
proteins by in-vitro transcription and translation experiments. Although the exact nature 
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ofthe distinct MELI transcripts and proteins has not been fully resolved yet, it seems that 
one of these products represents an EVIl-like (ELl) protein, that is, MELl without the 
N-terminal MDS1-like part. The existence of the ELl protein might be important in the 
diagnosis of human AML, as our previous study demonstrated that EVIl rather than 
MDSI-EVII is a strong indicator for poor treatment response in AML.2 
In this study, we investigated the expression of MELI transcripts in a cohort of 162 
de novo AML patients. We also studied the existence of the ELI rnRNA in human AML. 
We demonstrate that MELI expression is not restricted to AML with translocation 
t(l;3)(p36;q21). In fact, MELI transcripts are present in about 87% of the patients. 
Besides, we demonstrate the existence of an ELI transcript, which is normally tran-
scribed from the MELI locus (Figure lA-B). MELI and ELI expression in AML are 
highly correlated. Although expression levels of MELI and ELI varies extensively 
amongst AML patients, the expression of both genes are always low in the karyotypical-
ly defined 'favourable-risk' group, i.e., AML with translocations t(l5; 17), t(8;21) or 
inv( 16). Finally, we investigated the expression pattern of MELJ I ELI compared with that 
of MDSJ-EVIIIEVII in CD34 positive normal marrow precursors and in blood neu-
trophils and monocytes/macrophages. Our data suggest a tightly controlled expression 
regulation of these four transcripts during granulopoiesis and monopoiesis. 
Material and methods 
Patients, healthy volunteers and different cell fractions 
Bone marrow samples of AML patients at diagnosis and healthy volunteers (n=6) were 
obtained after informed consent. Blasts from AML patients and mononucleated fractions 
from healthy bone marrow specimens were isolated from the samples by Ficoll-Hypaque 
(Nygaard, Oslo, Norway) centrifugation.' The cells were then cryopreserved as described 
by Delwel et al.6 After thawing cells were washed with Hanks Balanced Salt Solution 
(HBSS) and further processed for RNA isolation. AML samples treated according to this 
procedures usually contain greater than 90% blasts after thawing. 6 A total of 162 de novo 
AML patients that had been referred to our institution between 1987 and 2000 were cho-
sen for analysis. Of these patients, 108 were treated according to the HOVON-29 (Dutch-
Belgian Haematology-Oncology Group) protocol and 54 according to the HOVON-4. 
These treatment protocols have been described previously.7 AML samples were classi-
fied according to the French-American-British nomenclature." 
Total RNA was also isolated from peripheral blood granulocytes and monocytes/ 
macrophages using the same procedures. Peripheral blood granulocytes were obtained 
from the cell pellet after Ficoll-Hypaque centrifugation.' Monocytes/macrophages were 
obtained from the interphase following Ficoll-Hypaque centrifugation and subsequent 
plastic adherence as described previously.9 
RNA isolation, eDNA synthesis and Real-time PCR 
Total RNA was extracted with guanidium thiocyanate followed by centrifugation in cesium 
chloride solution. Then 1 ml RNA was transcribed into eDNA using Superscript (Life 
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A 
B 
365 kb 
Exon 1 Exon 2 Exon 3 
!llf--------IJI 
\ // 
PAD 
I MDS1-IIke I EVI1-Iike (EL 1) 
MOS1/EV11-Iike (MEL 1) 
c 
qi: 18389434 
301 tccgagagtcctccatcccaggggctggcc 
331 tgggggtctgggccaagaggaagatggaa.g 
361 ccggggaga.ggctgggcccctgcgtggtgg 
1 
391 tgccccgggcggcggcaaaqqagacagact 
Pl 
421 tcggatgggagcaaatactgacqqacgtgg 
451 aagtgtcgccccaggaaggctgcatcacaa 
D 
76891 
76921 
76951 
76981 
77011 
77041 
E 
gi: 21912627 
stop 
gtgggctgggagccccgctgatgcccggag 
ggtgggctgaggtctggacgccgacttgcc 
ttcctacttgagcccaaacagccaggtttc 
tgggtgggcagaggctgtgtgcagactcca 
3 
gcacacagggcacctctgactcccgcttcg 
ctttcctcccagc 
gi:18389434 
P2 
481 agatctccgaagacctgggcagtgagaagt 
511 tctgcgtggatgcaaatcaggcgggggctg 
2 
541 gcagctggctcaagtacatccgtgtggcgt 
571 gctcctgcgatgaccagaacctcaccatgt 
stan 
601 gtcagatcagtgagcagatttactataatq 
631 tcattaaggacattgagccaggtgaggagc 
AD 
Technologies, Merelbeke, Belgium) and Random Hexamers in a 40 m1 reaction, under 
standard conditions. An aliquot of 1/20 th of the resulting eDNA was used for quantitative 
PCR amplification. Real-time PCR amplification was performed with the ABI PRJSM 
7700 Sequence Detector (PE Biosystems, Nieuwekerk aid IJssel, the Netherlands), using 
50 m1 mix containing 2 m1 eDNA sample; 250 mM deoxyribonucleoide triphosphates 
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(dNTPs Amersham Pharmacia Biotech Inc, Roosendaal, the Netherlands); 15 pmol 
forward and reverse primer (Life Technologies); 3 mM MgC12; 200 nM probe; labelled at 
the 5' end with the reporter dye molecule FAM (6-carboxy-fluorescein) for ELI and at the 
3' end with the quencher dye molecule TAMRA (6-carboxy-tetramethyl-rhodarnine) 
(Eurogentec, Maastricht, the Netherlands); 5 mllOx buffer A; 30 m1 water; and 1.25 U 
AmpliTaq Gold (PE Applied Biosystems). The thermal cycling conditions included 10 
minutes at 95°C followed by 45 cycles of denaturation for 15 seconds at 95°C, anneal-
ing/extension at 60°C for 30 seconds. The primer/probe combinations were chosen such 
that we could discriminate between ELI and MELI transcripts (Figure lB). The oligonu-
cleotide sequences of the primers and probes are shown in Figure I C-D. The Real-time 
PCR conditions and the oligonucleotide sequences of the primers/probe used for quantify-
ing PBGD, EVIl and MDSI-EVIJ are described elsewhere.2 
To determine the expression levels, all samples were tested in duplicate, and the aver-
age values were used for quantification. To quantify the relative expression of ELI and 
MELI, the Ct (threshold cycle) values were normalized for endogenous reference (oCt= 
Ct target- Ct PBGD) and compared with a calibrator, using the 'MCt' method (MCt= oCt 
Sample -oCt Calibrator). As the calibrator we used the average MELIor ELI Ct value in the 
six bone marrow samples from healthy volunteers. Using the MCt value, relative expres-
sion was calculated (2· Me'). As the MCt method is only applicable when the amplifica-
tion efficiencies of the target and the reference are essentially equal, we measured the 
efficiency of MELI, ELI and P BGD using 6 different dilutions of a eDNA sample (equal 
to 0.0005-50 ng total RNA). The mean oct values were plotted against the concentration 
of total RNA (log). The slope of less than 0.1 was indicative of equal efficiencies. 
Northern blotting 
Northern blotting was carried out on mRNA isolated from 1 healthy bone marrow and 9 
AML samples. Twenty micrograms of total RNA from each sample was separated on a 
1% agarose/6% formaldehyde gel, and blotted with lOx SSC (sodium chloride/sodium 
citrate; Amersham) onto hybond-N+ nylon membrane (Amersham). The blot was 
hybridized in IN NaH2P04-buffer containing 7% sodium dextran sulfate, and 1 mM 
EDTA pH 8.0. As probe, human MELI (639bp EcoRl-EcoRl fragment) and murine 
GAPDH (777 bp Hindiii-EcoRI fragment) 10 were 32P labeled by random priming 
(Boehringer, Mannheim, Germany). The blot was hybridized at 65 OC overnight and 
washed for 15 minutes at 65 OC in 2x SSC/ 0.5% SDS and for 15 minutes at 65 OC in 1x 
SSC/ 0.5 SDS. It was then analyzed by autoradiography. 
Cytogenetic analysis and stratification according to karyotype risk group 
Cytogenetic analysis was carried out according to standard techniques, and the abnormal-
ities were categorized in 3 cytogenetic groups. Patients with inv(l6)/t(l6;16), t(8;21) and 
t(15; 17) abnormalities were considered as favourable risk. The unfavourable-risk category 
was defined by the presence of -5/de1(5q), -7del(7q), t(6;9), t(9;22), 3q26 abnormality or 
complex karyotype (more than 3 abnormalities). All other patients were classified as inter-
mediate risk. Karyotypes were described according to ISCN nomenclature (1995). 
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Statistical Analysis 
Statistical analysis was performed with the SPSS Statistical Software 10. Spearman's 
rank correlation, Fisher's exact test, Kruskal-Wallis test and Mann-Whitney U-test were 
used to assess the association between ELI and MELI expression and the clinical and 
haematological characteristics of the patients. All tests were done two-sided. P-values 
<0.05 were considered statistically significant. 
Results 
MELI expression is constant in normal bone marrow but variable in AML samples 
MELI expression levels were measured in 6 ficoll fractionated normal bone marrow 
samples by real-time PCR. The mean Ct values of MELI in these normal samples was 
29.9 ± 0.5. The values obtained were normalized for the internal reference, (PBGD). The 
mean PBGD value for normal bone marrow samples was 25.3 ± 0.7. The small variation 
in mean i'JCt value (4.8 ± 0.6) indicates the rather constant expression level of MELI 
gene in normal bone marrow. 
MELI expression levels were subsequently measured in the bone marrow of 162 de 
novo AML patients using the same technique. The slope of the fitted line for the mean 
i'JCt value of MELI at different mRNA concentration was less than 0.1, indicating that 
the MCt method was applicable (data not shown). The values obtained were normalized 
for the internal reference (PBGD) and compared with the average expression in normal 
bone marrow (calibrator). MELI expression had an extensive variability among the AML 
patients, ranging from below detection level to 309 times more than the average expres-
sion in normal bone marrow (Figure 2). MELI transcripts were found in 141(87%) of 
162 patients withAML. None of the patients in our cohort carried a 1p36.3 aberration. 
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Figure 2. Relative expression of MELI in different karyotypic risk groups. 
MELI expression levels in different karyotypic risk groups, compared with the aver-
age expression in normal bone marrow. The average expression in normal bone mar-
row is equal to 1 (confidence interval: 0.4-2.3). Each box indicates a patient. Cases 
with a CEBPA mutation are indicated as black boxes. 
58 
2345678 9N 
MEL 
GAPDH -
9.49 
7.46 
4.40 
2.37 
Figure 3. Expression of MELJ gene in mRNA isolated from 9 AML patients and a 
healthy volunteer. Cases 1-6 had relatively high MELJ expression levels (52, 24, 64, 
42, 247 and 56 respectively) as quantified by Real-time PCR. In addition to the full 
lengths MELJ (8 kb), two other bands (5 kb and 4 kb) are observed in these cases. 
MELJ expression levels in cases 7-9 were 0.2, 0.9 and 0.001 (not detectable). N indi-
cated a normal bone marrow sample. 
MELJ transcripts of different sizes are present in AML 
Northern blot analysis was carried out using MELJ eDNA probe P3 (Figure1B) to con-
firm the real-time PCR results. Total mRNA samples were selected from 6 patients with 
high MELJ expression, 3 patients with low MEL I levels and from one normal bone mar-
row (Figure 3). High MELJ expression in AML patients 1 through 6 was confirmed by 
Northern blot analysis. In addition to the 8 kb MELJ transcript, 2 other bands (5 and 4 
kb) were detected, which is in line with observations of Mochizuki et all. No MELJ 
mRNA was found by Northern blot analysis in normal bone marrow (N) or in samples 
from patients 7 through 9, which showed low or non-detectable transcript levels as deter-
mined by real-time PCR. 
Favourable-risk karyotype is associated with low MELJ expression 
AML patients were divided into 3 different groups based on MELJ expression levels. 
Patients with an expression level in the range of 95% confidence interval (0.4-2.3), 
defined for the average MELJ expression in normal bone marrow, were classified in the 
'intermediate' MELJ expressing group (19 patients). The other patients were divided 
equally between the 'high' (range 2.5- 309) and 'low' (range 0.001-0.41) MELJ express-
ing categories (72 and 71 cases, respectively). Characteristics of the different MELJ 
expressing groups are shown in Table 1. Low MELJ expression was observed in 96% (26 
of27) of the patients with a favourable-risk karyotype (Table 1; Figure 2). In contrast to 
the favourable risk, the other AML risk groups did not reveal any association with dis-
tinct MELJ expressing groups. Recently, an additional subgroup of AML with favourable 
prognosis was characterized by mutations in the CEBPA gene. 10CEBPA -mutated AML is 
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distinguished as a favourable-risk subset among AML with intermediate-risk cytogenet-
ics. Here we show that CEBPA mutation is also significantly associated with low MELI 
expression (Fisher's Exact test: P=0.046; Figure 2). In fact, 10 (71 %) of 14 patients with 
CEBPA mutation expressed low levels of MELI mRNA. Furthermore no significant cor-
relation between MELJ expression and other variables was observed (Table 1). 
Table 1. Clinical characteristics of 162 de novo AML patients based on the MELI 
expression level 
Characteristics Low MEL! (n ~ 1) Intermediate MEL 1 (n = 19) High MEL 1 (n ~ 2) 
Gender Male 36 10 34 
Female 35 9 38 
Age Median (range) 40 (16-59) 38 (19-61) 45 (16-60) 
FAB MO 2 0 2 
M1 17 18 
M2 16 14 
M3 12 0 
M4 15 I! 
M5 8 22 
M6 
Unclassified 
Cytogenetic risk group Favorable 26 
Intermediate 33 15 67 
Unfavorable 12 5 
CEBPA mutation + 10 2 
WBC count (109/L) Median (range) 20 (0.3-220) 9 (0.7-108) 38 (0.7-263) 
Blast count(%) Median (range) 63 (0-96) 68 (3-98) 73 (21-97) 
Platele1 count (109/L) Median (range) 40 (7-339) 36 (8-265) 60 (6-931) 
Alv1L, acute myeloid leukemia; FAB, French-American-British classification [8]; WBC, white blood cells. 
Cox regression analysis was applied to assess the prognostic value of MELJ expression 
levels for overall survival (OS) and event-free survival (EFS). Low MELJ expression 
level was associated with a significant decrease in hazard ratio (HR) for death (OS; HR= 
0.65, P= 0.03) and failure (EFS; no CR, death in CR or relapse, HR= 0.72, P= 0.04). 
After adjustment for karyotypic risk factors, age and FLT3-ITD in a multivariable analy-
sis low MELJ expression seemed to have no significant impact on the survival of AML 
patients within the karyotypically defined intermediate- or unfavourable-risk group (data 
not shown). 
ELl gene is expressed in normal bone marrow and in AML 
Because MELI is highly homologous to MDSl-EVIl, we decided to investigate the pres-
ence of an EVIl like gene (ELl). By searching the database, we came across a poten-
tially unique ELI transcript. To study the existence of this transcript, we designed spe-
cific primers to amplify this potential mRNA by RT-PCR (Figure lB). ELI transcripts 
were amplified in normal bone marrow as well as in AML samples. Subsequent 
sequence analysis of the PCR products confirmed the existence of this alternative tran-
script. ELl expression levels were measured by real-time PCR in the same 6 normal bone 
marrow samples described earlier. The mean Ct values of ELl in these normal samples 
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was 32.9 ± 1.3. ELI expression levels were subsequently determined in the cohort of 
AML patients. The values obtained were normalized for the internal reference (PBGD) 
and compared with the average ELl expression in normal bone marrow (calibrator). ELl 
expression levels in AML cases varied from 0.001 (below detection level) to 146 times 
more than the average expression in normal bone marrow. Remarkably, ELl expression 
levels highly correlated with MELI expression levels (Spearman's rho: correlation coef-
ficient=0.76, P<O.OOOl; Figure 4). Accordingly, ELI expression was also significantly 
lower in patients with favourable risk karyotype (Figure 4). 
Figure 4. ELI and 
MELl. expression 
mRNA levels highly 
correlate: 
Scatter plot demonstrate 
the correlation between 
ELI andMELI 
expression levels 
(Spearman's rho: 
Correlation coefficient= 
0.76, P<O.OOOl). The 
black boxes indicate 
cases with favorable 
risk karyotype. 
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Figure 5. ELI IMELI and EVIl IMDSl-EV!l expression levels in different cell frac-
tions. Expression levels of these genes are measured in normal CD34+ sample and 
distinct cell fractions isolated from peripheral blood (granulocytes and mono-
cytes/macrophages). The expression levels are compared with aCt of 40, which cor-
responds to the detection limit. Accordingly, each bar demonstrates the extent of 
expression over the detection limit. 
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MELIEL and MDSI-EVIIEVI expression in normal haematopoietic cells 
MELI, ELI, EVIl and MDSI-EVIJ expression levels were determined by real-time PCR 
in a normal CD34+ sample and distinct cell fractions isolated from peripheral blood, i.e., 
granulocytes and monocytes/macrophages (Figure 5). MELI!ELI as well as MDSI-
EVIJ I EVIl were highly expressed in CD34+ cells. The expression of ELI was relative-
ly high in granulocytes and monocytes/macrophages, whereas MELI expression was 
reduced in those cells. On the other hand, MDSI-EVIJ was expressed in the differentiat-
ed blood cells, whereas EVIl was below the detection level. 
Discussion 
MELI gene was recently identified at the breakpoint cluster region of chromosome band 
1p36.3 in cells from MDS/AML patients carrying a translocation t(1;3)(p36;q21).1·4 
Previous studies concluded that MELI is transcriptionally activated in haematopoietic 
cells as a result of the juxtaposition of MELI at the 1 p36.3 locus to the RPNI gene at 
3q21.'.4 It should be noted that in previous studies MELI expression analysis was only 
carried out in selected groups of AML patients carrying translocation t(1;3)(p36;q21). In 
those studies, AML cell lines without this particular translocation served as control cells. 
In the present study, we applied a sensitive assay to measure MELI expression in 162 
patients with AML. This cohort did not include patients with translocation 
t(l;3)(p36;q21). We demonstrate that MELI expression is not restricted to leukaemia 
cells with chromosome 1 p36 aberrations. In 87% of the AML patients, MELI transcripts 
were detectable by real-time PCR. We also demonstrated high MELI expression levels 
by Northern blot analysis in several AML samples. Based on these results we conclude 
that MELI is frequently expressed in AML and that expression of MELI does not require 
juxtaposition of the 3q21 locus. 
This study also establishes for the first time the existence of an alternative variant of 
the MELI transcript in AML and normal bone marrow, which encodes for an EVIl like 
protein (EL 1 ). The expression levels of ELI in AML patients highly correlate with MELI 
transcript levels. In fact, the existence of two different MELl protein products of 170-
kDa and 150-kDa in AML and in cells transfected with eDNA constructs has been 
demonstrated by Morishita and Nishikata.11 The shorter protein lacks theN-terminal PR 
domain ofMELl and appears to be initiated from an internal initiation codonATG597. 
Whether one of the bands observed on the Northern blot (Figure 3) truly represent the 
ELI variant is still unclear, as a suitable eDNA fragment that could discriminate between 
MELI and ELI has not yet been identified. 
It previously was suggested that MELI was not present in normal bone marrow sam-
ples.1A MELI transcripts are not detectable in normal marrow by Northern blot analysis. 
However, real-time PCR data clearly demonstrated that significant levels of MELI as 
well as ELI transcripts are present in the marrow cells of healthy individuals. These data 
suggest that MELli ELI expression is, in principle, not the effect of a genetic alteration. 
The fact that MELI and ELI expression is not restricted to cases with a translocation 
t(1;3)(p36;q21) does not implicate that this particular aberration has no effect on MELI 
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expression. In fact, a similar situation has been documented for EVIl. EVIl is abnor-
mally expressed as the result oftranslocations involving chromosome band 3q26, where 
the gene resides. 12 However, EVIl gene is also expressed in approximately 10 % of AML 
cases without 3q26 abnormalities.2 MELI and ELI are expressed in the majority of AML 
cases and in CD34+ purified marrow cells. In contrast, in neutrophils and 
monocyte/macrophage fractions, the ELl levels were high whereas MELJ levels were 
undetectable. This suggests that the relative expression between those two transcripts 
changes during differentiation. Most of the lp36.3 breakpoints cluster in a region 5' of 
the MELI gene.4 Translocation t(l;3)(p36;q21) may disrupt the tight control of tran-
scriptional regulation. MELI and ELI are then constitutively turned on under the control 
of the regulatory sequences of RPNJ, located on chromosome 3q21. In this model, 
MELI, which normally extinguishes during differentiation, remains transcriptionally 
active. In cases with 3q26 abnormalities, the breakpoints frequently occur 5' end of EVIl 
and 3'of MDSl. 12 As a result, EVIl, which normally is switched off during differentia-
tion (Figure 5), may remain transcriptionally active. Our data suggest that the homolo-
gous MELl/ELI and MDSl-EVIl/EVIl proteins may cooperate under tight control in 
the same pathway. Disruption of this control mechanism by chromosomal translocations 
could seriously alter the balanced expression of these genes and thereby disturb a criti-
cal pathway required for differentiation. It will be interesting to investigate the interac-
tion and the function of these proteins in normal haematopoiesis as well as in leukaemic 
transformation. 
Favourable-riskAML patients, i.e., patients with inv(16)/t(16;16), t(8;21) or t(15;17) 
showed consistently low MELJ and ELl expression levels. Furthermore, we also demon-
strated low MELJIELJ levels in another recently molecularly defined favourable-risk 
group, i.e., cases with CEBPA mutationsY3 An altered common pathway in favourable-
risk patients may result in down-regulation of MELI I ELI. High ELI and MELI expres-
sion levels in about half of the AML cases probably represent high numbers of non-dif-
ferentiated haematopoietic precursor cells. However, low expression of both MELJ and 
ELl in the patients with a favourable prognosis is unusual, because even in normally dif-
ferentiated cells (e.g. neutrophils) ELI is still highly expressed. Therefore, it seems that 
low expression of both genes is an aberrant phenotype associated with favourable dis-
ease. Obviously this phenotype is observed in all the patients with chromosomal translo-
cations involving critical transcription factors, e.g. CBF (Core Binding factors), C/EBPa 
or RARa. The modified proteins produced as a result of mutations or translocations may 
act as transcription repressors for MELJ and ELl. In fact, several potential binding 
domains for PML-RARa or AML-ETO were identified upstream of MELI (data not 
shown). It would be interesting to investigate whether these modified gene-products 
affect MELI promoter activity. Altogether, the association with favourable risk AML 
may suggest a relation between severity of the disease and MELJ I ELl expression in this 
particular group of leukaemia. 
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Abstract 
The CCAAT/Enhancer Binding Protein a is an essential transcription factor for granu-
locytic differentiation. Recent studies reported N-terminal and C-terminal CEBPA muta-
tions in approximately 7% of acute myeloid leukaemia (AML) patients. C-terminal 
mutations are usually in-frame and occur in the Basic-leucine zipper (bZIP) domain, 
resulting in deficient DNA binding. Using a rapid PCR approach, we screened for bZIP 
mutations and determined the prognostic value of these mutations in a cohort of277 de 
novo AMLs. In addition we set out to quantify CEBPA mRNA levels by 'real-time' PCR 
using TaqMan® technology. In-frame insertions were observed in 12 (4.3%) cases. All 
cases with mutations carried an intermediate-risk karyotype and all but one belonged to 
Ml or M2 FAB class. Further sequence analysis revealed that CEBPA C-terminal muta-
tions are associated with frameshift mutations in theN-terminus of CEBPA. These two 
mutations were always found in different alleles. Event free survival (EFS) and overall-
survival (OS) of patients with CEBPA mutations were significantly increased (P= 0.02 
and P= 0.03, respectively) in comparison to the patients lacking these mutations. 
Mutations were associated with a significantly reduced hazard ratio for death (OS, 
HR=0.35, P=0.04) and failure (EFS: no CR, death in CR or relapse, HR=0.37, P=0.03). 
This favourable hazard ratio was maintained after adjustment for cytogenetic-risk, FLT3-
ITD and CEBPA expression levels in multivariable analysis. In contrast, low CEBPA 
expression in AML with intermediate-risk karyotype (n=6) seemed to be associated with 
poor prognosis (not significant). By including this newly developed PCR assay, we 
define a subgroup of good-risk patients within the heterogeneous intermediate-risk 
group of AML. 
Introduction 
The CCAAT/Enhancer Binding Protein a (C/EBPa) is a transcription factor essential for 
granulocytic differentiation. The expression of C/EBPa initiates at the time of commit-
ment of stem cells to myeloid lineage, is specifically up-regulated in granulocytes and is 
down-regulated in peripheral blood monocytes. 1 The Cebpa knockout mice lack mature 
granulocytes, while the development of other haematopoietic lineages is not affected.1 
Using conditional expression constructs, it was demonstrated that expression ofC/EBPa 
in U937 and HL-60 cells is sufficient to induce granulocytic differentiation. Moreover, 
conditional expression of C/EBPa in U93 7 cells blocks the monocytic differentiation 
program. Thus, it seems that C/EBPa is able to induce a switch in differentiation towards 
neutrophils, thereby prohibiting monocytic development. 1 
C/EBPa specifically binds DNA through a domain that is rich in basic amino acids 
(basic region) and dimerises through two amphipathic a-helices (leucine zipper). Both 
the basic region and the leucine zipper are located in the C-terminus of the C/EBPa pro-
tein.' DNA binding depends on a stringently fixed three-dimensional relation between 
basic region and leucine zipper. If the register between these two regions (fork) is altered 
by either insertion or deletion, then the sequence-specific recognition of DNA is elimi-
nated.4 In contrast to the C-terminus of C/EBPa, which is highly conserved amongst 
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CEBPA family members and a number of oncogenes,S-7 the N-terminus is more diverse. 
This region contains an attenuator domain that is sandwiched by two distinct transacti-
vation domains. Although some studies report that the transactivation domains play no 
obvious role in the capacity of C/EBPa to bind to its DNA substrate,8-10 others suggest 
that N-terminal C/EBPa does influence DNA binding activity.11 
Recently, C-terminal mutations of CEBPA in acute myeloid leukaemia (AML) with 
intermediate-risk karyotype have been identified_ll-!3 These mutations are frequently in-
frame insertions within the bZIP region of CEBPA and result in proteins with deficient 
transcriptional activation and DNA binding_ These proteins though do not possess dom-
inant negative activityY-12 Besides the C-terminal mutations, N-terminal CEBPA muta-
tions have also been identified in AML These mutations usually result in a nonfunc-
tional truncated protein and an increase in the production of a 30 kD protein that is gen-
erated by use of an alternative initiation codon within the same reading frame. 11 •14 This 
30 kD protein exerts a dominant negative effect on DNA binding and transactivation of 
the wild type C/EBPa. 11 Apart from mutations in CEBPA, differences in CEBPA mRNA 
expression levels have also been observed in AML 15 
As the bZIP region of C/EBPa is highly conserved and is crucial for DNA binding 
and dimerisation, we decided to design a rapid assay to detect mutations in this region. 
Since the mutations in this region often involve insertions or deletions, a rapid PCR/EtBr 
electrophoreses strategy was applied to identify these abnormalities in a cohort of 277 
de novo AMLs. Subsequent sequence analysis of the entire gene was carried out in 35 
patients to investigate the presence of other mutations in CEBPA. Furthermore real-time 
PCR was performed to investigate the differences in CEBPA expression levels in the 
same cohort. Using these approaches we assessed the clinical, haematological and prog-
nostic impact of CEBPA mutations and variation in CEBPA expression levels. 
Material and methods 
Patients and healthy volunteers 
Bone marrow samples of AML patients at diagnosis and of healthy volunteers (n=6) 
were obtained after informed consent Blasts from AML patients and mononucleated 
fractions from normal bone marrow specimens were isolated from the samples by Ficoll-
Hypaque (Nygaard, Oslo, Norway) centrifugation. 16 The cells were then cryopreserved as 
described. After thawing cells were washed with Hanks Blanced Salt Solution (HBSS) 
and further processed for RNA isolation. AML samples treated according to this proce-
dures usually containmore than 90% blasts after thawing.17 A total of 277 de novo AML 
patients that had been referred to our institution and our collaborating centres between 
1987 and 2000 were collected for analysis. In all, 211 patients were treated according to 
the HOVON-29 (Dutch-Belgian Hematology-Oncology Co-operative Group) protocol 
and 66 patients according to the HOVON-4. These treatment protocols have been 
described elsewhere. 18 Table 1 shows the characteristics of 277 patients at diagnosis. 
AML samples were classified according to the French-American-British nomenclature_ 19 
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Table 1. Clinical characteristics of 277 de novo AML patients. 
Characteristics No. 
Gender 
Male 144 
Female 133 
Age 
Median (range) 43.4 (15.2-60.8) 
Age groups 
Younger than 35 85 
35-50 104 
50 and older 88 
FAB 
MO 10 
Ml 62 
M2 64 
M3 22 
M4 50 
MS 61 
M6 3 
Unclassified 5 
Cytogenetic risk group 
Favourable 55 
Intermediate 187 
Unfavourable 35 
WBC count (109/l) 
Median (range) 25.5 (0.3-282) 
Blast count (%} 
Median (range) 68 (0-98) 
Platelet count ( 109/ /) 
Median (range) 49 (3-931) 
RNA isolation, eDNA synthesis, real-time PCR 
Total RNA was extracted with guanidium thiocyanate followed by centrifugation in 
cesium chloride solution. RNA concentration, quality and purity were analysed applying 
the RNA 6000 Nano Assay (Agilent Technologies, Amstelveen, the Netherlands). All 
samples included in the study showed neither RNA degradation (28S/18S ration was ~2) 
nor DNA contamination. The 1 mg RNA was transcribed into eDNA using Superscript 
(Life Technologies, Merelbeke, Belgium) and Random Hexamers in a 40 ml reaction, 
under standard conditions. 
An aliquot of one 20th of the resulting eDNA was used for quantitative PCR ampli-
fication. Real-time PCR amplification was performed with the ABI PRISM 7700 
Sequence Detector (Appleid Biosystems, Nieuwekerk aid IJssel, the Netherlands), using 
50 ml mix containing 2 ml eDNA sample; 250 mM dNTPs (Amersham Pharmacia 
Biotech Inc, Roosendaal, the Netherlands); 15 pmol T-forward and T-reverse primer 
(Table 2, Figure 1) (Life Technologies); 3 mM MgC12 for CEBPA and 5 mM for PBGD 
(Porphobilinogen deaminase) reaction; 200 nM probe; 5 ml lOx buffer A; 30 ml water; 
and 1.25 U AmpliTaq Gold (Applied Biosystems). The thermal cycling conditions 
included 10 minutes at 95°C followed by 45 cycles of denaturation for 15 seconds at 
95°C, annealing/extension at 60°C for 30 seconds. TaqMan probe was labelled at the 5' 
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end with the reporter dye molecule FAM (6-carboxy-fluorescein), and at the 3' end with 
the quencher dye molecule TAMRA (6-carboxy-tetramethyl-rhodamine) (Eurogentec, 
Maastricht, the Netherlands). To check the PCR mix for any kind of contamination, we 
took a negative control (2 ml water instead of eDNA) with every TaqMan plate. 
To determine the expression levels inAML, all samples were tested in duplicate, and 
the average values were used for quantification. To quantify the relative expression of 
CEBPA, the Ct (threshold cycle) values were normalised for endogenous reference (&Ct 
= Ct target- Ct PBGD) and compared with a calibrator, using the 'MCt method' (MCt= 
&Ct Sample -&Ct Calibrator). As calibrator we used the average CEBPA Ct value in the 6 
bone marrow samples of healthy volunteers. Using the MCt value, relative expression 
was calculated (2-ooc'). As the MCt method is only applicable when the amplification effi-
ciencies of the target and the reference are essentially equal, we analysed the efficiency 
of CEBPA and PBGD using 6 different dilutions of a eDNA sample (equal to 0.0005-50 
ng total RNA). The mean &Ct values (&Ct = Ct target- Ct PBGD) were plotted against 
the concentration of total RNA (log). The slope of the fitted line was then determined. A 
slope of less than 0.1 was indicative for equal efficiencies. 
Polymerase chain reaction on N- and C-terminus and entire CEBPA 
The 3' coding region of CEBPA gene was amplified using forward primer 3 and reverse 
primer 8. TheN-terminus was amplified by forward primer 1 and reverse primer 5 (Figure 
1, Table 2). The PCR mix contained 2 ml eDNA sample; 1mM dNTPs (Amersham 
Pharmacia Biotech Inc, Roosendaal, the Netherlands); 20 pmol forward and reverse primer 
(Life Technologies); 2.5 mM MgC12; 5 ml expand 10 x PCR buffer; 5 ml DMSO; 30 ml 
water; and 5 U Taq DNA Polymerase (Amersham Pharmacia Biotech Inc). The thermal 
cycling conditions included 5 minutes at 95°C followed by 30 cycles of 1 minute denatu-
ration at 95°C, 1 minute annealing at 62°C, 1 minute extension at 72°C and a final step of 
2 4 TF p 3 
-- - - --~TADI I AD IITAD21 I Basie IFI L-ZJP ~ 
-- - -5 6 TR 8 
Figure 1. Schematic representation of CEBPA and the primers and probe used in this 
study. Primer TF and TR were used to detect CEBPA bZIP mutations and measure 
the mRNA expression level at the same time (using probe P). Primer 3 and 8 were 
applied to screen the remaining 3'coding region of CEBPA. Primer 1 and 5 were used 
to amplify the N-tenninal CEBPA. The amplified N-terminus was subsequently 
sequenced with primer 2. The entire CEBPA was amplified using primers that are 
described elsewhere. 12 Primers 4 and 6 were applied to sequence the entire coding 
region of CEBPA. Abbreviations: TAD, transactivation domain; AD, attenuator 
domain; F, Fork; L-ZIP, Leucine zipper. 
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Table 2. Nucleotide sequences of primers and probe. 
Oligonucleotides 
TF 
TR 
1 
2 
3 
4 
5 
6 
8 
Probe P 
Nucleotide sequence 
5'-TCGGTGGACAAGAACAG-3' 
5'-GCAGGCGGTCATTG-3' 
5'-CGCCATGCCGGGAGAACTCT -3' 
5'-TGGAGTCGGCCGACTTCTA-3' 
5'-GTGCTGGAGCTGACCAGTGAC-3' 
5'-GCGGCCGCTGTGACT AAG-3' 
5'-GGAAGAGGCCGGCCAGCG-3' 
5'-GGCGGCTGGTAAGGGAAGAGG-3' 
5'-CCCAGGGCGGTCCCACAGC-3' 
5'-TGGAGACGCAGCAGAAGGTG-3' 
The names or numbers of the oligonucleotides correspond to those indicated in Figure 1. 
10 minutes 72°C. The primers used for amplifying the entire coding region of CEBPA and 
the PCR condition are described elsewhere.12 The fragments were gel-purified and cloned 
in a TA-cloning vector (Invitrogen, Life Technologies, Merelbeke, Belgium). 
Nucleotide sequence analysis 
The real-time PCR products were electophoresed on an ethidium bromide 3 % agarose 
gel. Samples with a shifted/double band were cloned in to TA-cloning vector 
(Invitrogen), and sequenced in both directions using ABI Prism BigDye Terminator 
(Applied Biosystems) and an ABI Prism 3100 Genetic Analyser. TheN-terminal CEBPA 
was sequenced with primer 2 using the same technique. The entire CEBPA that was 
cloned in TA-cloning vector was sequenced with primer 4 and primer 6. 
Cytogenetic analysis and stratification according to karyotypic risk group 
Cytogenetic analysis was carried out according to standard techniques, and the abnor-
malities were categorised in 3 cytogenetic groups. Patients with inv(l6)/t(l6;16), t(8;21) 
and t(l5;17) abnormalities were considered as favourable-risk. The unfavourable-risk 
category was defined by the presence of -5/del(5q), -7del(7q), t(6;9), t(9;22), 3q26 
abnormality or complex karyotype (more than 3 distinct clonal abnormalities). All other 
patients were classified as intermediate-risk. Karyotypes were described according to 
ISCN nomenclature (1995). 
Analysis of FLT3 internal tandem duplication mutations in AML 
The internal tandem duplications (lTD) in exon 11 of the human FLT3 gene were deter-
mined as described previously.20 Briefly, eDNA (derived form 50 ng total RNA) and 
genomic DNA (1 mg) were subjected to PCR using primers llF 5'-CAATTTAGGTAT-3' 
and llR 5'-CAAACTCTAAATTTTCTCT-3'. The PCR cycling conditions were as fol-
lows: 3 minutes 94°C followed by 30 cycles 1 minute 94°C, 1 minute 54°C, 1 minute 72°C 
and a final step of 10 minutes 72°C. PCRproducts were resolved on a 2.5% agarose gel. 
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Statistical Analysis 
Statistical analysis was performed with the Stata Statistical Software Release 7.0. (Stata 
2001, College Station, TX). Spearman's rank correlation, Pearson's chi-square test and 
Kruskal-Wallis test were used to assess the association between CEBPA expression and 
the clinical and haematological characteristics of patients. Actuarial probabilities of 
overall survival (OS; with failure as death due to any cause) and event-free survival 
(EFS; with failure at day 1 in case of not attaining a CR, or at relapse or at death in first 
CR) were estimated by the method of Kaplan and Meier. The Cox proportional hazard 
model was applied to determine the relationship between CEBPA expression levels and 
mutations with OS and EFS, without and with adjustment for other factors as age, cyto-
genetic risk and FLT3-ITD. All tests were done two-sided. P-values <0.05 were consid-
ered statistically significant. 
Results 
CEBPA C-terminal in-frame insertions occur in 12 of 277 de novo AML patients and 
associate with CEBPA N-terminal mutations 
The primers chosen for the rapid PCR assay to detect bZIP mutation (T-forward and 
T-reverse) covered the most conserved domain of CEBPA (Figure 1). Analysis of the 
PCR products using ethidium bromide agarose gel electrophoreses revealed double 
bands in 12 cases (Figure 2). Cloning and subsequent nucleotide sequence analysis 
revealed in-frame insertions that often consisted of repeats (Figure 3). One patient had 
201--
154--
133--
c1 c2 6 11 7 3 
Figure 2. PCR products of 4 patients with mutated (6, 11, 7 and 3) and two 
patients with wild type bZIP CEBPA (cl and c2), analysed by EtBr agarose-gel 
electrophoresis. The size of the wild-type PCR fragment is 141 base pairs. 
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l IOO'l':S\l'DKNSNEYRWl<EBNNIAWXS>IDKYAK-Q·"----------llNVE-TQQK--VL!:L'I'S--DNDRI.lUU'lVl!Ql.SRF.l.D'lLRGlrn<;lL 
2 KAKKS'i"OKNSNEYRvru<BlUlNIAWXSlml<-AKK<;l-- ----------llNVE-79Ql<--VL!:LTS--DNDRI.lUU'lVEQLSI\E.LD:rLRGlrn<;lL 
I<AKKS\l'DKNS!iiEYR\IlUlllBlmiAWX&Rlll(-AKQQ------------llNVE-~--VI.>:;LTS--DtiORI.lll<RVEQl.SRE!LD:rLRGirn<;lL 
KAKRS\l'DKNSNEYRVRml:RNNIAVRK!>RDK-AI<- QRNV-- --- -DKQRNVE-TQQK--VLELTS- -CNDIU.!UCRVl!QLSI>.E.LD:rLRGl FRf,lL 
KAKRS\l'DKNSNEYRVRRE:RNNIAVRKSBI>K-AK-QRNVETQHHXAKQRWJ:l!.--.:'QQK--VL!:LT$--DHO=v:EQLSREL!nLRGlrnQL 
KAKK$WKNSNEYRVRroliOOUAVl'IKSru:>K-Al<-QRNVETQQ'-~--.:'QQK--VLEL$--OND=Vl!QLSRE!LD:rLllGirnQL 
7 KA.KK$WKN:SNEYR~ll!Vl'IKSPJ)~-Al<-Q ------- -----~l(--VLE:LTS--DHDIU.ru(RVEQLSRE!.D~UtGirnQI. 
e ~I(S'JOKN:Stlll'lRv=N-Q.rXAVI<!:SltOK-Al<- Q----------- -I\N'J:l!.-1QQ~- !>VL&L'!'S- -DHO=VllQJ..SRE!.D'I'LE\GI !'i<QL 
~ KAl<KS\l'DK!'Stlll'tR~IA'JN>;SltOli-M-Q-------- ----~-1QQK- I>VLELTS--DtoP=VllQL.SI\E.I.t>TI.RGIFf<QL 
10 ~!IS'iiPKtiSNE'lR~IAVl;l.ii;SRO~-M-Q-- --------- -~-~-I>VLELTS--DtlDRLI>J'.RVEQL51¢~1X'LRGirnQL 
ll ~S'iiPKN$tlEYR~IAVR!';5Rtlll-ru(- Q ------------llNVE-TQQ!;Q!:VL~LTS- -ONORLRI(P.VEQLSRELI>:tLE\G~ FRQL 
12 IW<!<S"roKNSNEYR~IAVR!';$.ROI<-M-Q------------1lNVE-TQQK--VL~LT-RLONORLRliRVEQl.SRELOO:IiRGIPRQL 
Figure 3. Comparison of amino acid sequence of wild type CEBPA with 12 AML 
cases carrying insertion-mutations in bZIP region. 
an insertion in the basic region, 6 patients carried insertions in the fork region and in 5 
patients insertions were apparent in the leucine zipper. In addition we carried out PCR 
analysis on the distal end of the 3' coding region of CEBPA gene in 150 patients using 
primers 3 and 8 (See Figure 1). No additional insertions or deletions were found follow-
ing the latter analysis. We next investigated whether N-terminal mutations in CEBPA 
were present in the 12 cases with C-terminal insertions as well as in 23 other patients. 
Nucleotide sequence analysis revealed N-terminal frameshifts in 11 out of 12 cases with 
CEBPA bZIP mutations. The only patient without an N-terminal mutation (patient 6) 
appeared homozygous for the bZIP mutation (Figure 2, 3; Table 3). NoN-terminal muta-
tions were found in the 23 cases without a C-terminal abnormality. Cloning of full-length 
CEBPA eDNA and subsequent nucleotide sequencing of 8 of the 11 cases with both types 
of mutations revealed that the distinct mutations never occurred in one transcript. This 
indicates the involvement of both CEBPA alleles. 
Patient Mutation 
number 
1 425insA 
2 395insGG 
3 252delCCGGGGCGCG 
4 213delC 
5 213delC 
6 - a 
7 333delC 
8 343insA 
9 437de1G 
10 302de1CGCTGGGCGGCA TCTG 
11 395insTGTI 
12 358delC 
. , 
K92fsX107 
L82fsX159 
P34fsX156 
S2lfsX159 
S21fsX159 
S61fsX159 
K65fsX107 
A96fsX159 
P51fsX154 
F82fsX108 
R70fsX159 
Table 3. Additional 
N-terminal 
mutations detected 
in patients with 
CEBPA bZIP 
mutations . 
a This patient is homozygous for bZIP mutation. Nucleotide numbering 
is based on Genbank sequence# XM_009180 [gi: 13632311]. 
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Mutations in CEBPA associate with intermediate risk karyotype 
and favourable prognosis 
The characteristics of patients with CEBPA mutations are shown in Table 4. The patients 
carried an intermediate-risk karyotype, expressed relatively high levels of CEBPA 
mRNA levels (See next paragraph) and all but one belonged to the Ml or M2 FAB-class. 
Only one patient with a CEBPA mutation harboured an FLT3-ITD. There was no signif-
icant difference in age, sex, blast count, WBC count, platelet count between the group 
with and without mutation. The distribution of patients within the randomisation arms of 
the study was equal. A total of 33% of the patients with mutation received stem cell 
transplantation of whom 1 autologous (AuSCT) and 3 allogenic (AlloSCT); Likewise 
29% (38 AuSCT, 38 AlloSCT) of the patients without mutation received stem cell trans-
plantation. Clinical outcome was investigated in the patients based on the presence or 
absence of CEBPA mutations. EFS and OS of patients with CEBPA mutations were sig-
nificantly increased (P= 0.02 and P= 0.03, respectively) in comparison to the patients 
lacking these mutations (Figure 4a and b). The actuarial overall survival probabilities at 
60 months were 63% in patients with CEBPA mutations and only 29% for patients lack-
ing these mutations. Besides, the EFS probabilities at 60 months were also higher in 
patients with CEBPA mutation than in patients without these abnormalities (57% and 
23% respectively) (Table 5). The survival probabilities for patients with and without 
mutations at 24 months showed the same pattern (OS: 57% versus 27% and EFS: 73% 
versus 38%, respectively). 
Table 4. Characteristics of patients with CEBP4 mutation 
No. Cytogenetics FLT3-ITD Age (years) FAB Blast(%) WBC (I0'/1) Platelet (10'/l) CEBP A expressionu 
46,XX 48 M4 51 92 20 28.1 
46,XY 45 Ml 75 8 8 118.2 
46,XX,del(9)( q I ?lql? I) 54 Ml 65 8 98 5.5 
4 46,XX,del(12)(pl2.3pl3.1) 58 M2 47 2 207 16.5 
5 46,XY 43 M2 54 20 55 34.7 
6 46,XY 41 M1 93 174 39 66.3 
7 46,XY 48 M1 91 95 43 13.6 
8 46,XX 31 M2 60 II 69 11.9 
9 46,XY 45 Ml 64 87 63 8.6 
10 46,XY,del(9)(q3?1) 35 Ml 72 34 25 69.3 
11 46,XY,del(l1)(ql4q25) 38 M2 53 35 23 II 1.0 
12 46,XY + 19 Ml 79 118 38 30.7 
' For details see text. 
Table 5. Therapy response and actuarial surviYal probability at 60 months based 
on CEBPA mutation. 
CEBPA mutation Total number of patients Complete remission n (%) 
+ 12 
265 
II (92%) 
210 (79%) 
EFS: Event-free survival. OS: Overall survival. 
_A_ctu_a_ria-'l p'--ro_b_ab_ili..:..ty_at_6_0 _mo_n_ths__ Relapse n (%) 
EFS 
57% 
23% 
OS 
63% 
29% 
4 (36%) 
104 (50%) 
73 
a N 0 b N 0 
WT 285 175 100 WT 285 196 100 Mut 12 4 Mut 12 5 
(]) P=0.03 P=0.02 
"' "' 75 "E 75 Mut Mut (]) 
~ 
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Figure 4. Overall survival (a) and event-free survival (b) of 187 AML patients with 
intermediate risk karyotype based on CEBPA mutation. Mut: CEBPA mutations 
(n=l2). WT: Wild type (n=l75). 
Variable expression levels of CEBPA in AML 
CEBPA expression levels in AML blasts were analysed using real-time PCR employing 
specific primer/probe combinations (Figure 1). The slope of the fitted line for the mean 
bCt value at different mRNA concentration was -0.08, indicating that the MCt method 
was applicable. As calibrator we used the average expression of CEBPA in 6 bone mar-
row samples of healthy volunteers. The mean Ct value of PBGD and CEBPA in these nor-
mal samples were 25.4 ± 0.7 (SD) and 27.01± 0.9l(SD), respectively. CEBPA expression 
was measured in 277 de novo AML patients using the same technique. The values 
obtained were normalised for the internal reference (PBGD) and compared with the cal-
ibrator. An expression level in the range of 99% confidence interval (0.2-5), defined for 
the average CEBPA expression level in the healthy population, was considered 'interme-
diate'. The majority of patients (141 of 277) had an intermediate CEBPA expression 
level. In all, 129 of 277 patients showed high expression levels (range 5.06-154) while 
only 9 cases showed an expression level below the intermediate range (range 0.19-
0.001). Characteristics of different CEBPA expressing groups are shown in Table 6. 
Although the number of patients with low CEBPA expression was small, they appeared 
to present distinct characteristics, i.e. a relative lower WBC and platelet counts. 
Furthermore one-third (3 of 9) of the patients with low CEBPA expression carried a 
t(8;21); while the other two-thirds carried a normal or intermediate-risk karyotype. 
Low CEBPA expression within the group with intermediate-risk karyotype 
A total of277 patients received induction therapy and were included in the survival analy-
sis. The percentage of patients receiving stem cell transplantation in the low, intermediate 
and high CEBPA expressing group was 44% (4 AuSCT), 30% (19 AuSCT, 23 AlloSCT) 
and 27% (16 AuSCT, 18 AlloSCT) respectively. Clinical outcome was investigated based 
on CEBPA expression levels. The actuarial probabilities of OS and EFS in patients with 
low, intermediate and high CEBPA expression at 60 months were essentially equal 
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Table 6. Clinical characteristics of 277 de novo AML patients based on the 
CEBPA expression level. 
Characteristics 
Gender 
Male 
Female 
Age 
Median (runge) 
Age groups 
Younger than 3 5 
35-50 
50 and older 
Fob 
MO 
Ml 
M2 
M3 
M4 
MS 
M6 
Unclassified 
Cywgenetic risk group 
Favourable" 
Intermediate 
Unfavourable 
FLT3-JTD 
WBC counr ( 10'/1) 
Median (range) 
Blast count (%) 
Median (range) 
Platelet count (109/l) 
Median (range) 
Low ( <0.2) 
44 (29-57) 
2 
2 
2 
0 
3 
0 
0 
0 
3 (0.9-27) 
71 (35-99) 
29 (3-181) 
Intermediate (0.2-5) 
84 
57 
43 (15-60) 
44 
56 
41 
6 
28 
33 
6 
25 
37 
3 
3 
28 
94 
19 
35 
23 (0.5-282) 
67 (0-98) 
53 (4--931) 
High {>5} 
57 
70 
44 (17-61) 
38 
45 
44 
2 
32 
29 
16 
22 
24 
0 
2 
24 
87 
16 
37 
33 (0.3-263) 
68 (0-98) 
47 (8-494) 
a The number of patients with t(8;21) in the low, intermediate and high CEBPA expressing 
groups were 3, 13 and 6, respectively. 
a N 0 b N 0 
L 6 6 L 6 6 
100 I 94 71 100 I 94 76 
"' 
H 87 56 H 87 64 
Ol P=0.09 P=0.11 
.$ 75 75 
c: 
"' <'
"' ~50 50 
H H ~ 
'5 
E 
:::J () 
25 25 
0 0 
L 
0 12 24 36 48 60 0 12 24 36 48 60 
Months Months 
Figure 5. Overall survival (a) and event-free survival (b) of 187 AML patients with 
intennediate risk karyotype based on CEBPA expression levels_ H: High expression 
(n=87), 1: Intermediate expression (n=94)_ L: Low expression (n=6). 
(OS: 22 versus 25 versus 25% and EFS: 22 versus 28 versus 34%, respectively). No sig-
nificant differences in EFS and OS among patients with different CEBPA expression lev-
els were apparent. 
We then investigated whether CEBPA expression levels had prognostic value within 
the distinct cytogenetic-risk groups. The prognosis of patients within the intermediate 
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Table 7. Univariable and multivariable analysis of CEBPA mutations and 
expression levels as prognostic factors for event-free survival and overall 
survival in 277 AML patients. 
Overall survival Event-free survival 
Hazard ratio 95% CI P-value Hazard ratio 95% CI 
Uni11ariable analysis CEBPA 
Mutations 0.35 0.13-().94 0.04 0.37 0.15-0.91 
E.'Cpre.'ision 0.65 
Intermediate 1 1 
High 0.91 0.67-1.22 0.95 0.72-1.27 
Low 1.24 0.58-2.68 1.16 0.54-2.49 
ukivariable mralysis 
Age 0.45 
35-50 years 1 1 
~35 years 0.87 0.6G-1.26 0.99 0.7G-1.39 
>50 years 1.37 0.97-1.93 1.36 0.98-1.89 
Cytogenetic-risk <0.0001 
Intermediate 1 1 
Good 0.32 0.19-0.53 0.40 0.26-().62 
Poor 1.68 1.11-2.54 1.59 1.07-2.36 
1t3 mutation 
Versus no mutation 1.61 1.16-2.23 0.004 1.54 1.13-2.11 
CEBPA mulations 0.35 0.13-().96 0.04 0.36 0.14-().89 
CEBPA expression level 0.46 
Intermediate 1 1 
High 0.95 0.70-1.29 0.99 0.74-1.32 
Low 1.62 0.75-3.51 1.60 0.74-3.47 
P-value 
O.Q3 
0.87 
0.94 
<0.0001 
0.006 
0.03 
0.53 
risk group seemed to be influenced by different CEBPA expression levels (Figure Sa and 
b). Particularly patients with low CEBPA expression (n=6) seemed to have a relatively 
poor OS and EFS (not significant). Variations in CEBPA expression levels had no impact 
on the survival of patients with other risk karyotypes (data not shown). 
CEBPA mutation, an independent marker for good prognosis in AML 
Cox regression analysis was applied to assess the prognostic significance of CEBPA 
mutations and expression levels for OS and EFS in relation to other prognostic variables 
(Table 7). CEBPA mutations were associated with a significantly reduced hazard ratio for 
death (OS; HR 0.35 P=0.04) and failure (EFS; no CR, death in CR or relapse, HR 0.37 
P=0.03). This favourable hazard ratio was maintained after adjustment for age, cytoge-
netic-risk, FLT3-ITD and CEBPA expression levels in multivariable analysis. 
Discussion 
This study introduces a rapid PCR-based assay to identify in-frame insertions within the 
bZIP region of CEBPA. In-frame insertions in CEBPA occur in AML cases with inter-
mediate-risk karyotype and are associated with N-terminal mutations in the other allele. 
We report that CEBPA mutations are independent prognostic markers, which appears to 
correlate with enhanced EFS and OS. Besides the mutations, CEBPA mRNA expression 
levels seem to influence the prognosis of patients with intermediate-risk karyotype. 
However, a larger cohort of AML patients is required to establish the prognostic value of 
CEBPA expression levels. 
Our study is in agreement with the data reported by Gombart et al., 12 Pabst et al.n and 
Preudhomme et al; 13 that is, CEBPA mutations often occur in patients with intermediate-
risk karyotype and FAB-classes Ml or M2. The fact that CEBPA mutations frequently 
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occur in certain subgroups suggests that this genetic alteration is a transforming event, 
affecting particular haematopoietic precursor cells arrested at specific stages of differ-
entiation. 
CEBPA mutations are reported in 10 out of 137 AML patients (7.3%) analysed by 
Pabst et al, 7 out of 78 cases (9%) screened by Gombart et al and in 15 out of 135 
patients (11 %) screened by Preudhomme et al. These studies report on both N-terminal 
and C-terminal mutations. 11 •13 However the exact distribution and frequencies of C-ter-
minal versus N-terminal mutations in CEBPA remains unclear. In this study, we demon-
strated that C-terminal mutations in de novo AML occur in 4.3% of the cases and are 
associated with N-terminal mutations in the other allele. Such biallelic mutations were 
also observed in 7 out of 15 patients with CEBPA mutation detected by Preudhomme et 
al. 13 The involvement of both CEBPA alleles seems to be a common event, as the only 
patient without N-terminal abnormality was homozygous for bZIP mutation. In this 
study, we analysed only 23 cases without a C-terminal abnormality for N-terminal muta-
tions. Although none of those 23 cases appeared to carry mutations in this gene, monoal-
lelic CEBPA mutations in theN-terminus are expected in a small group among the 242 
cases that are currently under investigation. As our study is carried out in a large num-
ber of patients, we may as well be able to define whether cases with monoallelic versus 
biallelic CEBPA mutations belong to separate subgroups of AML. 
Cytogenetic analysis provides a powerful approach to discriminate between 
favourable and unfavourable-risk AML. However, only 30-40% of AML cases can be 
classified by cytogenetic analysis. One major challenge is to classifY the remaining 60%-
70% of the cases that are currently included in the intermediate-risk group. In our study 
33% of the patients with intermediate-risk karyotype harboured an FLT3-ITD mutation 
that is generally considered a poor risk indicator.21 .23 Furthermore, we recently identified, 
in the same cohort of intermediate-risk AML, a sub-group (8%) with high EVIl expres-
sion and poor survival (this thesis). In this study, we describe a new subgroup (6.4%) 
within the heterogeneous intermediate-risk group that carries CEBPA mutations and has 
favourable prognosis. As these different subgroups hardly show any overlap, based on 
these molecular analyses, we have been capable of providing prognostic information for 
approximately half of AML cases within the intermediate-risk group. Taken together, 
these observations encourage additional gene expression studies and mutation analyses 
to further unveil specific subgroups of AML. 
Using real-time PCR we were capable of defining three subgroups, i.e. high, inter-
mediate and low CEBPA mRNA expressing patients. All low CEBPA expressing patients 
with intermediate-risk karyotype died within 18 months. As this subgroup only con-
tained 6 cases, CEBPA expression analyses should be carried out on larger cohort of 
AML patients to verifY the reproducibility of these observations. Compiling data from 
for instance gene-array studies in the coming years may reveal the impact of low CEBPA 
expression on clinical outcome of AML. 
In this study we developed a rapid PCR assay to detect bZIP mutations and distin-
guish more than 6.4% of AML patients for whom no valuable prognostic marker was 
available. A PCR/agarose gel electrophoresis assay to identifY FLT3-ITDs in human 
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AML, in particular in the group of cases with intermediate-risk karyotype, has been val-
idated20 and routinely used. Although, sequencing of the entire coding region of CEBPA 
in AML samples is required to identify both N-terminal and C-terminal mutations, a val-
idated PCR/agarose gel electrophoreses for CEBPA will be an easy and rapid assay that 
can be implemented in the molecular diagnosis of AML. 
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Abstract 
The transcription repressor gene TEL (ETV6) is involved in different translocations asso-
ciated with human malignancies. These translocations often associate with deletion or 
inactivation of the non-rearranged TEL allele, which appears to be a critical secondary 
event for leukaemogenesis. Although TEL-translocations are relatively infrequent in 
AML, structural mutations or abnormal expression of TEL may contribute to the patho-
genesis of the disease. In order to investigate the involvement of TEL in AML, we 
screened 300 newly diagnosed patients for mutations in the coding region of the gene by 
direct sequencing. Furthermore, we studied TEL protein expression in 77 patients using 
two specific antibodies. Five somatic heterozygous mutations were detected, which 
affected either the homodirnerization- or DNA-binding domain of TEL. The proteins 
translated from the cDNAs of these mutants were unable to repress transcription and 
showed dominant negative potentials. Moreover, we demonstrated that one third of AML 
patients have deficient TEL protein expression, which is not related to TEL mRNA 
expression levels. In this study we demonstrate that TEL abnormalities are not restricted 
to translocations and occur more frequently in AML than previously thought. Additional 
comprehensive studies are required to define the clinical consequence of TEL loss of 
function in AML. 
Introduction 
The TEL (translocation ets leukaemia) gene also known as ETV6 (ets translocation vari-
ant gene 6) is located on the short arm of chromosome 12 and is known to be involved 
in different translocations associated with human malignancies. 1•2 TEL is a transcription 
repressor with two functional domains; an ETS DNA binding domain in the C-terminus3,4 
that recognizes the ETS binding sites (EBS) in promoter regions of target genes5•6 and an 
N-terminal pointed (PNT) homo-dirnerization domain.7 Dirnerization of TEL through 
the PNT domain is indispensable for EBS-driven transcription repression.3 
The transcription repressor activity of TEL seems to be important in the regulation of 
cell growth and differentiation. Fenrick et aP demonstrated that expression of TEL in 
Ras-transformed NIH 3T3 cells inhibits cell growth through repression of target genes, 
such as stromelysin-1. Moreover, TEL has been shown to stimulate erythroid differenti-
ation of the murine erythroid leukaemia (MEL) cellline.8 Tel knockout mice are embry-
onic lethal at day 10.5-11.5 and exhibit yolk sac angiogenesis defect and intra-embryon-
ic apoptosis of mesanchymal and neural cells. Although Tel absence seems not to affect 
haematopoiesis at the yolk sac stage,9 it seems indispensable for the development of all 
lineages in adult bone marrow. Chimeric mice with Tel knockout embryonic stem cells 
present defective hematopoiesis within the first week after birth. 10 
The fusion partners of TEL in translocations have heterogeneous characteristics. 
Furthermore, the contribution of TEL to the oncogenic fusion-proteins is variable. For 
example, in translocation t(3;12)(q26;p13), the TEL promoter which is situated in the 
vicinity of the EVIl gene results in EVIl over-expression. 11 In several translocations, TEL 
provides dimerization domains, e.g. in TEL-MNI, 12 BTL-TEV 3 or TEL-ABL, 14 resulting 
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in constitutively activated signalling proteins. In other cases, TEL provides transcrip-
tional properties via the ETS DNA binding site, e.g. in TEL-PDGFRb 15•16 and TEL-
AML1.17 TEL-AMLJ, which is generated as a result of translocation t(12;21)(pl3;q22) is 
the most common genetic lesion in paediatric acute lymphoblastic leukaemia (ALL). 
This translocation is detected in up to 25-30% of the patients and often associates with 
a fully or partially deleted non-rearranged TEL allele. 18•20 Deletion of the wt allele in 
these cases results in loss of functional TEL expression, which might contribute to the 
pathogenesis of the disease. A few studies have demonstrated that deletion of the wt TEL 
allele in cases with t(l2;21)(p13;q22) is not the only mechanism that leads to the loss of 
functional TEL.21 •22 Small structural abnormalities or epigenetic modification may also 
lead to the loss of wt TEL expression. 21 Accordingly, TEL abnormalities in ALL seem not 
to be restricted to translocations or deletions. Approximately 23% of ALL patients that 
do not carry a t(12;21) show an abnormal expression pattern of TEL isoforms.23 
Although TEL translocations are infrequent in acute myeloid leukaemia (AML)/4 abnor-
mal expression patterns or mutations in TEL might contribute to the pathogenesis of the 
disease. Kibei et al 25'26 have demonstrated TEL mutations in 2 out of 19 patients with 
prostate carcinoma and in 3 of 25 xenografts and cell lines. The mutations in TEL often 
associated with loss ofheterozygosity/6 which fits well with Knudsen's 'two-hit' hypoth-
esis. In order to investigate the involvement of TEL in AML, we analyzed 300 newly 
diagnosed patients for mutation in the coding region of the gene. We identified 5 cases 
of AML with nonsence/frameshift mutations or in frame insertions in TEL and investi-
gated the consequential properties of such mutations. Furthermore, we studied TEL pro-
tein expression in 77 newly diagnosed AML patients using two highly specific antibod-
ies. We demonstrate that despite considerable TEL mRNA expression, the protein is fre-
quently absent in AML blasts. 
Material and methods 
Patient material 
Bone marrow samples of a total of 300 de novo AML patients at diagnosis were obtained 
after informed consent. Patients were treated as described previously.27 Bone marrow 
blast cells were purified and further processed for DNA and RNA isolation. eDNA syn-
thesis was performed according to standard protocols.28 The DNA samples, isolated from 
non-haematopoietic tissues (skin or intestinal) of 3 patients with TEL mutations were 
provided by the Department of Pathology at Erasmus MC Rotterdam, the Netherlands. 
Polymerase chain reaction and direct sequencing 
The entire coding region of TEL was amplified using 20 pmol forward primer (FW: 5'-
ttctgggttggggagag-3 ') and 20pmol reverse primer (REV: 5' -cgctgaggtggactgttg-3 '). In 
brief, the reaction was performed using 1.7 U Expand High Fidelity enzyme, 5 ml PCR 
buffer, 2 mM MgC12 (Roche diagnostics GmbH, Mannheim, Germany), lmM dNTPs 
(Amersham Pharmacia Biotech Inc, Roosendaal, The Netherlands) and eDNA. The ther-
mal cycling conditions included 5 minutes at 95°C followed by 30 cycles of 1 minute at 
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95°C, 1 minute at 53°C, 3 minutes at 72°C and a final step of 10 minutes at 72°C. PCR 
products were purified on Montage PCR96 filter plates (Millipore Corporation) and 
sequenced in both directions using ABI Prism 3100 Genetic Analyser (PE Applied 
Biosystems) and 10 pmol primer (FW, FW mid: 5'-tcccaccattgaactgt-3', REV, REV mid: 
5 '-cggtgatttgtcgtgatag-3 '). Similar PCR and sequencing conditions were used to confirm 
the mutations on genomic DNA using specific primers for exon 3 (FW 5'-ggctcttgagat-
gtggaga-3', REV 5'-catcccttccttgtgatga-3') exon 4 (FW: 5'-caggtgcgctccaattgta-3', 
REV: 5' -acacgaagaagaccagctta-3 ') ex on 6 and 7 (FW: 5' -tcttctggttagtgcctcaa-3' REV: 
5 '-caggtagagatcttaacagt-3 '). 
Constructs 
N-and C-terminal constructs of TEL were generated by PCR with primer combination 
FW- REVmid and FWmid- REV respectively. All PCR products together with the wt 
allele and the mutants (#2290, 2236, 2649) were cloned into TA vector (Promega) fol-
lowed by sub-cloning into Eco-RI sites of mammalian expression vector pCMY, which 
is derived from the pEGFP-Cl vector (Clonetech lab. Palo Alto, Ca) from which the 
EGFP fragment was removed following Nhel and Xho1 digestion and subsequent reli-
gation. Single point mutations were generated in the methionine 208,240, 315 and 319 
of the #2290 construct cloned into pCMY, using QuikChange Site-Directed Mutagenesis 
kit (Stratagene, CA, USA). The oligonucleotide sequence of the sense and antisense 
primers are available on request. 
Immunoblotting 
Phoenix cells were maintained in Dulbecco's modified medium with 10% FCS(Life 
Technologies, Breda, the Netherlands). 24 hours prior transfection 2x 106 cells were plat-
ed onto 10 em dishes. Cells were transfected with 20 11g of corresponding TEL construct. 
48 hours post transfection cells were harvested and lysed in lysis buffer (Tris-HCL pH 
8.0 20mM, NaCl 137mM, EDTA 10mM, NaF 100mM, NP40 1% and Glycerol 10%) 
with a cocktail of protease inhibitors. The protein extracts were fractionated on SDS-
12% polyacrylamide gels and transferred to nitrocellulose membranes by electroblot-
ting. The TEL protein was detected by rabbit polyclonal antibodies (1:1000) directed 
either to the first 54 amino acid or to the C-terminal half of TEL protein (serum #68 and 
#71 provided by J. Ghysdael, Universite Pierre et Marie Curie, Paris, France). Polyclonal 
Swine Anti-rabbit Immunoglobulines!HRP (DakoCytomation, Glostrup, Denmark) was 
applied as secondary antibody. 
Luciferase assays 
Luciferase assays were performed as described previously.29 In short, 8x104 phoenix cells 
were seeded in 24-well dishes and transfected after 24 hours by calcium phosphate pre-
cipitation method with corresponding plasmids. A volume of 100 ~-tl calcium phosphate 
precipitate was used for each well with in total 2 11g of plasmid DNA. Cells were trans-
duced with 1 11g of luciferase construct pGL2-754TR (provided by S.W Hiebert, 
Vanderbilt University School of Medicine, TN, USA) containing EBS sites. Variable 
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amounts (15-100 ng) of TEL-expressing plasmids plus 0.2 [!g of LacZ supplemented 
with empty pCMY. The luciferase assay was carried out 48 hours post transfection. After 
two days cells were lysed and assayed for luciferase activity using steady-Glo reagents 
(Promega, Madison, WI). In parallel, the transfection efficiency was determined using 
lacZ staining. Luciferase activity levels were corrected for transfection efficiency using 
~-galactosidase expression levels. All experiments were carried out in triplicate. 
Results 
Somatic heterozygous TEL mutations in de novo AML 
Nucleotide sequence analysis on the eDNA samples, prepared from leukaemic blast cells 
of 300 AML patients, revealed 7 distinct novel heterozygous mutations in the coding 
region of TEL (Table 1). In addition to these mutations, we observed 2 previously 
described polymorphism at nucleotide 532 (G->A, Thr->Thr) and 876 (T ->C, 
Leu-> Pro) in 17% and 5% of the patients respectively. Furthermore, we detected a rare 
polymorphism at nucleotide 654 (G->A, Arg->Gln) in 4 patients. This mutation was 
described earlier in CWR31 xenograft.25 
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From the 7 novel mutations identified, 2 were silent point mutations at nucleotide 1159 
(C->T) and 1349 (C->A) while in the other 5 cases(# 2210,2290,2236,2649 and 3102) 
the predicted amino acid sequence and consequently the structure of the protein were 
affected (Tablel and Figure 1). The presence of these mutations was confirmed by 
nucleotide-sequencing analysis on genomic DNA isolated from leukaemic blasts of the 
same patients. ln all 5 cases, wt non-mutated TEL was observed at equal levels as the 
mutated forms. Nucleotide-sequence analysis on genomic DNA extracted from non-
haematopoietic tissues (skin or intestine) of patients# 2210,2290 and 2236, revealed the 
absence of mutations, indicating that the TEL mutations were somatic and confined to 
the leukaemia clone. Interestingly, 4 of the 5 mutations that affected TEL protein struc-
ture occurred in the well-characterized functional domains of TEL; i.e. in 2 cases (#221 0 
and 2290) in the pointed (PNT) domain and in another 2 cases (#2649 and 3102) in the 
DNA-binding ETS domain (Figure 1). Mutation #2236 that did not localize within the 
functional domains was situated at 3 amino acid downstream of the PNT domain. The 
mutations in cases #2210, 2290, 2236 and #3102 resulted in an early stop whereas the 
in-frame mutation (GGG) in-patient #2649, introduced an extra glycine between amino 
acids 344 and 345. The clinical and cytogenetic characteristics of the patients are given 
in Table 1. The functional mutations in TEL were found in AML of FAB subtypes Ml 
andM2. 
Cytogenetic risk gronp 
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Abnormal TEL proteins translated from the eDNA of the mutants 
We next studied the effects of the structural mutations on TEL protein expression using 
TEL eDNA. Mutant TEL cDNAs obtained from four patients (#2290, 2236, 3102 and 
2649) were cloned into pCMV and transfected into phoenix cells. Subsequently, the 
expression of TEL constructs was studied by Western blot analysis using specific anti-
TEL antibodies. As expected, the wt construct produced two isoforms (50 and 57 kDa), 
generated by the first two in frame ATGs (codon 1 and 43).4 These isoforms were detect-
ed by the antibody directed to the C-terminal part ofTEL (Figure 1 ). The antibody direct-
ed to the first 54aa ofTEL (theN-terminal antibody) only recognizes the 57 kDa wt-pro-
tein (Figure 1 ). 
N-terminal mutants. Western blot analysis of cells transfected with TEL-mutant 
#2290 showed no TEL bands when stained with N-terminal TEL antibody (Figure 2A). 
However, staining with C-terminal TEL antibody revealed three short fragments (44, 28 
and 23 kDa) (Figure 2B). These bands were not observed when wt-TEL was introduced 
into these cells (Figure 2B). To investigate whether these short fragments are generated 
by translation initiation from alternative ATGs, we mutated putative in-frame ATG-start 
codons in eDNA #2290 into ACG. Mutation ofthe ATGs representing Methionine M89, 
M208 or M240, resulted in disappearance of the 44, 28 and 23 kD proteins respectively 
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(Figure 2C). However, mutating the other ATGs (Methionine M315 or M319) had no 
effects on the distinct protein bands. Using the N-termina1 TEL antibody, we demon-
strated the production of an expected short 20kDa TEL protein in phoenix cells trans-
fected with eDNA #2236 (Figure 2A). The expression of the short C-terminal TEL frag-
ments was significantly reduced as compared to the mutant # 2290 (Figure 2B). 
C-termina1 mutants. The frame-shift mutation in #31 02 presented an expected 48kDa 
band, which could be detected by both C- and N- terminal TEL antibodies. However, the 
presence of an 18 kDa fragment in #3102, detected by N-termina1 antibody, was unex-
pected (Figure 2A). As expected, the in-frame mutation in patient #2649 did not visibly 
alter the TEL protein size. 
Mutant TEL in AML samples 
AML blasts from 3 patients with TEL mutations were available for Western blot analysis: 
N-terminal mutants. Western blot analysis on the protein lysate, obtained from AML 
blasts of patient # 2290, revealed complete absence of the 57kDa and 50kDa TEL pro-
teins, using N- and C-terminal TEL antibodies (Figure 3A). The same was observed in 
cells from patient #3, which did not harbour mutations in TEL. Using the C-terminal 
TEL antibody, multiple smaller fragments could be identified. These smaller bands were 
also observed in CD34+ bone marrow cells and in the other AML blasts samples, irre-
spective of TEL mutation (Figure 3A). Western blot analysis comparing patient samples 
with phoenix cells transfected with TEL construct # 2290 revealed that the bands corre-
spond to the sizes of C-terminal TEL isoforms (44, 28 and 23 kD) (Figure 3B). Taken 
together, these data suggest that TEL has normally several short C-terminal isoforms, 
which lack the N-terminal homo-dimerization domain. Certain AML cases, such as 
patient #3 and #2290 express only these short isoforms of TEL. 
Western blot analysis using N-terminal TEL antibodies, failed to show the short N-
terminal protein encoded by mutant #2236. The normal sized isoforms (57 and 55 kD) 
produced by the non-mutated allele and the short C-terminal TEL fragments could be 
detected by C-terminal TEL antibody (Figure 3A). 
C-terminal mutant. Neither N- nor C-terminal specific antibodies were able to detect 
the expected 48kD TEL protein in case #3102. The normal sized isoforms (57 and 55 
kD) produced by the non-mutated allele and the short C-terminal TEL fragments could 
be detected in this case (Figure 3A). 
Deficit TEL protein expression in one third of the patients 
Western blot analysis on 3 patients with intact TEL alleles revealed the lack of TEL pro-
tein expression in 1 case (patient #3, Figure 3A). To investigate the relevance of this 
finding and determine the frequency of TEL protein loss, we studied TEL protein 
expression pattern in 77 AML patients that had already been screened for TEL muta-
tions. The coding sequence of TEL was intact in all these patients. The presence of TEL 
protein was studied by Western blot analysis using the C-terminal TEL antibody. 
Immunostaining with ERKl antibody demonstrated equal loading of the samples on the 
Western blot. Surprisingly, 24 cases lacked the 57 and 50kD TEL proteins (Figure 3C). 
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However, all the patients showed expression of shorter bands that corresponded to the 
sizes of the C-terminal short isoforms ofTEL detected in-patient #2290 (44, 28 and 23 
kD). The clinical characteristics of the 77 AML cases studied by Western blot analysis 
are demonstrated in Table 2. The distribution of TEL negative cases varies between dis-
tinct karyotypic risk groups. Remarkably all of the unfavourable risk patients expressed 
TEL protein, whereas the majority of favourable-risk patients showed no expression. 
To investigate whether the absence of TEL protein was the consequence of altered 
transcription, we investigated the levels of TEL mRNA in these AML cases. Previously 
we had determined gene expression profiles of 285 AML cases, 27 which included the 77 
cases that were investigated in the present study. Analysis of mRNA hybridization to the 
TEL-probe set on the gene-chip revealed various levels of TEL mRNA expression among 
these cases. However, we did not observe any relation between TEL mRNA transcript 
levels and the loss ofTEL protein (Figure 3D). To validate the gene-chip data, we car-
ried out quantitative real-time PCR analysis on TEL transcripts using eDNA of 3 AML 
cases with TEL and 3 cases in whom the TEL protein expression was lost. In all these 
cases, comparable levels of TEL mRNA were detected irrespective of absence or pres-
ence of TEL protein (data not shown). 
TEL mutants and the short C-terminal isoforms ofTEL lack 
transcription repression potentials 
Using a luciferase assay applying the pGL2-754TR reporter construct, which contains an 
ETS binding site (EBS), we determined the transactivation repressing potentials of distinct 
TEL mutants including those that generate short C-terminal TEL isoforms (#2290 and C, 
FigurelB and D). Figure 4A shows significant repression of luciferase activity by the wt 
TEL. The mutants expressing C-terminal TEL isoforms (#2290 and C) as well other 
mutants of TEL (#2236, 3102 and 2649) were unable to repress luciferase activity. 
Remarkably, the luciferase activity of the mutants was even higher than the basal levels 
observed with the empty vector control. This effect might be caused by a dominant nega-
tive effect of the mutants on a possible low endogenous repression activity in phoenix cells. 
TEL Mutants act as dominant negative in a luciferase repression assay 
In order to investigate whether mutant TEL constructs harbour dominant negative activ-
ity, wt TEL (15 ng) was co-transfected with lOOng of the TEL mutants (Figure 4B). 
N-terminal mutant. Both N-terminal TEL mutants (#2290 and #2236) abolished the 
transactivation repression potential ofthe wt TEL. However, the inhibition by #2236 was 
much stronger than #2290 that only expresses short C-terminal isoforms. Similar to 
#2290, the C-terminal construct (C), which expresses two C-terminal TEL isoforms (28 
and 23 kD) showed weak dominant negative effect on the wt. 
C-terminal mutant. The two C-terminal mutants ( #31 02 and #2649) had strong dom-
inant negative potentials and completely abolished the TEL-induced repression (Figure 
4B). The dominant negative effect of truncated TEL proteins seems to be strong in the 
presence of an intact homo-dimerization domain. Accordingly, the constructs encoding 
theN-terminal half of TEL (N) had a strong dominant negative effect on the wt TEL. 
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Discussion 
In this study we report the occurrence of somatic heterozygous mutations of the TEL 
gene in de novo AML patients. Furthermore, we demonstrate that one third of AML 
patients have deficient TEL protein expression. Several studies have demonstrated the 
involvement of TEL in distinct chromosomal translocations associated with haematolog-
ical malignancies. 11' 17 However, somatic TEL mutations in human AML have to our 
knowledge not been reported before. The functional TEL mutations identified in this 
study affected either the PNT domain in theN-terminus or the C-terminal DNA binding 
ETS domain. The three mutations in theN-terminus resulted in premature termination of 
translation by either single point mutation or out-of-frame insertion/deletion. 
Accordingly, translation of the cDNAs of these mutants demonstrated the loss ofwt TEL 
isoforms. However, the downstream ATGs managed to initiate translation and generated 
44, 28 and 23 kD C-terminal TEL fragments. The C-terminal TEL mutations were either 
in-frame or resulted in truncation of the ETS domain by out-of-frame mutation. In con-
cordance with earlier studies, 8'30 the truncated TEL proteins were impaired in repressing 
transcription in a TEL-specific luciferase assay. Moreover, co-expression of the mutants 
with an intact homo-dimerization domain(# 2236, 3102, 2649 and N) completely abol-
ished the transcription repression by wt TEL. This is in accordance with the fact that 
dimerization of TEL through the PNT domain is indispensable for EBS-driven tran-
scription potentials.3 
Many forms of cancer involve nonsense or frame-shift mutations that generate pre-
mature termination codons.31.36 However the predominant consequence of such mutations 
is not always the synthesis of truncated proteins.37 Accordingly, Western blot analysis on 
the protein extracts obtained from AML blasts of2 mutants (#2236 and #3102) failed to 
show the expression of truncated TEL proteins. Generally, the absence of abnormal pro-
tein is justified by the possible degradation of mutant transcripts through a nonsense-
mediated rnRNA decay pathway.37.39 Nucleotide sequence analysis on patient #2236 
demonstrated that the mutant transcript level was decreased to only one-third of the wt 
level (data not shown). All the other patients with mutations presented no evidence of 
nonsense-mediated decay, as the mutants' transcript levels in these cases were as abun-
dant as the wt TEL. The fact that despite the equal mutant/ wt transcription levels (data 
not shown), no abnormal protein could be detected is intriguing. It should be noted that 
only a minority of the AML cells, the AML colony forming cells (AML-CFU), prolifer-
ate and give rise to undifferentiated AML progeny.40 It is possible that the expression of 
truncated TEL proteins is restricted to AML-CFUs. As demonstrated in the luciferase 
assay, truncated TEL proteins interfere with the wt function and may in this way disrupt 
the development of the myeloid precursor cells. Thus, the fact that truncated TEL pro-
teins are undetectable in the bulk of the AML cells does not exclude their potential 
involvement in AML development. 
Western blot analysis on the AML blast of patients and CD34+ cells suggested the 
expression of short C-terminal TEL fragments. These fragments, which were generated 
by downstream initiation codons lacked the wt TEL transactivation potentials. In the nor-
mal situation, the C-terminal TEL isoforms may regulate the repressing potentials of 
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TEL. Accordingly the abnormal ratio of different TEL isoforms may relate to leukaemia. 
In this study we demonstrated that the wt TEL isoforms (57 and 50 kD) are absent in one 
third of AML cases. The absence of TEL expression is also observed in ALL cases with 
t(12;21)21•22 • Loss ofTEL expression in these cases seems to be a critical secondary event 
for leukaemogenesis, as expression of the TEL/AMLl fusion protein alone is not suffi-
cient for induction of malignant haematological disorder in transgenic mice.41 In ALL 
cases without t(12;21 ), the wt TEL protein is present, however the expression level and 
the ratio of the two 57 and 50 kD TEL isoforms can be altered.23 It is presently unknown 
why TEL protein is absent in some AML cases. The absence of protein in the presence 
of significant levels of mRNA suggests that TEL is post-transcriptionally regulated. 
Joosten et al.42 have demonstrated that Nm23M2 mRNA is normally non-polysome 
bound and therefore not translated. However, upon stimulation of growth factors such as 
Epo, SCF, IL3 or G-CSF, Nm23M2 mRNA relocates to the polysomes. It would be inter-
esting to investigate the ratio of polysome-bound TEL to the non-translatable free mRNA 
fraction in distinctAML samples. Furthermore, nucleotide sequencing analysis of the 5' 
and 3' untranslated regions of TEL mRNA might reveal mutations or polymorphisms, 
which could explain the TEL protein loss. Other explanations for the TEL protein loss 
are alterations in the pathways that regulate translation or accelerated TEL protein degra-
dation. 
The data presented here demonstrate that TEL abnormalities are not restricted to translo-
cations and occur more frequently in AML than previously thought, i.e. either by somat-
ic mutations or by the absence of wt TEL protein through a currently unknown mecha-
nism. A comprehensive study in a large series of AML patients is needed to define the 
clinical consequence ofTEL loss of function. 
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Abstract 
Purpose: Homozygous deletion-polymorphism of GSTMI and GSTTJ leads to the 
absence of major detoxifying enzymes and might affect the cytotoxicity of chemothera-
peutic agents, such as anthracyclines. The present study was conducted to examine 
whether GSTs modify the prognosis of AML patients. 
Patients and Methods: We developed a Q-PCR assay to measure GSTMI and GSTTJ 
expression in a cohort of 269 AML patients. 
Results: This assay proved to be not only as efficient as the genomic-PCR, which 
detects the GST-deletions but also capable in detecting cases that are negative for GSTTJ 
mRNA expression (GSTTJ-null). GSTTI-null associated with a significantly improved 
event-free (P= 0.003) and overall survival (P= 0.006), particularly in favourable-risk 
patients with t(8;21) and t(15;17). The presence of GSTTI expression proved to be an 
independent prognostic factor for event-free survival. In contrast to GSTTJ, GSTMJ had 
no prognostic value. 
Conclusion: We conclude that GSTTJ is a determinant of response in AML with 
t(8;21) and t(l5;17) and that these patients may benefit from an adapted treatment pro-
tocol. 
Introduction 
Cytogenetic analysis is the major tool for risk-classification of acute myeloid leukaemia 
(AML). Although favourable and unfavourable-risk AML appear to be well defined by 
cytogenetics, notable differences in therapeutic response and outcome are still observed, 
implying the involvement of genetic variations or abnormalities within particular risk-
groups. Glutathion S-transferases (GST) are detoxifying cytosolic enzymes that conju-
gate glutathione with compounds contaiillng an electrophilic center.1•2 In humans, at least 
20 GST isoenzymes exist, subdivided in four major subfamilies, i.e. GSTa, GST:rt, 
GSTf!, and GST8. Within the GSTf! and GST8 subfamilies, GSTMI and GSTTJ respec-
tively exhibit deletion polymorphisms, which in case of homozygosity lead to the 
absence of the enzymes. The percentages of homozygous deletions in different ethnical 
groups varies between 22 to 90 %for GSTMI and 12 -38% for GSTTJ.3 Deletions of 
these genes may alter the cytotoxic effect of several chemotherapeutic agents, such as 
anthracyclines, used in the treatment of AML.3·5 Although several studies have focused 
on the relationship between GST-null polymorphism and the failure of chemotherapy, the 
results of these studies remain contradictory. The main reasons for these controversial 
results are the small cohort sizes and the variety in chemotherapeutic regimens used. We 
developed a Quantitative PCR (Q-PCR) assay to assess the prognostic impact of GSTMJ 
and GSTTI polymorphisms and expression levels in a cohort of 269 cases with AML. 
Material and Methods 
Bone marrow samples of 269 AML patients at diagnosis were obtained after informed 
consent. Patients were treated as described previously.6 Blasts were isolated and further 
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processed for DNA and RNA, and eDNA synthesis as described.7 The multiplex PCR 
was carried out using 10 pmol of each forward and reverse primers for GSTTI, GSTMI' 
and albumin (5'-tgaaacatacgttcccaaagag-3' and 5'-ctctccttctcagaaagtgtgca-3') in a 50 all 
mixture containing 200 ng DNA, 2 mM MgC12, 5 ml10x PCR buffer, 2 U Taq DNA-
polymerase (Amersham Pharmacia Biotech Inc, Roosendaal, the Netherlands), 250 mM 
deoxyribonucleoide triphosphates (dNTPs) (Amersham Pharmacia). PCR conditions 
were: 10' 95°C, followed by 1' at 95°C, 1' at 55°C and 2' at 72°C (40 cycles). Products 
were analyzed on a 2% EtBr-agarose gel. 
GSTTI, GSTMI and PBGD (porphobilinogen deaminase) mRNA expression levels 
were measured separately by Q-PCR (ABI PRISM 7700 Sequence Detector, PE 
Biosystems, Nieuwekerk aid IJssel, The Netherlands), using 50 m1 mix containing 2 ml 
eDNA sample, 250 mM dNTPs, 15 pmol forward and reverse primer (same as with mul-
tiplex -PCR), 3 mM MgC12, 200 nM probe, 5 ml1 Ox buffer A and 1.25 U AmpliTaq Gold 
(PE Applied Biosystems). Q-PCR conditions: 10' at 95°C, followed by 15" at 95°C and 
30" at 60°C (40 cycles). Probes sequences were VIC-aggccgacccaagctggccaca-TAMRA 
(PE Biosystems) for GSTTI and FAM-agcggccatggtttgcaggaaac-TAMRA (Eurogentec, 
Seraing, Belgium) for GSTMI. The Q-PCR conditions and primers/probe combination 
used for quantifying PBGD have been described elsewhere.7 
Statistical analysis was performed two-sided using Stata/SE 8.2. P-values <0.05 were 
considered statistically significant. 
Results and Discussion 
GSTMI and GSTTI deletion-polyrnorphisms were detected by multiplex-PCR in 50% 
(66/131) and 22% (29/131) of the AML patients respectively. Q-PCR confirmed that 
cases with a GSTTI-null or GSTMI-null genotype did not express the respective tran-
scripts (Table1A). All cases that were GSTMI positive on DNA level showed GSTMI 
mRNA expression. However, sixteen AML patients without GSTTI deletions appeared 
mRNA negative, suggesting an alternative mechanism leading to the absence of GSTTI 
transcripts. Thus, Q-PCR is superior to multiplex-PCR in detecting GSTTI negative 
cases. 
We expanded the cohort of AML patients (TablelB) and determined GSTTI!GSTMI 
mRNA levels. GSTMI or GSTTI were absent in 48% (128/269) and 35% (93/269) of the 
patients respectively. In accordance with a previous report 9 we observed a significantly 
higher frequency of GSTTI-null expression in patients with t(15;17) (P=0.01) and 
t(8;21) (P=0.06) (TablelB). The absence of GSTTI detoxifying activity in these patients 
might have resulted in accumulation of genotoxic agents, which could play a role in the 
aetiology of translocations. 
In concordance with previous studies10. 12 GSTMI mRNA expression did not have an 
impact on complete remission (CR) rate, relapse and survival of the patients (TablelB). 
Remission and relapse rates for GSTTI-null cases were 86% and 37% versus 76% and 
46% for GSTTI-positiveAML. The OS and EFS probabilities for GSTTI-null patients at 
60 months were 44% and 36% respectively as compared to 26% and 18% in the GSTTI-
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B 
Table 1. GSTTJ and GSTMJ-null expression: (A) the concordance between genom-
ic PCR and Q-PCR techniques in detecting the GSTTJ and GSTMJ negative cases 
(n=l31). (B) Clinical characteristics, therapy outcome and hazard ratio for survival 
of 269 de novo AML patients. 
Genomic PCR on GSTTJ Total 
Null Positive 
Q-PCR on GSTTJ* I Null expression 29 16 45 
I Positive 0 86 86 
Total 29 102 131 
Genomic PCR on GSTMJ Total 
Null Positive 
Q-PCR on GSTMJ* -~ Null eXPression 66 0 66 
I Positive 0 65 65 
Total 66 65 131 
Characteristics Total nr GSTTJ-null GSTMJ-null 
ofuatients 
Gender Male 138 49(36%) 63 (46%) 
Female 131 44(34%) 65 (50%) 
Age (years) Median 44 40 (16-61) 41 (16-63) 
(range) (15-65) 
FAB MO 9 4 4 
Ml 57 24 33 
M2 64 24 29 
M3 21 13 7 
M4 48 11 29 
M5 62 17 25 
M6 3 0 1 
Unclassified 5 0 0 
Cytogenetic risk Favourable 56 29 (52%) 29 (52%) 
group inv (16) 13 5(38%) 10(77%) 
t(15;17) 20 12 (60%) 6 (30%) 
t(8;21) 23 12i52%l 13 (56%) 
Intermediate 179 51 (28%) 85 (47%) 
Unfavourable 34 13 (38%) 14 (41%) 
Complete remission % 86% of GSTTJ-null 81% ofGSTMI-null 
(versus 76% GSTil+) (versus 78% GSTMl+) 
Relapse% 37% ofGSTTJ-null 43% of GSTMI-null 
(versus46% GSTil+) (versus 43% GSTMl+) 
HR•forOS 0.64 (CI: 0.47-0.88, P-0.005) 0.94 (CI: 0.70-1.27) 
HR for OS adjusted for cytogenetic-risk 0.74 (CI: 0.53-1.02, P=0.06) 0.99 (CI: 0.74- 1.33) 
Favourable-risk: HR.= 1 
Intermediate-risk: HR~2.68, CI: 1.66- 4.33 
Unfavourable-risk: HR~ 4.56, CI: 2.57- 8.11 
HRforEFS 0.64 (CI: 0.47- 0.87, P=0.003) 0.95 (CI: 0.72-1.27) 
HR for EFS adjusted for cytogenetic-risk 0.70 (CI: 0.52-0.96, P~ 0.025) 0.99 (CI: 0.74-1.30) 
Favourable-risk: HR=l 
Intermediate-risk: HR=2.02, CI: 1.32- 3.08 
Unfavourable-risk: HR= 3.55, CI: 2.09- 6.00 
* Cases that showed no amplification product after 40 Q-PCR cycles were considered 
negative. The Ct values of GSTTJ and GSTMJ positive patients varied from 30-38 and 22-38 
respectively. All samples were PBGD positive (Ct values: 25-29). The amplified GSTTJ 
fragment was 255 bp and GSTMl was 133 bp. + hazard ratio of GST-null 
(negative by Q-PCR) versus GST-positive (GST+). 
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positive group. Thus, GSTTI-null correlated with a higher event-free (P= 0.003) and 
improved overall survival (P= 0.006) (TablelB, Figure lA). Accordingly, the hazard ratio 
(HR) for death (OS, HR 0.64, P=0.005, CI: 0.47-0.88) and failure (EFS: no CR, death in 
CR or relapse, HR 0.64, P=0.003, CI: 0.47-0.87) was significantly lower in GSTTJ-null 
AML. Bone marrow transplantation had no effect on the survival analysis, as the percent-
age of transplanted patients was similar in both GSTTI-null and positive group (29% and 
28% respectively). After adjustment for karyotypic risk factors in a multivariable analysis, 
GSTTJ-null expression remained an independent prognostic marker for EFS (P= 0.025) 
but no longer for OS (P= 0.06) (TablelB). An association between GSTTI-null genotype 
and favourable prognosis has previously been demonstrated in de novo myelodysplastic 
syndrome11 and childhood acute lymphoblastic leukemia,13 consistent with the hypothesis 
that GSTTl detoxifies chemotherapeutic agents and reduces the effective dose of drug 
within the celL In accordance with these findings, Koberda et al. 14 reported that AML 
patients who achieved CR had the lowest value of GST enzyme activity. 
The effect of GSTTJ within each of the three karyotypically defined risk groups 
(Legends Figure 1), was different (test for interaction: P=0.048 for OS anq P=0.035 for 
EFS). GSTTI expression showed no impact on the EFS and OS' of intermediate-risk 
patients (Figure lB). GSTTJ-positivity in the favourable risk p~tients was associated 
with a significant decrease in EFS (P= 0.007) and OS (P= 0.01). In fact, the effect of 
GSTTJ within the favorable-risk group was only apparent within the t(l5;17) and t(8;21) 
subgroups and not in the patients with an inv(16) (test for interaction: P=0.04 for OS and 
P=0.07 for EFS). GSTTJ expression in patients with a poor-risk karyotype was associat-
ed with a low, though not significant, EFS and OS. It is at present uriclear why GSTTJ 
expression has an effect on the outcome of therapy in particular cytoge»etic risk-groups 
and not in others. 
A few studies reported on increased toxic deaths in patients with a GSTTJ-null geno-
type.10·12 However, in agreement with findings reported by Voso et al., 8 we did not observe 
such an association. From the 6 cases that died from toxicity, only one was GSTTJ-null 
and two were GSTMJ-null. A possible explanation for this discrepancy may be the dis-
tinct treatment protocols that were applied in different studies.12 
Several studies have shown that the sensitivity of cells to the cytotoxic effect of 
anthracycline is inversely related to the cellular glutathione level.4•15 Conjugation of 
anthracyclines with glutathione prevents their access to the nucleus and decreases their 
cytotoxicity.4 Likewise, glutathione depletion of APL cells has been shown to be effec-
tive in overcoming resistance to arsenic trioxide. 16 Accordingly, we observed that glu-
tathione and glutathione S-transferases are determinants of response in subsets of AML, 
particularly in cases with t(8;21) or t(15;17). The GSTTJ-positive patients might benefit 
from adapted treatment protocols in which either the GSTTl is inhibited or glutathione 
is depleted. 
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Introduction 
Acute myeloid leukaemia (AML), with an incidence of approximately 3 per 100.000, is 
the most common type of acute leukaemia in adults.1 Treatment aims at eradicating 
leukaemia. Intensive chemotherapy may first lead the patient into a complete remission.2 
After a complete remission has been accompli;;;h~d,, ponsolidation therapy is applied to 
prevent the relapse of the di'sease. Cotisolidatioil: the~apy might involve additional 
chemotherapy or high-dose therapy in conjunction with autologous or allogeneic stem 
cell transplantation (SCT). Chemotherapy alone is associated with·the highest risk of 
relapse, but it has the lowest treatment-related mortality (TRM). Autologous SCT has an 
intermediate risk of relapse and TRM, ~hereas allogeneic SCT has the lowest risk of 
relapse with the highest TRM. The choice for allogeneic SCT is based upon the eligibil-
ity criteria such as age, cytogenetics and the availability of a matched donor.'A 
Standard chemotherapy induces complete remission in 60-80% of patients.2•4 
Unfortunately, some patients are resistant to therapy or die in the induction period. Those 
who initially enter a remission, may experience a relapse of leukaemia after some time.2 
This means that a large number of patients are exposed to chemotherapy while they do 
not benefit from it. Therefore, it would be useful to apply prognostic markers to distin-
guish good- from poor responders. 
The determinants of response in AML can be divided in three major categories: 
1) factors related to the characteristics of the leukaemic cells e.g. cell type, cytogenetic 
and molecular aberrations, 2) the patient-related factors, e.g. age, sex and genetic varia-
tions affecting pharmacodynamics and pharmacokinetics of the drugs and 3) the drug 
arsenal available (Figure 1). Obviously, these three factors are inter-related and their 
interactions determine the treatment outcome in each individual. In this chapter, the dis-
ease or patient-related markers that can be used in determining prognosis of AML will 
be discussed 
Patient-related 
factors 
Leukaemia-related 
factors 
Drug arsenal 
Figure 1. Prognosis triangle: the treatment outcome in each AML patient is deter-
mined by interactions between the nature of the therapy and the disease- and patient-
related factors. 
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1- The molecular characteristics of the leukaemic cells as 
determinants of prognosis 
At present, cytogenetics provides the best validated prognostic information available on 
the outcome oftherapy.5 Patients with translocations t(l5;17), t(8;21) and inv(l6) have a 
relatively favourable prognosis with a 4-year survival probability of 70% or more. In 
contrast, monosoniies or deletions of the long arms of chromosomes 5 and 7, inversions 
and translocations of chromosome 3, translocation t(6;9), translocation t(9;22) and 
abnormalities of chromosome llq23 have been associated with poor response to 
chemotherapy. The overall survival rate in this group is less than 20% at 4 years and the 
relapse rate is more than 70%.6 Strikingly, the majority of patients withAML have either 
a normal karyotype or infrequent abnormalities with unknown prognostic value. These 
patients are currently classified in the standard or intermediate-risk category_?.& The inter-
mediate-risk group, which is by number the largest category, is heterogeneous and is 
assumed to consist of mixed clinical and prognostic entities. At present FLT3 internal 
tandem duplications (lTD), which occur in 20-30% of de novo AML patients, offer 
molecular markers for recognising poor-risk patients within the intermediate-risk 
group.9· 11 The major goal in this thesis was to pursue molecular biological approaches for 
defining subgroups of favourable- and unfavourable-risk AML, currently hidden within 
this heterogeneous group of patients. 
The search for molecular aberrations in AML 
We pursued two approaches in searching for molecular aberrations, which determine 
patients' prognosis. Firstly, we examined whether abnormal expression of genes that had 
been identified in the vicinity of common virus integration sites ( c VIS) in murine 
myeloid leukaemia were involved in AML and predicted disease outcome. In Chapter 2 
we demonstrated abnormal mRNA expression of EVIl, a c VIS in murine leukaemia, in 
almost 10% of newly diagnosed AML patients. High EVIl expression was associated 
with an increased hazard ratio for death (OS; HR= 1.85, CI: 1.25-2. 73) and failure (EFS; 
HR=l.82, CI: 1.25-2.67). 
Secondly, we studied aberrations in haematopoietic transcription factors. with· 3h 
established critical role in myeloid development. Transcription factors regulate the 
expression of genes that induce cell differentiation. Natur~lly, any aberration in the strUc-
ture or expression of genes encoding transcription factors may have drastic effects on 
haematopoiesis. In fact, the involvemeU:t of transcription facto.rs has been demonstrated 
in several leukaemic translocations, including t(8;21), t(l5;17), idt(i6).and llq23 a,bnor-
malities.12'14 Moreover, many transcription factors have been identified as c VIS in murine 
leukaemia, e.g. HOXa9, HOXa7, MEISJ, PUJ, and c.:.MYBy-zo In Chapter 4 we demon-
strated that mutations in the gene encoding transcription factor C/EBPtx provide inde-
pendent prognostic information with respect to enhanced survivaL CEBPA mutations. 
were associated with a decreased hazard ratio for de~th (OS; HR=0.35: 0.13-0.94) ~nd 
failure (EFS; HR=0.37, CI: 0.15-0~91). Besides the mutations, ·CEBPA mRNA expres~ 
sion levels seemed to influence the prognosis of patients with intermediate-risk kary-
otype. A preliminary study has revealed that methylation of th~ CpQ island in the 
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promotor region of CEBPA associates with transcriptional silencing of this gene in a sub-
set of AML patients (C. Erpelinck and R. Delwel, Personal communication, 2004). In 
Chapter 4 we demonstrate that low transcription levels of CEBPA predict poor progno-
sis. 
Interestingly, we observed hardly any overlap between patients with low CEBPA or 
high EVIl expression and cases carrying CEBPA mutations or FLT3-ITD. This observa-
tion was further confirmed in a gene expression study using A:ffymetrix U133A 
GeneChips. Alike the major leukaemic translocations, e.g. t(8;21), t(15;17) and inv(16), 
both AML with CEBPA mutations and AML with high EVIl expression represented dis-
tinct subclasses of leukaemia characterized by a unique composite expression signature 
(Figure 2).21 
FAD WBC FLT.Jo.rTD OS EfS EVI1 CEBPA 
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Stratification of intermediate-risk group based on molecular aberrations 
and gene-expression signatures 
We analysed a series of 187 AML patients with cytogenetically defined intermediate risk 
for the presence of molecular aberrations with independent prognostic significance. 
Thirty-one percent harboured FLT3-ITD mutations; 8% had high EVIl mRNA expres-
sion and 3% had low CEBPA mRNA levels. These molecular features correlated with 
poor prognosis. In contrast, mutations in CEBPA, detected in 8% of the intermediate-risk 
patients, correlated with favourable prognosis. These molecular markers allowed us to 
distinguish 50% of the intermediate-risk group as poor and good responders (Figure 3). 
These results encouraged us to further unravel different classes of AML through addi-
tional gene expression studies and mutation analyses. 
We studied rnRNA expression patterns of potentially transforming genes, identified 
in murine leukaemia, i.e. Hoxa9, Hoxa7, Meisl, Cb2, Pu.l, Nm23 and Sox4 in patients 
with AML (data not shown). All patients with favourable cytogenetics showed reduced 
levels of HOXa9, HOXa7 and MEISJ transcripts. In fact, their expression patterns were 
very similar to those of MELJ and ELl, which is demonstrated in Chapter 3. An altered 
common pathway in favourable risk patients may result in down regulation of transcrip-
tion in these genes. The transcript levels of PU.l, NM23-Hl, NM23-H2 and SOX4 did 
not correlate to any cytogenetic category and had no prognostic value. Although rnRNA 
expression levels of CB2 in AML were comparable to those in normal bone marrow, 
abnormal levels of CB2 protein might be involved in leukaemia. In fact, Rayman et al 
observed variable protein expression of CB2 in AML patients, with possible prognostic 
significance (manuscript in preparation). 
Retroviral insertion may disrupt the coding region of genes, resulting in production 
of abnormal proteins. Therefore we searched for possible mutations in the coding region 
of two transcription factors, which are also targeted by virus integration, c-MYB and 
PU.l (data not shown). Mutational analysis of the coding region of c-MYB in a series of 
patients with AML did not reveal any functional mutations. In PU.l, we detected silent 
point mutations in two cases only. Mueller et aF2 had reported the presence of PU.l 
somatic mutations in 7% (9/126) of patients with AML. However, these findings could 
not be confirmed by others.23•25 Our study, which is the largest study on PU.l mutations, 
was based on the same methodology as Mueller et al, i.e. direct sequencing of the eDNA. 
In this way we could detect the large deletion mutations that were described earlier. 
However, it seems that differences in methodology or clinical characteristics can not 
explain these controversial findings. As suggested,24' 25 ethnical differences might explain 
the discrepancy, as the patient cohort studied by Mueller et al. mainly consisted of 
Japanese patients with AML. 
In Chapter 5 we demonstrated heterozygous somatic mutations in the TEL gene. 
Several studies have shown the frequent involvement of TEL in chromosomal transloca-
tions associated with haematological malignancies.26.31 In addition to mutations in TEL, 
we demonstrated that the TEL protein is absent in one third of AML patients. Western 
blot analysis on 77 AML patients revealed loss of TEL protein in 24 cases. Remarkably, 
loss of TEL protein within the intermediate-risk category, was associated with an 
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increased hazard ratio for death (OS; HR=2,06, CI: 1.04-4,09) and failure (EFS; 
HR=l.98, CI: 1.05-3,76). 
Subsequently, we studied the heterogeneity within the unclassified half of the inter-
mediate-risk group, using microarray data.21 Within the intermediate-risk group, 70 
patients did not carry any known molecular aberrations, including FLT3-ITD, CEBPA 
mutations and high EVIl expression. Figure 4 shows pairwise correlation between gene 
expression profiles of these 70 AML patients. Except the few clear clusters, which relate 
to the cell morphology (Ml, M2 and M5), the expression profiles of the rest of the 
patients hardly show any homology. One explanation could be that these cases present 
leukaemias with extremely infrequent aberrations. In that case, we might be able to 
define novel AML clusters by screening a larger cohort of patients. In addition, applica-
tion of other approaches, such as proteomics might improve the classification of AML. 
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Figure 3. Stratifying AML patients (n=l87) with intermediate risk karyotype by 
means of the known prognostic markers. 
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2- Patient-related factors affecting prognosis of patients 
The genetic aberrations of the leukaemic cells provide valuable information about the 
outcome of the disease. In addition, patient-related factors might modify prognosis. 
Polymorphisms in genes encoding drug metabolising enzymes are considered as consti-
tutional factors of therapy response.32 For example cellular resistance to antracyclines in 
AML is related to the activity of a family of phase II metabolising enzymes, the 
Glutathion S-transferases.33 Glutathion S-transferase theta 1 (GSTTJ), a member of this 
family, shows homozygous deletion-polymorphism in approximately 12-38% of the pop-
ulation34, which results in the absence of a major detoxifying enzyme. In Chapter 6 we 
demonstrated that GSTTJ expression is an independent prognostic factor for a subset of 
AML cases. As GSTT1 normally detoxifies chemotherapeutic agents and reduces their 
effective dose within the cell, the absence of the enzyme may associate with increased 
drug availability and more effective treatment. Based on this assumption, the treatment 
protocols for GSTTJ positive patients might require dose-adjustment for allowing effec-
tive intracellular drug concentration. This study shows how individualized dosing based 
upon genotype or phenotype of relevant drug metabolising enzymes might be relevant 
for improving the therapy outcome of AML patients. 
3- AML drug arsenal 
The remission induction therapy in AML consists of a combination of anthracyclines 
(idarubicin and daunorubicin) and cytarabine, sometimes supplemented with a third 
drug (e.g. etoposide, thioguanine).4 Moreover, sensitisation ofleukemic cells with gran-
ulocyte colony-stimulating factor (G-CSF) factor might reduce relapse and improve 
overall and disease-free survival of AML patients, especially within the intermediate-risk 
group.4 However, the heterogeneous characteristics of AML make it difficult to design 
an effective uniform treatment protocol for treating all the patients. Until now more than 
200 different mutations and chromosomal trans1ocations have been described in AML. 
Acute promyelocytic leukaemia (APL) which associates with translocation t(15; 17), can 
specifically be treated with all trans retinoic acid (ATRA). ATRA plus chemotherapy has 
improved the cure rate of APL patients from less than 40% to over 70%. 35•36 Nevertheless, 
with the exception of acute promyelocytic leukaemia (APL ), we have not yet succeeded 
in developing effective targeted therapies for other subsets of AML. 
Through molecular genetic studies on leukaemic populations a number of genetic 
abnormalities and aberrant pathways associated with the disease have been identified. 
The ultimate goal of these studies is to disclose novel therapy targets in leukaemia. In 
this thesis, we have demonstrated the prognostic value of high EVIl expression and 
CEBPA mutation in AML patients. Whether these molecular markers will also offer valu-
able targets for therapy, remains to be seen. In order to answer this question elaborate in-
vitro and in-vivo studies are required to examine whether high EVIl expression or 
CEBPA mutations provide critical transforming signals in leukaemic cells and whether 
these molecular targets can be inhibited. In fact, circumstantial evidence does suggest 
that high EVIl expression or CEBPA mutation provide critical transforming signaL High 
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FAB 
Figure 4. Pairwise correlation between gene expression profile of 70 AML patients 
with an intermediate/unknown-risk karyotype using 2856 probe sets. The intermedi-
ate-risk patients with high EVIl expression, FLT3-ITD or CEBPA mutations are 
excluded. The colors of the cells relate to Pearson's correlation coefficient value. Red 
indicates positive and blue negative correlation. Negative correlation means that 
genes that have high expression I in one sample have low level of expression in the 
other sample. The FAB classification is shown in the diagonal column: MO =black, 
Ml =green, M2 =purple, M3 =1 orange, M4 =yellow, M5 =blue and M6 =gray. 
expression of EVIl in cell-lines and bone marrow is known to impair terminal differen-
tiation of progenitors into erythroid cells'7 and granulocytes.38 Furthermore, conditional 
overexpression of EVIl in mice erythroid cells seems to induce dysplasia, as observed in 
patients with 3q26 abnormalities (E. van de Akker and D. Spensberger, 2004 personal 
communication). In theory, inhibition of EVIl function through for instance small mol-
ecules that interfere with EVIl complex formation might recover the EVIl-induced dif-
ferentiation block. Unlike EVIl overexpression, CEBPA mutations seem to block differ-
entiation only in man but not in mice. Schwieger et aP9 have demonstrated that the 
expression of anN-terminal CEBPA mutant in primary human progenitors blocks differ-
entiation of both erythroid and myeloid lineages, supporting the role of such mutations 
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in leukaemic transformation. The N-terminal mutations in CEBPA result in the produc-
tion of a dominant negative protein, which blocks the DNA binding and transactivation 
potentials of the wt C/EBPa.40 Interestingly, microarray analysis shows that the gene 
expression signature of CEBPA mutants is similar to that of cases with low CEBPA 
expression (R. Delwel, 2004, personal communication). By interfering with the function 
of mutant C/EBPa protein or with critical downstream targets, we might be able to res-
cue the differentiation blockade induced by CEBPA aberrations. Interestingly, Zheng et 
al41 have recently demonstrated that FLT3-ITD blocks myeloid differentiation through 
suppression of CEBPA mRNA expression. In the past years, pharmaceutical companies 
have shown interest in developing kinase inhibitors that abrogate FLT3-ITD activity. 
Several kinase inhibitors such as SU11248, PKC412, CEP-701 and CT53518 are cur-
rently in phase I -II of clinical development.436 The critical role of C/EBPa in leukaemic 
transformation suggests that treatments based on modulation of C/EBPa activity may 
provide a new approach in the therapy of a subset of AML patients. 
Conclusions 
At present, a profound understanding of the individual prognostic factors is becoming of 
significant importance for treatment choice in AML. A classic example of this approach 
is treatment of patients with acute promyelocytic leukaemia with oral retinoidsY 
Unfortunately, in most AML cases, we are still not capable of pointing out a dominant 
abnormality with defined prognostic value that also offers a target for drug intervention. 
This study represents a series of efforts to identify novel molecular prognostic markers 
in AML. We demonstrated the prognostic impact of aberrations in two major 
haematopoietic transcription factors, C/EBPa and EVIL Both aberrations defined dis-
tinct subclasses of leukaemia with unique gene expression signatures.21 Aberrations in 
another transcription factor, TEL, were frequently demonstrated in AML and were shown 
to alter patients' prognosis. Furthermore, we demonstrated that patient-related constitu-
tional genetic variations, such as GSTTI deletion-polymorphisms may impact on disease 
prognosis. We anticipate that in the near future, additional discoveries of prognostic 
markers will enable a progressively precise prediction of the outcome and thus be of sig-
nificant clinical value for developing and applying risk-adapted treatment in AML. 
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Hoofdstuk 7 
Algemene discussie en samenvatting: 
De prognose driehoek 
117 
Introductie 
Acute myeloide leukemie (AML) is, met een frequentie van ongeveer 3 per 100.000, de 
meest voorkomende vorm van acute leukemie bij volwassenen.1 De behandeling van 
patienten met AML is gericht op de uitroeiing van de leukemie. Met intensieve chemo-
therapie kan bij de patient een complete remissie worden bereikt.> Na het bereiken van 
de complete remissie wordt aanvullende therapie toegepast om de terugkeer van de ziekte 
te voorkomen. Deze therapie kan bestaan uit een extra kuur van chemotherapie of een 
hoge-dosis chemotherapie en/of radiotherapie in combinatie met autologe of allogene 
stamceltransplantatie (SCT). Chemotherapie zonder SCT betekent een hogere kans op 
terugkeer van de ziekte, maar anderzijds is de therapie-gerelateerde mortaliteit (TRM) 
geringer. All ogene SCT impliceerde laagste kans op recidief van de leukemie, maar de 
meeste morbiditeit en mortaliteit ten gevolg van de behandeling. Autologe SCT neemt 
een tussenpositie in ten aanzien van terugkeer van leukemie en behandelings mortaliteit. 
Allogene SCT is dus de meest krachtige anti-leukemische behandeling bij volwassenen 
met AML in remissie. De keuze voor allogene SCT wordt gemaakt op basis van geschik-
theidcriteria zoals leeftijd, leukemie-prognose ( cytogenetische kenmerken) en de 
beschikbaarheid van een donor. 3•4 
Chemotherapie leidt in ongeveer 60-80% van de patienten naar complete remissie.2.4 
Bij patienten die een remissie bereiken kan na enige tijd de leukemie terugkeren.2 Ret is 
daarom noodzakelijk om prognostische merkers te identificeren, die ons in staat stellen 
om voor de aanvang van de therapie de goede 'responders' te onderscheiden van de slechte 
'responders'. 
De factoren die de response van AML patienten bepalen kunnen worden onderver-
deeld in drie categorieen: 1) factoren die gerelateerd zijn aan de karakteristiek van leu-
kemische cellen e.g. eel type, cytogenetica en moleculaire afwijkingen, 2) de patientge-
relateerde factoren, e.g. leeftijd, geslacht en genetische variaties die effect hebben op de 
farmacodynamiek en farmacokinetiek van geneesmiddelen en 3) het arsenaal aan genees-
middelen (Figuur 1, pagina 106). Deze drie factoren zijn bovendien sterk met elkaar ver-
bonden en hun interactie bepaalt de uitkomst van de behandeling bij elke patient. In dit 
proefschrift beschrijven we ziekte- of patientgerelateerde merkers die kunnen worden 
gebruikt bij het vaststellen van de prognose. 
1- De moleculaire karakteristieken van de leukemische cellen als determinanten 
van de prognose 
Tegenwoordig verschaft cytogenetica belangrijke informatie om zowel de uitkomst van de 
remissie-inductie als het postremissie verloop te voorspellen.5 Chromosoom translocaties 
t(15;17), t(8;21) en inv(16) worden als gunstige afwijkingen beschouwd. Patienten met 
deze afwijkingen hebben een kans van 70% of meer op een overleving van 4 jaar. 
Daarentegen wordt een inferieure response op chemotherapie veelal waargenomen bij 
patienten met afwijkingen aan de lange arm of compleet verlies van een chromosoom 5 
of 7, translocaties of inversies van het chromosoom 3, t(6;9), t(9;22), of afwijkingen aan 
chromosoom llq23. De kans op overleving na 4 jaar bij deze laatste groep van patienten 
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is minder dan 20% en de kans op een terugkeer van de ziekte hoven 70%.6 Een beperking 
van de cytogenetische risico-classificatie is dat een aanmerkelijke deel van de patienten 
geen informatieve cytogenetische afwijkingen hebben. Dit maakt het moeilijk om de 
prognose bij een grote groep van patienten vast te stellen. Deze patienten worden geclas-
sificeerd als standaard of behorend tot de intermediaire risicogroepY De intermediaire 
risicogroep is niet scherp gedefinieerd en bestaat uit leUkemien met verschillende klini-
sche en prognostische entiteiten. Op dit ogenblik is FLT3 internal tandem duplicatie 
(lTD), die bij 20-30% van de novo AML voorkomt, een aanvullende moleculaire merker 
die wordt gebruikt om patienten met een slechte prognose te herkennen binnen de inter-
mediaire risico groep.9· 11 Ret hoofddoel van het in dit proefschrift beschreven onderzoek 
was nieuwe moleculaire merkers te identificeren om subgroepen te definieren binnen de 
heterogene intermediaire risicogroep. 
De zoektocht naar moleculaire a.fivijkingen in AML 
Voor de zoektocht naar de moleculaire afwijkingen die de prognose bepalen, is gebruik 
gemaakt van twee verschillende methoden van aanpak. Bij de eerste aanpak wordt onder-
zocht of transformerende genen die zijn opgespoord in leUkemie bij de muis, ook een rol 
spelen bij menselijke leUkemie. Deze genen werden in muizen met leUkemie geidentifi-
ceerd door middel van retrovirale insertionele mutagenese. In hoofdstuk 2 tonen we abnor-
male mRNA expressie van een van deze genen, EVIl aan bij ongeveer 10% van de 
patienten met leUkemie. Roge expressie van EVI I, een gen dat oorspronkelijk als een c VIS 
gevonden is, gaat gepaard met een slechtere overlevingskans (OS: HR= 1.85, CI: 1.25-2. 73) 
ten gevolg van een hogere kans op recidiefvan leukemie (EFS; HR=1.82, CI: 1.25-2.67). 
De tweede benadering die werd gevolgd, betreft de opsporing van afwijkingen in 
transcriptiefactoren, die kritische functies hebben bij de myeloide ontwikkeling. Ret gaat 
in dit verband om transcriptiefactoren die de expressie van genen reguleren die een 
belangrijke rol spelen in de differentiatie van hematopoietische voorlopercellen. Eerder 
is de betrokkenheid van transcriptiefactoren bij de ontwikkeling van leukemie al aange-
toond bij de verschillende chromosoom translocaties bij AML, zoals t(8;21), t(15;17), 
inv(l6) en 11 q23 afwijkingen. 12. 14 Bovendien zijn er bij muizeleukemie veel transcriptie-
factoren geidentificeerd als c VIS, bijvoorbeeld Roxa9, Roxa7, Meis 1, Pu.1, of c-My b. 15. 
20 Vanzelfsprekend kan iedere afwijking in de nucleotide volgorde of expressie van een 
van de genen een drastisch effect hebben op de bloedcelvorming. In hoofdstuk 4 tonen 
wij aan we dat mutaties in het gen dat voor de transcriptiefactor C/EBPa codeert, een 
onafhankelijke prognostische merker is. Patienten met CEBPA mutaties hebben een betere 
overleving (OS: HR=0.35, CI:0.13-0.94) en een lagere kans op recidief van leukemie 
(EFS; HR=0.37, CI: 0.15-0.91). Verder blijkt dat de hoeveelheid aan CEBPA mRNA 
transcripten in een eel ook een voorspellende waarde heeft bij patienten met AML die 
behoren tot de intermediaire risico groep, een lage CEBPA expressie voorspelde, name-
lijk een slechte prognose (hoofdstuk 4). Voorlopige studies hebben aangetoond dat 
methylatie van de CpG eilanden in de promotorregio van CEBPA in de meeste gevallen 
de oorzaak is van de transcriptionele 'silencing' van dit gen bij deze subgroep vanAML 
patienten (C. Erpelinck and R. Delwel, Persoonlijke communicatie, 2004). 
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Ret valt op dat er nauwelijks sprake is van overlap tussen patienten met een lage CEBPA 
expressie, met CEBPA mutaties, hoge EVIl expressie of FLT3-ITD mutaties. Deze 
observatie werd bevestigd door een genexpressie-studie met behulp van biochips 
(Affymetrix Ul33A GeneChips). Net zoals AML samples met de bekende leukemische 
translocaties, namelijk t(8;21), t(15;17) en inv(16), hebben AML cellen met CEBPA of 
EVIl afwijkingen een kenmerkend genexpressie-patroon. Dit onderstreept dat we hier te 
maken hebben met specifieke subgroepen van leukemie (Figuur 2, pagina 108).21 
Stratificatie van de interrnediaire risicogroep, gebaseerd op moleculaire afivijkingen en 
het genexpressie patroon 
In totaal werden 187 AML monsters van patienten met intermediair risico geanalyseerd 
op de aanwezigheid van de hierboven genoemde moleculaire afwijkingen. Bij 31% van 
deze patienten werden FLT3-ITD mutaties gevonden; 8% van de patienten toonde een 
hoge EVIl expressie en 3% had een laag CEBPA mRNA niveau. Deze moleculaire afwij-
kingen correleerden elk met een slechte prognose. Mutaties in CEBPA werden gevonden 
bij 8% van de patienten met intermediair risico en correleerde daarentegen met een 
goede prognose (Figuur 3, pagina 110). Met behulp van deze serie moleculaire merkers 
waren we in staat om 50% van de patienten binnen de intermediaire risico groep te 
onderscheiden als patienten met een goede of slechte prognose. Deze kennis heeft ons 
aangemoedigd door middel van aanvullende genexpressie-studies en verdere mutatie 
analyses de andere subgroepen van AML te analyseren. 
We bestudeerden het mRNA-expressiepatroon van potentiele oncogenen bij AML 
patienten. De betrokkenheid van deze genen was al aangetoond bij muizeleukemie. Deze 
onderzochte genen waren onder andere HOXa9, HOXa7, MEISJ, CB2, PUJ, NM23-Hl, 
NM23-H2 en SOX4. Alle patienten met cytogenetische afwijkingen die correleren met 
een gunstige ziektebeloop, bijvoorbeeld t(8;21) of t(15; 17), vertoonden een laag expres-
sieniveau van HOXa9, HOXa7 en MEISI transcripten (data niet gepresenteerd). In feite 
was het expressieniveau patroon van deze genen vergelijkbaar aan die van MELI en ELI 
(Zie hoofdstuk 3). De verlaagde expressie van deze transcriptiefactoren bij patienten 
met een relatief gunstige prognose kan het gevolg zijn van een verandering in een 
gemeenschappelijke intra-cellulaire signaalroute. De mRNA-expressieniveaus van PUI, 
NM23-Hl, NM23-H2 en SOX4 hielden geen verband met bepaalde cytogenetische 
afwijkingen en bleken geen prognostische waarde te hebben. Alhoewel het mRNA-
expressieniveau van het oncogen CB2 bij AML vergelijkbaar was met dat in normaal 
beenmerg zou een afwijkend aantal CB2 receptoren op AML cellen wel degelijk geas-
socieerd kunnen zijn met verschillende subgroepen van leukemie, maar dit vereist nader 
onderzoek. Afgezien van de inductie van veranderingen in het transcriptieniveau, kan 
retrovirale insertie ook de coderende regio's van genen verstoren. Dit kan vervolgens lei-
den tot de productie van eiwitten met een afwijkende structuur. Daarom is tevens onder-
zoek gedaan naar mogelijke mutaties in c-MYB and PUI, twee genen die ook zijn 
ge1dentificeerd als leukemie-genen door middel van retrovirale insertionele mutagenese. 
Nucleotide sequentie analyse van de coderende regio's van c-MYB heeft geen structurele 
mutaties aangetoond bij patienten met AML. Mueller et aF2 hebben gerapporteerd dat 
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somatische mutaties van PUI voorkomen bij 7% (9/126) van patienten met AML. Deze 
bevinding kon echter niet door anderen worden bevestigd.23.25 Gebruik makend van 
dezelfde methodologie als Mueller et a1,02 i.e. 'direct sequencing' van PUI eDNA, heb-
ben wij celmonsters van meer dan 300 patienten geanalyseerd op de aanwezigheid van 
mutaties. Op deze manier konden we in principe ook de grote deletie-mutaties, die door 
Mueller et aF2 gevonden waren, aantonen. In PUI hebben wij slechts twee 'silent' punt-
mutaties gevonden. Het lijkt niet dat de methodologie of verschillende klinische ken-
merken van patienten deze controversiele bevindingen kunnen verklaren. Zoals eerder 
werd gesuggereerd24.25 zouden etnische verschillen deze tegenstrijdigheid mischien wei 
kunnen verklaren: de groep bestudeerd door Mueller et al. bestaat voornamelijk uit 
Japanse patienten. 
In hoofdstuk 5 laten we heterozygote somatische mutaties zien in het TEL-gen. Vele 
studies hebben aangetoond dat TEL vaak betrokken is bij chromosomale translocaties, 
die voorkomen bij hematologische maligniteiten.26-31 Afgezien van de TEL-mutaties bij 
AML laten we zien dat bij een derde van het aantal van AML-patienten het TEL-eiwit 
ontbreekt. Western blot analyse bij 77 AML patienten toonde het verlies van de TEL-
eiwit expressie in 24 gevallen. Het is opmerkelijk dat binnen de intermediaire risico-
groep, het verlies van het TEL-eiwit geassocieerd was met een ongunstiger overleving 
(OS: HR=2.06, CI:l.04-4.09) en een hogere kans op terugkeer van leukemie (EFS; 
HR=l.98, CI: 1.05-3.76). 
Met behulp van microarray analyse21 hebben wij getracht de heterogeniteit binnen de 
intermediaire risicogroep verder op te helderen. Binnen de intermediaire risicogroep ble-
ken 70 patienten geen van de bekende moleculaire afwijkingen met een prognostische 
waarde te hebben, zoals FLT3-ITD, CEBPA mutaties en hoge EVIl expressie. De gen-
expressieprofielen van deze patienten toonden nauwelijks overeenkomst (Figuur 4, pagina 
112). De clusters met onderscheiden expressie-profielen waren gerelateerd aan de celmor-
fologie (M1, M2 and M5). De aanwezigheid van gevarieerde en uiterst zeldzame afwij-
kingen in deze groep van patienten en de betrokkenheid van uiteenlopende signaalroutes 
kan een verklaring zijn voor de opmerkelijke verscheidenheid van de genexpressie profie-
len. De analyse van grotere aantallen patienten kan wellicht leiden tot de herkenning van 
nieuwe AML clusters. Daarnaast kan wellicht, door toepassing van andere methoden, zoals 
het analyseren van eiwitexpressie, de classificatie van AML verder worden ontwikkeld. 
2- Patient-gerelateerde factoren die de prognose beinvloeden 
De genetische afwijkingen van de leukemiecellen verschaffen waardevolle informatie 
over het beloop van de ziekte en de uitkomst van therapie. Verschillende andere factoren 
zoals het voorkomen van gelijktijdige niet-hematologische aandoeningen en andere 
patientgerelateerde factoren (bijvoorbeeld leeftijd) kunnen de prognose eveneens bein-
vloeden. Polymorfismen in genen, die voor geneesmiddel-metaboliserende enzymen 
coderen, worden als een belangrijke erfelijke basis voor verschillen in therapierespons 
beschouwd.32 Zo kan bijvoorbeeld cellulaire resistentie tegen antracyclinen bij AML wor-
den gerelateerd aan de activiteit van een familie van fase II-metaboliserende enzymen, de 
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Glutathion S-transferases.33 Glutathion S-transferase theta 1 (GSTTJ), een lid van deze 
familie, vertoont homozygote deletie-polymorfismes bij ongeveer 12-38% van de popu-
latie,34 hetgeen een afwezigheid van dit belangrijke detoxificerende enzym tot gevolg 
heeft. In hoofdstuk 6 tonen wij aan dat de GSTTJ-expressie een onafhankelijke prog-
nostische factor is. De afwezigheid van het GSTTl-enzym zou kunnen leiden tot een 
verhoogde beschikbaarheid van chemotherapeutica en een effectievere behandeling. Op 
basis van deze theorie zou de behandeling van GSTTJ-positieve patienten wellicht aange-
past moeten worden, opdat de concentratie van de chemotherapeutica binnen de eel, ook 
bij de subgroep met GSTTJ deletie, het beoogde niveau kan bereiken. Deze studie sugge-
reert dat een gemdividualiseerde dosering gebaseerd op het genotype of fenotype van een 
relevant metaboliserend enzym de uitkomst van de therapie zou kunnen verbeteren. 
3- Het arsenaal aan geneesmiddelen 
De remissie-inductie therapie in AML bestaat uit een combinatie van anthracyclinen 
(idarubicin en daunorubicin) en cytarabine en in sommige gevallen etoposide.4 
Bovendien verbetert sensitisatie van leukemische cellen met granulocyte colony-stimu-
lating factor (G-CSF) de kans op een ziektevrije overleving van AML patienten, vooral 
van die binnen de intermediaire risicogroep.4 Vanwege de heterogene kenmerken van 
leukemie is toepassing van een uniform en effectief behandelingsprotocol voor alle 
patienten onwaarschijnlijk. Tot nu toe zijn er meer dan 200 verschillende mutaties en 
chromosomale translocaties inAML beschreven. Acute promyelocyten leukemie (APL), 
is geassocieerd met de translocatie t(15;17) en wordt behandeld met All Trans Retinoic 
Acid (ATRA). ATRA gecombineerd met chemotherapie heeft de kans op genezing in 
APL-patienten verbeterd van globaal40% tot meer dan 70%.35•36 Tot heden is het buiten 
de behandeling van APL nog niet gelukt om effectieve doelgerichte therapieen te ont-
wikkelen voor patienten met AML. 
Door middel van moleculaire genetische studies op leukemische populaties zijn een 
aantal genetische afwijkingen en abnormale signaalroutes in leukemiecellen ge!dentifi-
ceerd. Het ultieme doel van dergelijke studies is om nieuwe cellulaire doelwitten op te 
sporen voor de behandeling van leukemie. In dit proefschrift hebben we de prognosti-
sche waarde van een hoge EVIl-expressie en van CEBPA-mutatie bij AML aangetoond. 
Dit roept de vraag op of deze moleculaire merkers als doelwitten voor therapie-benade-
ringen zouden kunnen dienen. Om deze vraag te kunnen beantwoorden, dienen functio-
nele in-vitro en in-vivo studies verricht te worden. Daarbij zou moeten worden nagegaan 
of en indien in hoeverre een hoge EVIl-expressie en CEBPA-mutatie voor kritische 
transformerende signalen zorgen en of deze signalen kunnen worden onderbroken. In 
feite ondersteunen verschillende studies de hypothese dat een hoge EVIl-expressie of 
CEBPA -mutatie kritische transformerende signalen leveren. Het is bekend dat een hoge 
EVIl-expressie in cel-lijnen en beenmerg de terminale differentiatie van voorlopercellen 
tot erythroide cellen37 en granulocyten38 verhindert. Conditionele overexpressie van EVIl 
in erythroide cellen van muizen schijnt bovendien dysplasie te induceren, die ook bij 
patienten met een 3q26 afwijking gezien wordt (E. van de Akker and D. Spensberger, 
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2004 persoonlijke communicatie). Theoretisch gezien is het denkbaar dat remming van 
de EVIl-functie door bijvoorbeeld 'small molecules', die met het EVIl-complex kunnen 
interfereren, het EVIl-geinduceerde differentiatieblok zou kunnen herstellen. In tegen-
stelling tot hoge EVIl expressie schijnen CEBPA-mutaties alleen in de mens een diffe-
rentiatieblok te kunnen induceren en niet in de muis. Schwieger et aP9 hebben aangetoond 
dat de expressie van een N-terminale mutant van CEBPA in primaire voorlopercellen van 
de mens, de differentiatie blokkeert van zowel erythroide als myeloide cellen, hetgeen de 
betekenis van deze mutaties voor leukemische transformatie bevestigt. Als gevolg van de 
N-terminale mutaties van CEBPA wordt een dominant negatief eiwit geproduceerd, dat 
de DNA-binding en het transactivatie potentieel van het wild type eiwit teniet doet.40 In 
dit verband is het interessant dat de rnicroarray analyse laat zien dat het genexpressie-
patroon van de CEBPA-mutanten vergelijkbaar is met genexpressiepatronen van patienten 
met een lage CEBPA-expressie (R. Delwel, 2004, persoonlijke communicatie). Door 
regulatie van het gemuteerde C/EBPa of daaraan gerelateerde eiwitten zouden we het 
C/EBPa gei:nduceerde differentiatieblok kunnen herstellen. Zheng et al41 hebben recen-
telijk laten zien dat het FLT3-ITD gei:nduceerde differentiatieblok van myeloide cellen 
mede veroorzaakt is door de onderdrukking van CEBPA mRNA-expressie. Sinds enige 
jaren hebben farmaceutische industrieen actief interesse getoond in de ontwikkeling van 
FLT3-inhibitoren, onder andere vanwege de hoge frequentie van deze mutaties in AML. 
Verschillende FLT3-inhibitoren, zoals SU11248, PKC412, CEP-701 en CT53518, zijn 
op dit ogenblik in klinisch onderzoek.4•36 De kritische rol van C/EBPa bij leukernische 
transformatie suggereert dat therapieen gebaseerd op modulatie van de C/EBPa-acti-
viteit nieuwe mogelijkheden zouden kunnen verschaffen voor de behandeling van een 
subgroep van AML. 
Conclusie 
Specifieke kennis van individuele prognostische factoren wordt steeds belangrijker voor 
het kiezen van een therapie in AML. Een inmiddels klassiek voorbeeld van deze aanpak 
is de behandeling van patienten met acute promyelocyten leukernie met retinoi:denY In 
de hier gerapporteerde onderzoekingen zijn nieuwe genetische prognostische merkers 
gevonden bij AML. Het betreft afwijkingen in twee belangrijke hematopoietische tran-
scriptiefactoren (C/EBPa en EVIl). Beide afwijkingen vertegenwoordigen twee sub-
ldassen van leukernie met unieke genexpressie patronen.21 Frequente afwijkingen in een 
andere transcriptie factor (TEL) werden ook aangetoond. Voorlopige studies doen sug-
gereren dat patienten waarbij het TEL-eiwit afwezig is, een relatief slechte prognose heb-
ben. Verder is in deze studies aangetoond dat patient-gerelateerde factoren, zoals consti-
tutionele GSTTJ deletie-polymorphismen, de prognose kunnen bei:nvloeden. Wij ver-
wachten dat in de nabije toekomst de identificatie van nieuwe prognostische merkers een 
aangepaste, op risico gebaseerde behandeling van AML mogelijk zal maken. 
Voor noten: zie bladzijden 114-115. 
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List of Abbreviations 
ABC 
ABLl 
ALL 
AML 
APL 
ATRA 
BCL2 
BCR 
BTL 
bZIP 
BCR 
CAN 
CB2 
CBF 
eDNA 
C/EBP 
cFES 
CFU 
CI 
cKIT 
CML 
CR 
Ct 
cVIS 
DEC 
DNA 
dNTP 
EBS 
EFS 
ELl 
Epo 
ES 
ETV6 
EVI 
FAB 
FISH 
FLT3 
FMS 
GAPDH 
G-CSF 
GSH 
ATP-binding cassette 
abelson murine leukaemia viral oncogene homolog 1 
acute lymphoblastic leukaemia 
acute myeloid leukaemia 
acute promyelocytic leukaemia 
all-trans retinoic acid 
B-cell CLL!lymphoma 2 
breakpoint cluster region 
BRX-like gene translocated in leukaemia 
basic-leucine zipper 
breakpoint cluster region 
NUP214, cain gene 
peripheral cannabinoid receptor 
core binding factor 
copy DNA 
CCAAT/enhancer binding protein 
feline sarcoma oncogene 
colony forming unit 
confidence interval 
mast cell growth factor receptor 
chronic myeloid leukaemia 
complete remission 
threshold cycle 
common virus integration site 
deleted in endometrial carcinoma 
deoxyribonucleic acid 
deoxyribonucleoside triphosphate 
ETS binding sites 
event-free survival 
EVIl-likel 
erythropoietin 
embryonic stem 
ets translocation variant gene 6 
ecotropic virus integration site 
French-American-British 
fluorescence in situ hybridisation 
fins like tyrosine kinase 3 
macrophage colony stimulating factor I receptor precursor 
glyceraldehyde-3-phosphate dehydrogenase 
granulocyte colony-stimulating factor 
glutathione 
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GST glutathion s-transferases 
HBSS hanks balanced salt solution 
HDAC histone deacetylase 
HOVON Dutch-Belgian hemato-oncology cooperative study group 
HOX homeobox 
HR hazard ratio 
IL interleukin 
ISCN 
lTD 
IWCL 
MDR 
MDS 
MEISl 
MELl 
MEL 
MLL 
MN 
mRNA 
MRP 
MYB 
Myc 
MYH 
N-coR 
NFl 
NM23 
OS 
P53 
PBGD 
PCR 
PDGFR 
PML 
PNT 
PU.l 
Q-PCR 
RA 
RAEB-t 
RAR 
RNA 
RPNl 
RT-PCR 
SCF 
SCT 
SDS 
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International System for Human Cytogenetic Nomenclature 
internal tandem duplication 
International Workshop on Chromosomes in Leukemia 
multidrug resistance 
myelodysplastic syndrome 
homeobox protein Meisl 
MDSl-EVIl-like 1 
murine erythroid leukaemia 
mixed lineage leukaemia 
superoxide dismutase 
messenger RNA 
multidrug resistance-associated protein 
avian myeloblastosis viral oncogene homolog 
avian myelocytomatosis viral oncogene homolog 
myosin heavy chain 
nuclear receptor co-repressor 
neurofibromatosis Type 1 
nonmetastatic protein 23 
overall survival 
transformation related protein 53 
porphobilinogen deaminase 
polymerase chain reaction 
platelet-derived growth factor receptor 
promyelocytic leukaemia 
pointed 
spleen focus forming virus (SFFV) proviral integration oncogene spil 
quantitative polymerase chain reaction 
retinoic acid 
refractory anaemia with excess ofblasts in transformation 
retinoic acid receptor 
ribonucleic acid 
ribophorin 1 
reverse transcriptase PCR 
stem cell factor 
stem cell transplantation 
sodium dodecyl sulfate 
SOX4 
Spi-1 
sse 
TEL 
TRM 
YYl 
WBC 
WHO 
wt 
SRY-box4 
spleen focus forming virus (SFFV) proviral integration 1 
saline sodium-citrate 
translocation ets leukaemia 
treatment-related mortality 
Yin Yang 1 
white blood cell 
World Health Organization 
wild type 
127 

Curriculum Vitae 
Sahar Khosrovani was born in Tehran, Iran (Persia), August 24 1972 in a family with a 
great passion for art. Her father, Mohammad Reza Khosrovani, is an architect and her 
mother, Fereshteh Pishvaee, a film producer and a graphic designer. As a child, she and 
her sister Sara spent much of their free time running after their mother in the film stu-
dios. Sometimes they had roles in the films for children, which were made by their moth-
er's colleagues. At high school, two great teachers, Mrs. Farid, and Mrs. Olang, infested 
her with an interest in chemistry and biology. In 1990, she embarked on the study of 
pharmacy: the first 3 months at the Jondi-Shapour Medical University in Ahwaz and the 
following 5'h years at the Tehran Medical University. As part of her graduation 
research and thesis she studied the medicinal effects of allin and allicin under super-
vision of Dr. Mohammad Reza Niakan. At that time she also published A Guide to the 
Management of Common Illnesses. At the end of her study, her aunt Dr. Parvin 
Khosrovani invited her to teach a course on 'using medicine during pregnancy' at the 
Tehran Azad University. Preparing that course, she noticed how intriguing the study of 
gene-drug interaction could be. 
In November 1995, she met Leo (Ferydoun) Barjesteh van Waalwijk van Doorn, 
brother of her friend Lisa, who was visiting his family in Iran. It was love at very first 
sight. In 1996, she graduated and started working as a pharmacist in the North Tehran 
Health Centre. Soon afterwards though, she married and moved to Rotterdam. Her first 
year in the Netherlands was filled with Dutch language lessons and a Dutch integration 
course that mainly consisted of how to use public transport and how not to be surprised 
being offered only one cookie when visiting a Dutch friend!!! In 1997, a dear relative, 
Dr. Jelle T. Braaksma, then chairman of the board of the hospital, introduced Sahar to the 
Pharmacy of the Dijkzigt Hospital, where Dr. Arnold G. Vulto made her familiar with 
Dutch Hospital Pharmacy. In June 1997, Leo and Sahar were blessed with the birth of a 
lovely son, Shayan. Later she passed her Dutch NT2 state examination and started the 
post graduate study of pharmacy at the University of Utrecht. By then Sahar was deter-
mined to do a PhD research in the field of genetics. Through Arnold Vulto and Professor 
Pieter Sonneveld she met Dr. Ruud Delwel. His Revolving Fund project 'Studying prog-
nostic markers in acute myeloid leukemia' was a great challenge. As a result, in June 
2000, when she had just finished the post graduate study in Utrecht, she started working 
in the lab of Ruud Delwel and Professor Bob Lowenberg. Four years of research, in 
which a tremendous lot was learned about genetic techniques and molecular biology. 
The results are partly presented in this book. In September 2004, Professor Frederik-
Jan van Schooten en Professor Jos Kleinjans offered her the opportunity to combine her 
knowledge of pharmacy with genetics by conducting pharmacogenetic/toxicogenetic 
studies. She was appointed to the post of assistant professor of genetic toxicology at the 
University of Maastricht, after which the family moved to Gronsveld. 
Sahar Khosrovani is a member of the Royal Dutch Society for the Promotion of 
Pharmacology (KNMP), the Dutch Society for Gene Therapy (NVGT) and The 
Pharmacogenetics Study Group (University of Utrecht). Since the founding in 2000, she 
129 
has been an active member of the International Qajar Studies Association and has helped 
organizing conferences at the University ofLeiden, the Kantonal Hospital in Geneva and 
at Santa Barbara City College. She has also been made honorary member of the Kadjar 
Family Association. Since 2004, she is a member of the founding and administrative 
committees of the Archives and Collections of the Imperial Kadjar (Qajar) Family, the 
Qaleh Kiab Family Foundation and the Shahab Khosrovani Memorial Trust. 
130 
List of Publications 
1. Barjesteh van Waalwijk van Doom-Khosrovani S, Khaleghparast S. Rahnama-ye 
tashkhis va darman-e bimariha-ye shaye (A Guide to the Management of Common 
Illnesses). Tehran 1996. 
2. Barjesteh van Waalwijk van Doom-Khosrovani S, Erpelinck C, van Putten WL, Valk 
PJ, vanderPoel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, 
Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Lowenberg 
B, Delwel R: High EVIl expression predicts poor survival in acute myeloid 
leukemia: a study of 319 de novo AML patients. Blood. 2003 Feb 1;101(3):837-45. 
3. Vulto AG, Barjesteh van Waalwijk van Doom-Khosravani S. Impact of genome tech-
nology on drug use in individually optimised pharmacotherapy. The European 
Association of Hospital Pharmacists. 4 o Curso de biotechnologia, Madrid, April 
2003: 12.1-12.11. 
4. Barjesteh van Waalwijk van Doom-Khosrovani S, Erpelinck C, Lowenberg B, 
Delwel R. Low expression of MDSl-EVIl-like-1 (MELl) and EVIl-like-1 (ELl) 
genes in favorable-risk acute myeloid leukemia. Experimental Hematology. 2003 
Nov;31 (11 ): 1066-72. 
5. Barjesteh van Waalwijk van Doom-Khosrovani S, Erpelinck C, Meijer J, van 
Oosterhoud S, van Putten WL, Valk PJ, Bema Beverloo H, Tenen DG, Lowenberg B, 
Delwel R. Biallelic mutations in the CEBPA gene and low CEBPA expression levels 
as prognostic markers in intermediate-risk AML. The Hematology Journal. 
2003;4(1):31-40. 
6. Barjesteh van Waalwijk van Doom-Khosrovani S, Barjesteh van Waalwijk van Doom 
(Khosrovani) LAF. An Overview of the State of Health and Hygiene in the Qajar Era, 
in: Qajar Era Health, Hygiene and Beauty. Rotterdam, Santa Barbara, Tehran 2003: 
27-61. 
7. Valk P, Verhaak R, Beijen A, Erpelinck C, Barjesteh van Waalwijk van Doom-
Khosrovani S, Boer J, Beverloo B, Moorhouse M, van der Spek P, Lowenberg B, 
Delwel R. Expression profiles in acute myeloid leukemia distinctly associate with 
diverse genetic aberrations and have prognostic impact. The New England Journal of 
Medicine. 15 April2004;350(16):1617-28. 
8. Landrette SF, Kuo YH, Hensen K, Barjesteh van Waalwijk van Doom-Khosrovani S, 
Perrat PN, Van de Ven WJ, Delwel R, Castilla LH. Plagl and Plagl2 are oncogenes 
that induce acute myeloid leukemia in cooperation withCbfb-MYHll. Blood. Dec 7, 
2004. 
131 
9. Barjesteh van Waalwijk van Doorn-Khosrovani S, Spensberger von Wiorogorski D, 
Lowenberg B, Delwel R. Somatic heterozygous mutations in the functional domains 
of TEL (ETV6) and frequent absence of TEL protein in acute myeloid leukemia, 
Oncogene, in press. 
lO.Barjesteh van Waalwijk van Doorn-Khosrovani S, Lowenberg B, Delwel R. GSTTl 
mRNA expression as an independent prognostic marker for AML, submitted. 
132 
Acknowledgements 
One does not often come across a pharmacist doing genetic research in a haematology 
department! As a matter of fact, a pharmacist is not really trained for such research. To take 
up that challenge I needed a qualified supervisor! So, before accepting the PhD position, I 
talked to Marieke Joosten and I inquired after the supervising capabilities of Dr. Ruud 
Delwel. "He is great" she said." ... with an extensive knowledge of and skills in molecular 
biology and genetics'. Marieke said right words indeed! I cannot imagine that I could have 
found a better adviser and mentor for my PhD ... Ruucl, thank you for your help, guidance, 
and most of all your warm friendship during the past 4 years: I have always enjoyed your 
wonderful sense of humour. I'm also grateful to you for travelling all around the 
Netherlands and Belgium with me, to gather bone marrow samples for this study. 
My promoter, Bob Lowenberg, I would like to thank you for your outstanding advice 
throughout these years. It was sometimes difficult to judge whether you were content 
with the way the research was preceding or not, but with an occasional pat on the back 
you managed to motivate and encourage me again! 
Professor Ivo P. Touw, dear Ivo, I admire your passion for scientific discussions! Sitting 
in my room at the University of Maastricht, I miss hearing your voice in the background! 
I hope you and Ruud, when cycling in Limburg, do find the time and opportunity to 
come and visit us. Thank you for all your compliments and comments and for accepting 
to be a member of the examining committee. I also wish to express my gratitude to the 
other members ofthe committee, Professors Rob Pieters, Theo de Witte, Riccardo Fodde 
and Wolter Oosterhuis for the critical reading of this thesis. 
Professor Pieter Sonneveld, thank you for showing your trust in me ... by introducing me 
to Ruud, by supporting my ideas of starting a 'pharmacogenomic group' at the Erasmus 
MC and by giving me the opportunity to write those grants with you. I will be looking 
forward to our future collaboration. 
Dr. Jelle T. Braaksma, dear Jelle, thank you for introducing me into the world of (what 
was then named) AZRJDijkzigt Hospital and I hope that, as we now do live a bit closer 
to each other, we will meet more often. 
A very special thanks goes out to Professor Arnold G. Vulto, who taught me to always 
keep a critical view and mind. Arnold, without you I might not have considered a career 
in research. 
Many thanks to Claudia Erpelinck and Fokke Lindeboom for being my paranymphs. 
Claudia it was a great pleasure to work next to you in the lab. Thank you for all your help 
and for sharing your experiences with me. Fokke, the model father who adores his chil-
dren, the passionate Sparta hooligan ... and a most sociable colleague! Thank you for the 
133 
festivities of a very diverse nature and the soccer pools you organised for the depart-
ment. 
Dominik Spensberger, in a short period of time you taught me quite a number of dif-
ferent techniques. I really appreciate your collaboration on the TEL paper. Dominik, 
thank you for everything! Peter Valk, I often appeared in front of your door asking for 
something! Thank you for never closing that door on me. I would also like to thank the 
charming ladies of diagnostics, especially Wendy Geertsma, Sonja van der Poel and 
Pauline Hogenbirk. Roel Verhaak, thank you for the heatmaps! I hope you will win many 
more poster prices in the future! Wim van Putten, thank you for your statistical analysis 
and for all your suggestions and comments, which improved our publications. I really did 
learn a lot from you on statistical matters. Inge de Greef, thank you for the lessons in 
leukaemia and your collaboration on the EVIl paper. Ronald Hack, when shall we have 
another cup of coffee together? Thank you for helping me to look through all those files. 
Karola van Rooyen, thank you for designing all the figures and all the friendly conver-
sations! 
I also would like to thank all the students who did their training or graduation thesis 
with me: my friend Joost Meijer, a great 'big bear' lover, thank you for all the energy you 
put in the experiments and for all those exciting stories! Susanne van Oosterhoud, I 
admired the precision, with which you carried out the research as well as your self-con-
fidence during your training. Thanks for all the CEBPA sequencing! Michelle Tang, do 
you remember checking all those TEL sequences? We were so excited each time we 
found another TEL mutation! I wish you success with your career. Yvonne de Knegt, 
always friendly, understanding and energetic! Thank you for all your support in sequenc-
ing and cloning. 
Nazik Rayman, my friend and my soul mate, we had so much fun together! .... As 
always, a big hug for you and Hayretin, and we are waiting for your visit to the Limburg 
countryside! Montserrat Blazquez-Domingo and Harald Oderwald thank you for your 
friendship! Let us know when you will organise the next BBQ! Eric van den Akker, I will 
always remember the great time we had in that cellar in Florence, after you received the 
Jose Carreras prize. Although I got laryngitis afterwards and had to take bottles of 
brandy to be able to chair a session the next day!!! Antoinette van Hoven, you were the 
one who introduced me to the lab the very first day I started working on the 13th floor. 
Thank you for all your help and support. I would also like to thank all the ex-colleagues 
in the Delwel group, Sandra Verbakel, Matjolein Tas, Marion van de Broek and Yolanda 
Vankan for the serious scientific discussions (!) during all those lunches. Meritxell 
Alberich, Gert-Jan van de Geijn and Stephan Erkeland, we were room mates for more 
than 4 years. The ongoing battle between Stephan and Gert-Jan for control of the room 
temperature in the' aio hok' resulted in an average temperature, but with a large standard 
deviation. Gert-Jan thank you for chocolates, tea, gossip and the luciferase assay! 
Stephan and Meri, I wish you all the best in Boston ... I shall not forget my ex-room mate 
Marieke Mossink, who may well soon become Minister of Health, and my pseudo room 
mates: Alexandra, Onno and Marijke! Lamberto Felida and Godfrey Grech, thank you 
for your mental support during the Western Blots! I miss you all! 
134 
Marieke von Lindern, the most distant in-law family member I am aware of... and still 
so close to my heart! I admire your tireless and energetic personality. Ineke Kraats, 
bedankt voor alles! Thomasia, jij ook bedankt! Als je weer een foto wenst te maken, kan 
je voor mijn computer gaan zitten!!! Elwin Rombouts, thank you for teaching me how to 
make Kaplan-Meyer curves in SPSS, even before I started with the statistic course! 
David Alexander, I thoroughly enjoyed our discussions. I would also like to thank 
Jules Meijerink, the best specialist on real-time PCR, the cytogenetic gurus Anne 
Hagemeijer, Rosalyn Slater, Berna Beverloo, Elisabeth M. E. Smit and the HOVON 
group: Gregor Verhoef, Leo F. Verdonck, Gert J. Ossenkoppele. 
The BMT group: Peter van Geel, Lianne Broeders, Hans Hoogerbrugge and Arie 
Prins, I really appreciate the time and energy you invested in finding the right patient 
material for our studies! 
My dear Jan van Kapel, our floor manager, thank you for your patience ... and for the 
nice flat screen computer! Ans Mannens and Eveline van Heese, you were always so 
friendly and helpful! No matter how many times I interrupted your work to ask for some 
assistance. Jeanne Vlasveld, what a tremendous support you gave me during the prepa-
ration of my thesis. It was so comforting every time you wrote: "het komt wei goed alle-
maal, hoor!". 
I would like to thank Professor Frederic-Jan van Schooten and Professor Jos 
Kleinjans for giving me the opportunity to start new projects at Maastricht University. 
Frederic-Jan, I really do appreciate your interest and full support in the final steps of 
preparing this thesis and we are so pleased to have you, Karin, Frits and Jelle as our 
neighbours in Gronsveld. Marie-Claire van de Voort, thank you too for all the heart-
warming words and enormous support. 
The members of our Persian Ladies Club at Erasmus MC, Setareh Shamsili, Mahban 
Irandoust ( ... another one of my husband's cousins), Zohreh Jafari, Sara Khosrovani and 
Roya Sharafi, it was always fun to have lunch with you. Keep up the tradition! Roya, my 
devoted friend, thank you for all the love you've given me and my family. I wish you all 
the best with your academic career. Sara, it was short, but it felt great to have a baby sis-
ter at Erasmus MC! Tell me how can I drag you to Maastricht in the near future? 
I would like to express my deepest gratitude to the two wonderful families I am 
blessed with. My parents, Fereshteh and Reza Khosrovani, have always been a great sup-
port to me. Although they live in Tehran, the distance has not stopped them from show-
ing their love, support and concern on a daily basis! My in-laws Ada and Jaap van 
Waning have been there for me ever since I live in the Netherlands. They have never 
once complained about how frequently our son, Shayan, was left with them, because I 
had to study, work, travel or attend a course or a conference. 
Leo, my love, you are the driving force behind my ambitions! This thesis would not have 
been ready without your assistance; and it certainly would not have been published! I 
have to thank you and Shayan for leaving your beloved Rotterdam behind and coming 
with me to Maastricht. You two have showered me with your unconditional love despite 
all my moods! Thank you for everything and I love you so much! 
135 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
